<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><?covid-19-tdm ?><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">65962</article-id><article-id pub-id-type="doi">10.7554/eLife.65962</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-219100"><name><surname>Sanders</surname><given-names>David W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1835-6895</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-219101"><name><surname>Jumper</surname><given-names>Chanelle C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund14"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-219102"><name><surname>Ackerman</surname><given-names>Paul J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219103"><name><surname>Bracha</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219104"><name><surname>Donlic</surname><given-names>Anita</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184237"><name><surname>Kim</surname><given-names>Hahn</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219105"><name><surname>Kenney</surname><given-names>Devin</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219106"><name><surname>Castello-Serrano</surname><given-names>Ivan</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219107"><name><surname>Suzuki</surname><given-names>Saori</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5233-6604</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219108"><name><surname>Tamura</surname><given-names>Tomokazu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1395-6610</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219109"><name><surname>Tavares</surname><given-names>Alexander H</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219110"><name><surname>Saeed</surname><given-names>Mohsan</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169231"><name><surname>Holehouse</surname><given-names>Alex S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4155-5729</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-127471"><name><surname>Ploss</surname><given-names>Alexander</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9322-7252</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund17"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216291"><name><surname>Levental</surname><given-names>Ilya</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184235"><name><surname>Douam</surname><given-names>Florian</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund16"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219111"><name><surname>Padera</surname><given-names>Robert F</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-190570"><name><surname>Levy</surname><given-names>Bruce D</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-13024"><name><surname>Brangwynne</surname><given-names>Clifford P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1350-9960</contrib-id><email>cbrangwy@princeton.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund17"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution>Department of Chemical and Biological Engineering, Princeton University</institution><addr-line><named-content content-type="city">Princeton</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Princeton University Small Molecule Screening Center, Princeton University</institution><addr-line><named-content content-type="city">Princeton</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Chemistry, Princeton University</institution><addr-line><named-content content-type="city">Princeton</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Microbiology, Boston University School of Medicine</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>National Emerging Infectious Diseases Laboratories, Boston University</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Molecular Physiology and Biological Physics, University of Virginia</institution><addr-line><named-content content-type="city">Charlottesville</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Department of Molecular Biology, Princeton University</institution><addr-line><named-content content-type="city">Princeton</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Department of Biochemistry, Boston University School of Medicine</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine</institution><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution>Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution>Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital and Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution>Howard Hughes Medical Institute</institution><addr-line><named-content content-type="city">Princeton</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Prinz</surname><given-names>William A</given-names></name><role>Reviewing Editor</role><aff><institution>National Institutes of Health</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Malhotra</surname><given-names>Vivek</given-names></name><role>Senior Editor</role><aff><institution>The Barcelona Institute of Science and Technology</institution><country>Spain</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>23</day><month>04</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e65962</elocation-id><history><date date-type="received" iso-8601-date="2020-12-21"><day>21</day><month>12</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-04-01"><day>01</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Sanders et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Sanders et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-65962-v2.pdf"/><abstract><p>Many enveloped viruses induce multinucleated cells (syncytia), reflective of membrane fusion events caused by the same machinery that underlies viral entry. These syncytia are thought to facilitate replication and evasion of the host immune response. Here, we report that co-culture of human cells expressing the receptor ACE2 with cells expressing SARS-CoV-2 spike, results in synapse-like intercellular contacts that initiate cell-cell fusion, producing syncytia resembling those we identify in lungs of COVID-19 patients. To assess the mechanism of spike/ACE2-driven membrane fusion, we developed a microscopy-based, cell-cell fusion assay to screen ~6000 drugs and &gt;30 spike variants. Together with quantitative cell biology approaches, the screen reveals an essential role for biophysical aspects of the membrane, particularly cholesterol-rich regions, in spike-mediated fusion, which extends to replication-competent SARS-CoV-2 isolates. Our findings potentially provide a molecular basis for positive outcomes reported in COVID-19 patients taking statins and suggest new strategies for therapeutics targeting the membrane of SARS-CoV-2 and other fusogenic viruses.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SARS-CoV-2</kwd><kwd>coronavirus</kwd><kwd>COVID-19</kwd><kwd>syncytia</kwd><kwd>spike</kwd><kwd>ACE2</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund17"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007242</institution-id><institution>Office of the Dean for Research, Princeton University</institution></institution-wrap></funding-source><award-id>Princeton COVID-19 research funds</award-id><principal-award-recipient><name><surname>Ploss</surname><given-names>Alexander</given-names></name><name><surname>Brangwynne</surname><given-names>Clifford P</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><award-id>Investigator lab</award-id><principal-award-recipient><name><surname>Brangwynne</surname><given-names>Clifford P</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007161</institution-id><institution>Boston University</institution></institution-wrap></funding-source><award-id>Start-up fund</award-id><principal-award-recipient><name><surname>Douam</surname><given-names>Florian</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007161</institution-id><institution>Boston University</institution></institution-wrap></funding-source><award-id>Peter Paul Career Development Professorship</award-id><principal-award-recipient><name><surname>Douam</surname><given-names>Florian</given-names></name></principal-award-recipient></award-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM095467</award-id><principal-award-recipient><name><surname>Levy</surname><given-names>Bruce D</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL122531</award-id><principal-award-recipient><name><surname>Levy</surname><given-names>Bruce D</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM134949</award-id><principal-award-recipient><name><surname>Levental</surname><given-names>Ilya</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM124072</award-id><principal-award-recipient><name><surname>Levental</surname><given-names>Ilya</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM120351</award-id><principal-award-recipient><name><surname>Levental</surname><given-names>Ilya</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001663</institution-id><institution>Volkswagen Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Levental</surname><given-names>Ilya</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004412</institution-id><institution>Human Frontier Science Program</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Levental</surname><given-names>Ilya</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000861</institution-id><institution>Burroughs Wellcome Fund</institution></institution-wrap></funding-source><award-id>Award for Investigators in Pathogenesis</award-id><principal-award-recipient><name><surname>Ploss</surname><given-names>Alexander</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100003085</institution-id><institution>Longer Life Foundation</institution></institution-wrap></funding-source><award-id>Longer Life Foundation—RGA/Washington University Collaboration</award-id><principal-award-recipient><name><surname>Tavares</surname><given-names>Alexander H</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008732</institution-id><institution>Uehara Memorial Foundation</institution></institution-wrap></funding-source><award-id>Postdoctoral fellowship award</award-id><principal-award-recipient><name><surname>Tamura</surname><given-names>Tomokazu</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>Research Fellowships for Young Scientists</award-id><principal-award-recipient><name><surname>Tamura</surname><given-names>Tomokazu</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008667</institution-id><institution>SENSHIN Medical Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Suzuki</surname><given-names>Saori</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000038</institution-id><institution>Natural Sciences and Engineering Research Council of Canada</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Jumper</surname><given-names>Chanelle C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A high-throughput microscopy screen for drugs that modulate SARS-CoV-2 spike-mediated membrane fusion identifies an essential role for cholesterol in both virus entry and syncytia formation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>COVID-19 has caused over a million deaths in the year following identification of its causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (<xref ref-type="bibr" rid="bib167">Zhu et al., 2020a</xref>). Building on knowledge of similar enveloped coronaviruses (<xref ref-type="bibr" rid="bib5">Belouzard et al., 2012</xref>; <xref ref-type="bibr" rid="bib59">Heald-Sargent and Gallagher, 2012</xref>), recent studies made astonishing progress toward a holistic understanding of SARS-CoV-2 pathobiology, suggesting amenable targets to therapeutic intervention (<xref ref-type="bibr" rid="bib56">Haynes et al., 2020</xref>; <xref ref-type="bibr" rid="bib133">Stratton et al., 2021</xref>; <xref ref-type="bibr" rid="bib135">Tay et al., 2020</xref>). In particular, the unprecedented pace of SARS-CoV-2 research led to key insights into viral fusion (<xref ref-type="bibr" rid="bib143">V'kovski et al., 2021</xref>). Many early studies, including most small molecule and genetic screens, focused on entry (<xref ref-type="bibr" rid="bib20">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Dittmar et al., 2020</xref>; <xref ref-type="bibr" rid="bib116">Riva et al., 2020</xref>; <xref ref-type="bibr" rid="bib151">Wei et al., 2020</xref>; <xref ref-type="bibr" rid="bib168">Zhu et al., 2020b</xref>). Central to these efforts are trimeric spike glycoproteins (or 'peplomers’), which give the viral envelope its crown-like appearance, and ACE2, their essential human receptor (<xref ref-type="bibr" rid="bib39">Duan et al., 2020</xref>; <xref ref-type="bibr" rid="bib106">Mittal et al., 2020</xref>). Association of the two proteins underlies virus-cell adhesion, which precedes a conformational change in spike that unleashes its fusion machinery to infiltrate the cell (<xref ref-type="bibr" rid="bib62">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib63">Hoffmann et al., 2020b</xref>; <xref ref-type="bibr" rid="bib74">Ke et al., 2020</xref>; <xref ref-type="bibr" rid="bib81">Lan et al., 2020</xref>; <xref ref-type="bibr" rid="bib122">Shang et al., 2020</xref>; <xref ref-type="bibr" rid="bib153">Wrapp et al., 2020</xref>; <xref ref-type="bibr" rid="bib157">Yan et al., 2020</xref>).</p><p>While essential protein-protein interactions for infectivity have been forthcoming, equally important aspects of SARS-CoV-2 pathobiology have received less attention. For example, amplification of systemic infection requires mass production of functional virions, each of which relies on a specific set of biomolecules to orchestrate the optimal number and spacing of spike trimers in its envelope (<xref ref-type="bibr" rid="bib74">Ke et al., 2020</xref>; <xref ref-type="bibr" rid="bib79">Klein et al., 2020</xref>). How assembly occurs efficiently in the crowded cellular environment is unclear. One favored hypothesis is that viral proteins are similarly trafficked to the ER-Golgi intermediate compartment (ERGIC). While cargo receptor-binding likely plays a role, an alternative possibility is that such proteins feature an intrinsic preference for membrane domains of distinct lipid composition (<xref ref-type="bibr" rid="bib15">Cattin-Ortolá et al., 2020</xref>; <xref ref-type="bibr" rid="bib88">Li et al., 2007</xref>; <xref ref-type="bibr" rid="bib90">Liao et al., 2006</xref>; <xref ref-type="bibr" rid="bib95">Lu et al., 2008a</xref>; <xref ref-type="bibr" rid="bib100">McBride et al., 2007</xref>; <xref ref-type="bibr" rid="bib137">Thorp and Gallagher, 2004</xref>). Indeed, certain viruses require association between receptor proteins and specific lipids to trigger endocytosis (<xref ref-type="bibr" rid="bib85">Levental et al., 2020</xref>; <xref ref-type="bibr" rid="bib111">Pelkmans, 2005</xref>). Whether this is the case for ACE2 remains to be determined. Regardless, lipid bilayers’ differential propensity to incorporate spike vs. ACE2 might determine whether premature interactions promote unproductive membrane fusion in the cell interior, or if present at the cell surface, fusion of apposing cells (<xref ref-type="bibr" rid="bib10">Buchrieser et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Cattin-Ortolá et al., 2020</xref>; <xref ref-type="bibr" rid="bib87">Li et al., 2003</xref>; <xref ref-type="bibr" rid="bib101">McBride and Machamer, 2010a</xref>; <xref ref-type="bibr" rid="bib109">Ou et al., 2020</xref>; <xref ref-type="bibr" rid="bib110">Papa et al., 2020</xref>; <xref ref-type="bibr" rid="bib154">Xia et al., 2020</xref>).</p><p>For many enveloped viruses, infection indeed causes fusogenic viral protein display on the host cell plasma membrane, which allows neighboring cells to fuse into multinucleated ‘syncytia’ (<xref ref-type="bibr" rid="bib22">Ciechonska and Duncan, 2014</xref>; <xref ref-type="bibr" rid="bib24">Compton and Schwartz, 2017</xref>; <xref ref-type="bibr" rid="bib40">Duelli and Lazebnik, 2007</xref>). Past studies of respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and others suggest that cell-cell fusion can play key roles in pathogenicity, whether it be in viral replication, or evasion of the host immune response (<xref ref-type="bibr" rid="bib47">Frankel et al., 1996</xref>; <xref ref-type="bibr" rid="bib70">Johnson et al., 2007</xref>; <xref ref-type="bibr" rid="bib99">Maudgal and Missotten, 1978</xref>). Pioneering work on SARS-CoV-1 (<xref ref-type="bibr" rid="bib87">Li et al., 2003</xref>) as well as recent studies on SARS-CoV-2 identified similar syncytia (<xref ref-type="bibr" rid="bib10">Buchrieser et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Cattin-Ortolá et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib109">Ou et al., 2020</xref>; <xref ref-type="bibr" rid="bib110">Papa et al., 2020</xref>; <xref ref-type="bibr" rid="bib154">Xia et al., 2020</xref>; <xref ref-type="bibr" rid="bib160">Zang et al., 2020b</xref>), which may or may not be relevant to patient pathology (<xref ref-type="bibr" rid="bib9">Bryce et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Giacca et al., 2020</xref>; <xref ref-type="bibr" rid="bib117">Rockx et al., 2020</xref>; <xref ref-type="bibr" rid="bib138">Tian et al., 2020</xref>). It remains an open question if syncytia are related to viral and host cell membrane composition, and whether their formation provides mechanistic insights into cholesterol-targeting therapeutics repurposed for COVID-19 treatment (<xref ref-type="bibr" rid="bib29">Daniels et al., 2020</xref>; <xref ref-type="bibr" rid="bib163">Zhang et al., 2020</xref>).</p><p>Here, we address these significant gaps in our understanding of COVID-19 pathobiology by employing a suite of microscopy-based approaches built around the finding that co-cultures of ACE2- and spike-expressing cells amass widespread syncytia. Mechanistically, ACE2-spike clusters assemble at transcellular, synapse-like contacts, which precede fusion pore formation and multinucleation. A high-throughput screen for modulators of cell-cell fusion, involving ~6000 compounds and &gt;30 spike variants, collectively underscore an essential role of biophysical features of the membrane, particularly spike-associated cholesterol, for SARS-CoV-2 infection. Our results suggest that modulation of membrane composition may inhibit viral propagation, and further informs critical lipid-protein assemblies in physiological syncytia and cell adhesion.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Syncytia derive from fusion events at synapse-like, spike-ACE2 protein clusters</title><p>Given the central role of the ACE2-spike interaction in viral infection (<xref ref-type="bibr" rid="bib63">Hoffmann et al., 2020b</xref>; <xref ref-type="bibr" rid="bib87">Li et al., 2003</xref>; <xref ref-type="bibr" rid="bib106">Mittal et al., 2020</xref>), we sought to develop a live cell microscopy assay of binding and membrane fusion. We generated pooled populations of human osteosarcoma (U2OS) cells, chosen for their flat morphology and lack of critical fusion machinery (<xref ref-type="bibr" rid="bib4">Beck et al., 2011</xref>), which stably express fluorescently tagged ACE2 or spike (full-length, ‘FL’ vs. receptor-binding domain, ‘RBD’; see <xref ref-type="fig" rid="fig1">Figure 1A</xref> for domain organization), using the B7 transmembrane (‘TM’) domain (<xref ref-type="bibr" rid="bib89">Liao et al., 2001</xref>; <xref ref-type="bibr" rid="bib92">Lin et al., 2013</xref>) as a control. Upon co-culture, ACE2 and spike RBD cluster at cell-cell interfaces in a binding-dependent manner (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). By contrast, and in agreement with others (<xref ref-type="bibr" rid="bib10">Buchrieser et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Cattin-Ortolá et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib109">Ou et al., 2020</xref>; <xref ref-type="bibr" rid="bib154">Xia et al., 2020</xref>; <xref ref-type="bibr" rid="bib160">Zang et al., 2020b</xref>), spike FL/ACE2 interactions drove membrane fusion, with the vast majority of cells joining multinucleated syncytia after a day of co-culture (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Syncytia derive from fusion events at synapse-like, spike-ACE2 protein clusters.</title><p>(<bold>A</bold>) Top: Domain structure of a single monomer of the SARS-CoV-2 spike trimer. Domains/motifs is from left to right (see KEY RESOURCES table for residue boundaries): SS (signal sequence), NTD (N-terminal domain), RBD (receptor-binding domain), S1/S2 (subdomain-1/2 cleavage site), S2’ (subdomain-2’ cleavage site), FP (fusion peptide), HR1 (heptad repeat 1), HR2 (heptad repeat 2), TM (transmembrane alpha helix), CTD (cytoplasmic domain). Bottom: Cartoon depiction of live cell co-culture assays to detect spike-ACE2 binding and cell-cell fusion. Magenta, acceptor cells (human ACE2-mCherry or ACE2-iRFP); Green, donor cells (GFP-tagged spike variant). (<bold>B</bold>) ACE2-iRFP U2OS (human osteosarcoma) acceptor cells (magenta) co-cultured for 24 hr with U2OS cells expressing GFP-tagged proteins (green): B7 transmembrane (TM, left), ACE2 (middle), spike receptor-binding domain (RBD-TM/CTD, right). Red asterisks indicate single cell nuclei in isolation (no syncytia); arrowhead, synapses (select examples noted). (<bold>C</bold>) Co-culture of U2OS acceptor cells expressing ACE2-iRFP (magenta) with spike full-length (‘FL’)-GFP U2OS cells (green). White asterisks: cell nuclei in syncytium. (<bold>D</bold>) Co-culture of ACE2-mCherry (magenta) and spike RBD-TM/CTD-GFP (green) cells for indicated amount of time (hours:minutes:seconds). Arrow: synapse-like interfaces between cells. Scale-bar, 5 µm. See also <xref ref-type="video" rid="fig1video1">Figure 1—video 1</xref> for long-lived ACE2-Spike FL synapses. (<bold>E</bold>) Similar to (<bold>D</bold>), but spike FL-GFP and ACE2-mCherry co-culture. Dashed box indicates site of synapse formation and cell-cell fusion. See <xref ref-type="video" rid="fig1video2">Figure 1—video 2</xref> for time-lapse movie. (<bold>F</bold>) Zoom-in on synapse formation (arrow, left image) and fusion event (arrow, sixth image from left) of dashed box in (<bold>E</bold>). (<bold>G</bold>) ACE2-mCherry cell added to pre-plated spike FL-GFP U2OS cell monolayer (time since ACE2 cell plating indicated). Syncytium forms by multiple cell-cell fusion events (dashed boxes). See (<bold>H,I</bold>) for zoom-in events (i) and (ii). See <xref ref-type="video" rid="fig1video3">Figure 1—video 3</xref> for time-lapse movie. (<bold>H</bold>) First cell fusion event (i from <bold>G</bold>) at spike-ACE2 synapse. Time since ACE2-mCherry cell plating indicated. Arrow: retracting synapse prior to cell fusion. (<bold>I</bold>) Similar to (<bold>H</bold>) but second cell-cell fusion event (ii from <bold>G</bold>). (<bold>J</bold>) Representative image of small syncytia (stage 1) common at early time points following co-culture of ACE2-mCherry (magenta) and spike-GFP (green) U2OS cells but rare at 24 hr (blue, Hoechst DNA stain). (<bold>K</bold>) Similar to (<bold>J</bold>), but representative of more common, larger syncytia (stage 2) at 24 hr. Nuclei (blue) clump in center of syncytium. (<bold>L</bold>) Similar to (<bold>J</bold>), but representative of typical syncytium with extensive vacuolization (stage 3) at 48 hr. (<bold>M</bold>) Similar to (<bold>J</bold>), but representative of remnants (spherical membranous structures) of dead syncytium at 72 hr (stage 4). See also <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="video" rid="fig1video1">Figure 1—video 1</xref>–<xref ref-type="video" rid="fig1video3">3</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Syncytia derive from fusion events at synapse-like, spike-ACE2 protein clusters.</title><p>(<bold>A</bold>) Indicated non-transduced cells (or ACE2-mCherry/U2OS control) co-cultured with U2OS spike-GFP (green) cells for 24 hr. White asterisks indicate nuclei in syncytia; red, in isolation. (<bold>B</bold>) Indicated GFP-spike variant (green) U2OS cells co-cultured with U2OS ACE2-mCherry (magenta) cells for 24 hr. White asterisks indicate nuclei in syncytia; red, in isolation; arrowhead, synapses (select examples noted). (<bold>C</bold>) Similar to (<bold>B</bold>), but using spike variants that disrupt its two cleavage sites (S1/S2 vs. S2’). (<bold>D</bold>) U2OS cells expressing spike or ACE2 with indicated fluorescent tag, co-cultured for 24 hr. White asterisks indicate nuclei in syncytia; red, in isolation; arrowhead, synapses (select examples noted).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig1-figsupp1-v2.tif"/></fig><media id="fig1video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-65962-fig1-video1.mp4"><label>Figure 1—video 1.</label><caption><title>Transcellular ACE2-spike synapses are long-lived cellular assemblies.</title><p>ACE2-mCherry, magenta; Spike-GFP, green. Twenty min time lapse, human U2OS osteosarcoma cells stably expressing indicated proteins. Time since start of imaging is indicated.</p></caption></media><media id="fig1video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-65962-fig1-video2.mp4"><label>Figure 1—video 2.</label><caption><title>ACE2-spike synapse formation and cell-cell fusion following co-culture.</title><p>ACE2-mCherry, magenta; Spike-GFP, green. Two hr time lapse, human U2OS osteosarcoma cells stably expressing indicated proteins. Time since plating of spike-GFP cells is indicated.</p></caption></media><media id="fig1video3" mime-subtype="mp4" mimetype="video" xlink:href="elife-65962-fig1-video3.mp4"><label>Figure 1—video 3.</label><caption><title>Building a syncytium: multiple cell-cell fusion events following addition of a single ACE2 cell to a spike cell monolayer.</title><p>ACE2-mCherry, magenta; Spike-GFP, green. Five hr time lapse, human U2OS osteosarcoma cells stably expressing indicated proteins. Time since plating of ACE2-mCherry cell is indicated.</p></caption></media></fig-group><p>We reasoned that if this co-culture system recapitulates established findings regarding spike/ACE2-mediated viral entry, it might serve as a useful high-throughput proxy assay for infection, without need for enhanced biosafety protocols. To examine this possibility, we first confirmed that fusion events occur following co-culture of spike cells with infection-competent cell lines (VeroE6, Calu3) in absence of ACE2 overexpression, but not with those that do not support infection (Beas2B, U2OS without ACE2) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib63">Hoffmann et al., 2020b</xref>). We further validated the relevance of the assay by showing that domains required for virus-cell entry (e.g. binding domain: RBD; fusion machinery: heptad repeats and fusion peptide) are needed for cell-cell fusion (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Similar to results obtained with infectious virus (<xref ref-type="bibr" rid="bib62">Hoffmann et al., 2020a</xref>), fusion required the spike S2’ cleavage site but not the S1/S2 site (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Finally, different fluorescent tags (GFP, mCherry, iRFP) gave similar results (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref> ) expanding the fluorescent toolkit for live cell studies.</p><p>We hypothesized that spike/ACE2-mediated syncytia form in a stepwise manner, which might illuminate mechanisms of formation and pathogenesis. We performed live cell microscopy of co-cultures, documenting dozens of fusion events preceding large syncytia. Invariably, contact between opposite cell types (spike vs. ACE2) results in near instantaneous accumulation of spike protein clusters at ACE2-containing membrane protrusions (<xref ref-type="fig" rid="fig1">Figure 1D–E</xref>). These punctate structures are long-lived (minutes) (<xref ref-type="video" rid="fig1video1">Figure 1-video 1</xref>), similar to physiological synapses (e.g. neuronal, immunological) (<xref ref-type="bibr" rid="bib23">Cohen and Ziv, 2019</xref>; <xref ref-type="bibr" rid="bib41">Dustin, 2014</xref>). In all observed cases, fusion events proceed from such synapses (<xref ref-type="fig" rid="fig1">Figure 1E–F</xref>; <xref ref-type="video" rid="fig1video2">Figure 1—video 2</xref>), often within a few minutes of their formation, but frequently following longer durations of time. In most (but not all) examples, fusion pore dilation follows retraction of an individual spike cluster toward the interior of an ACE2 cell (<xref ref-type="fig" rid="fig1">Figure 1F–I</xref>), suggesting that motility-associated mechanical forces (e.g. actomyosin contractility) and/or endocytosis is pivotal to overcoming the energetic barrier to lipid bilayer mixing. When cells are plated at high density, most ‘primary’ fusion events occur within 60 min (<xref ref-type="fig" rid="fig1">Figure 1G–J</xref>), with latter ‘secondary’ amalgamation of small syncytia into progressively larger structures (<xref ref-type="fig" rid="fig1">Figure 1K</xref>; <xref ref-type="video" rid="fig1video3">Figure 1—video 3</xref>). Over time, syncytia undergo vacuolization, likely from fusion-driven collapse of intracellular organelles into hybrid compartments (<xref ref-type="fig" rid="fig1">Figure 1L</xref>). By 48–72 hr, cells disintegrate into immobile spike/ACE2-coated vesicles, having eaten themselves from within (<xref ref-type="fig" rid="fig1">Figure 1M</xref>).</p></sec><sec id="s2-2"><title>Syncytia are a defining pathological feature of COVID-19</title><p>While clearly useful for interrogating spike domains that modulate membrane fusion, a critical gap in our knowledge concerns the pathophysiological relevance of the syncytia themselves. Given the cytotoxic consequences of cell fusion (<xref ref-type="fig" rid="fig1">Figure 1M</xref>), an appealing hypothesis is that ACE2/spike-mediated cell vacuolization contributes in part to the diffuse alveolar damage observed in the lungs of COVID-19 patients (<xref ref-type="bibr" rid="bib104">Menter et al., 2020</xref>). Intriguingly, SARS-CoV-2 spike is a particularly potent mediator of syncytia formation relative to both SARS-CoV-1 spike and commonly studied fusogens (e.g. p14 FAST, MYMK/MYMX) (<xref ref-type="bibr" rid="bib6">Bi et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Chan et al., 2020b</xref>) based on side-by-side comparisons of cell populations with similar expression levels (<xref ref-type="fig" rid="fig2">Figure 2A–C</xref>; see Materials and methods for details on expression measurements).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Syncytia are a defining pathological feature of COVID-19.</title><p>(<bold>A</bold>) ACE2-mCherry (magenta) U2OS cells co-cultured with GFP-tagged (green) SARS-CoV-2 spike cells (left) or SARS-CoV-1 spike cells (right) for 24 hr. White asterisks indicate nuclei in syncytia; red, in isolation; arrowhead, synapses (select examples noted). (<bold>B</bold>) Quantification of (<bold>A</bold>) by percent cells fused (also tested VeroE6 donor cells, which express endogenous ACE2, and control SARS-CoV-2 spike variants that lack ability to promote fusion). Mean and SEM: n = 4 biological replicates (16 images per). p-Values of &lt;0.01, &lt;0.001, and&lt;0.0001 are represented by *, **, and ***, respectively. (<bold>C</bold>) Indicated fusogen-expressing cells lines co-cultured for 24 hr. Red asterisk indicates nuclei of single cells (not in syncytia). (<bold>D</bold>) Lung from SARS-CoV-2 decedent demonstrating syncytia formation (H and E stained section, ×400 original magnification). Syncytium labeled with arrow. (<bold>E</bold>) Similar to (<bold>D</bold>), but sample obtained from different deceased COVID-19 patient and at ×100 magnification. Syncytium labeled with arrow. (<bold>F</bold>) Immunohistochemistry for lung epithelia marker TTF-1 (NKX2-1; brown) showing nuclear positivity in the syncytial cells (×400 original magnification). (<bold>G</bold>) Lung from control decedent with diffuse alveolar damage unrelated to SARS-CoV-2 infection (died pre-2019), showing hyaline membranes (remnants of dead cells; bright pink) but no syncytia (H and E stained section, ×100 original magnification). (<bold>H</bold>) Table summarizing decedents examined for syncytia pathology.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig2-v2.tif"/></fig><p>We speculated that this superior ability to promote cell-cell fusion might be reflected by unique pathological attributes in vivo. If so, we predicted that syncytia would be readily detected in the lungs of COVID-19 patients. To test this, we histologically evaluated lung samples from 24 deceased patients (‘decedents’) with diffuse alveolar damage secondary to SARS-CoV-2 infection; six decedents who were positive for SARS-CoV-2 but did not have pulmonary manifestations (died of other causes); and nine control decedents with diffuse alveolar damage (died prior to SARS-CoV-2 discovery in 2019). Multinucleated syncytia were detected in 18 of 24 decedents who died as a direct consequence of SARS-CoV-2 infection (<xref ref-type="fig" rid="fig2">Figure 2D–H</xref>), a finding supported by other patient cohorts (<xref ref-type="bibr" rid="bib48">Giacca et al., 2020</xref>; <xref ref-type="bibr" rid="bib138">Tian et al., 2020</xref>). These syncytia were of lung epithelial origin, as demonstrated by nuclear staining for TTF-1 (NKX2-1) (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). In contrast, only one of the nine decedents with diffuse alveolar damage from other causes demonstrated multinucleated syncytia, indicating that these syncytia are not a common feature of lung inflammation (<xref ref-type="fig" rid="fig2">Figure 2G,H</xref>). They were also absent in lung tissue from the six SARS-CoV-2 decedents who did not show pulmonary manifestations and died of other causes. Thus, pathological syncytia are a direct consequence of pulmonary involvement by SARS-CoV-2 (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). These syncytia, however, were generally not positive for the SARS-CoV-2 nucleocapsid protein, similar to previous reports (<xref ref-type="bibr" rid="bib9">Bryce et al., 2020</xref>; <xref ref-type="bibr" rid="bib117">Rockx et al., 2020</xref>). Thus, we cannot rule out a yet-to-be identified pulmonary abnormality specific to SARS-CoV-2 infection (but spike-independent), or related to free spike proteins in the alveolar debris, in pathological syncytia formation.</p></sec><sec id="s2-3"><title>A novel high-throughput screening platform identifies modulators of syncytia formation</title><p>Given the potential pathological relevance of syncytia and their ability to interrogate SARS-CoV-2 entry, we sought to adapt our cell model into a high-throughput assay to uncover molecular mechanisms and drug targets. We developed and evaluated three different fixed-cell microscopy assays, each of which used fluorescent proteins as readouts for fusion (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B,D</xref>), with total nuclei number serving as a toxicity measure. Two of these assays (human U2OS-ACE2 vs. monkey VeroE6 heterokaryon) leveraged RNA-binding proteins’ ability to shuttle between the nucleus and cytosol (<xref ref-type="bibr" rid="bib68">Iijima et al., 2006</xref>; <xref ref-type="bibr" rid="bib170">Zinszner et al., 1997</xref>), with nuclear co-localization of mCherry/GFP reflecting cell fusion. The third assay used split-GFP (<xref ref-type="bibr" rid="bib10">Buchrieser et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Feng et al., 2017</xref>), which only fluoresces when its two halves come into contact (e.g. after fusion). After careful assessment, the U2OS-ACE2 heterokaryon system was shown to be the superior assay based on its Z’-factor (0.85), a measure of separation between positive (spike RBD/ACE2 co-culture, no fusion) and negative (spike FL/ACE2 co-culture) controls (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>); generally Z’-factor &gt; 0.5 is considered excellent for a high-throughput assay (<xref ref-type="bibr" rid="bib162">Zhang et al., 1999</xref>). To determine an optimal time point for quantification, co-cultures were performed for 1–6 hr: fusion was detectable by 1 hr, and Z’-factor peaked by 4–5 hr (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>A novel high-throughput screening platform identifies modulators of syncytia formation.</title><p>(<bold>A</bold>) Heterokaryon assay workflow overview (top) and characterization (bottom). Equal parts acceptor cells (express ACE2-iRFP and FUS-mCherry) plus donor cells (express spike FL-iRFP and HNRNPA1-EYFP) are co-cultured in 384-well microtiter plate: positive control (spike RBD, red column), negative control (DMSO, blue column), test compounds (other columns). After 5 hr, cells are fixed and nuclei are stained (Hoechst) then identified/segmented by automated confocal microscopy. Fraction cells fused is determined by percent co-positive (mCherry and EYFP) nuclei. Sample images and schematic interpretation of a positive control well (top), test well with reduced fusion (middle), negative control well (bottom). Z’-factor measures window size with higher score indicating a more robust screening platform. (<bold>B</bold>) Schematic of assay dose-response and interpretation. Fraction of cells fused (black curve) relative to cell count (toxicity measure, blue curve), both normalized by plate negative control, indicate compound efficacy (pink, strong inhibitor; gray, weak inhibitor; white, no-effect). Compounds are designated as effective if the maximum dose z-score is &lt;-3. Strong vs. weak inhibitor designation is based on an arbitrary cutoff. (<bold>C</bold>) A panel of spike protease inhibitors (n = 10), which includes antagonists of both established SARS-CoV-2 entry pathways (cathepsin-dependent endocytosis vs. TMPRSS2/furin-mediated direct fusion), was tested. Mean and SEM: n = 4 biological replicates (16 images per). (<bold>D</bold>) Similar to (<bold>C</bold>), but displaying dose-response relationships for select inhibitors of indicated routes of endocytosis (e.g. clathrin, macropinocytosis) and steps in secretory pathway (e.g. ER-Golgi transport). See <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref> for additional tested compounds. (<bold>E</bold>) Similar to (<bold>C</bold>), but displaying dose-response relationships for compounds that strongly inhibit cell-cell fusion in ACE2-U2OS heterokaryon assay. See <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> for similar effect in VeroE6 assay (no exogenous ACE2 expression). (<bold>F</bold>) Summary of targeted drugs (n = 41) in U2OS and Vero based co-culture assays. Identified inhibitors are largely similar between cell types. Cell type-specific effects are noted. See also <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s2">2</xref>; <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>A novel high-throughput screening platform identifies modulators of syncytia formation.</title><p>(<bold>A</bold>) U2OS cells co-expressing spike-GFP (yellow) and iRFP-tagged (cyan) endocytic markers (indicated) co-cultured with ACE2-mCherry (magenta) cells, with cell-cell fusion events assessed by live cell microscopy. Representative images show lack of co-localization between spike and iRFP-tagged proteins at synapses (white arrows) and vesicles (red arrowheads) prior to fusion. Scale-bar, 5 µm. (<bold>B</bold>) Optimization of ACE2-U2OS heterokaryon assay. Co-cultures were performed and fusion was quantified upon altering: spike to ACE2 cell ratio (left); length of co-culture time prior to fixation (middle); DMSO concentration (right). Default experimental parameters: 1-to-1 ratio, 5 hr, 0.5% DMSO. Mean and SEM: n = 4 biological replicates (16 images per). (<bold>C</bold>) Dose-response for membrane-permeabilizing compounds in ACE2-U2OS heterokaryon assay. Cell count (blue) and fraction fused (black) curves are similar, indicating lack of toxicity-independent inhibition of cell-cell fusion. Mean and SEM: n = 4 biological replicates (16 images per). (<bold>D</bold>) Comparison of three different heterokaryon microscopy assays, each of which use fluorescent proteins as readouts for fusion. Bottom: relative fusion for positive (spike RBD donor cells; fusion-incompetent) and negative (spike full-length donor cells + DMSO; fusion-competent) controls for indicated assay (top, with graphical depiction) with measured Z’-factor, which indicates assay strength (higher = more robust). Mean and SEM: n = 4 biological replicates (16 images per). (<bold>E</bold>) Schematic of ACE2-U2OS assay dose-response and interpretation. Fraction of cells fused (black curve) relative to cell count (toxicity measure; blue curve), both normalized by plate negative control, indicates compound efficacy (pink, strong inhibitor; gray, weak inhibitor; white, no-effect). (<bold>F</bold>) Dose-response relationships for additional compounds tested in ACE2-U2OS heterokaryon assay. Mean and SEM: n = 4 biological replicates (16 images per). See <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> for same compounds in VeroE6 heterokaryon assay.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>A novel high-throughput screening platform identifies modulators of syncytia formation.</title><p>(<bold>A</bold>) Schematic of VeroE6 heterokaryon assay (no exogenous ACE2 overexpression) dose-response and interpretation. Fraction of cells fused (black curve) relative to cell count (toxicity measure; blue curve), both normalized by plate negative control, indicates compound efficacy (pink, strong inhibitor; gray, weak inhibitor; white, no-effect). (<bold>B</bold>) Dose-response relationships for all compounds (n = 41) tested in VeroE6 heterokaryon assay. Mean and SEM: n = 4 biological replicates (16 images per). See <xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> for effect of same compounds in ACE2-U2OS heterokaryon assay.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig3-figsupp2-v2.tif"/></fig></fig-group><p>Armed with a tractable assay (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>), we sought to characterize essential pathways for fusion, employing dose-response studies of a panel of drugs with well-characterized mechanism of action. Given that protease-mediated S2’ cleavage is essential for cell-cell fusion (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>), we anticipated a large effect for specific classes of protease inhibitors. We thus tested a panel of spike protease inhibitors (n = 10), which included antagonists of both established SARS-CoV-2 entry pathways (cathepsin-mediated endocytic vs. TMPRSS2/furin-dependent direct fusion) (<xref ref-type="bibr" rid="bib62">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib63">Hoffmann et al., 2020b</xref>; <xref ref-type="bibr" rid="bib64">Hoffmann et al., 2020c</xref>; <xref ref-type="bibr" rid="bib73">Kawase et al., 2012</xref>; <xref ref-type="bibr" rid="bib105">Millet and Whittaker, 2014</xref>; <xref ref-type="bibr" rid="bib109">Ou et al., 2020</xref>; <xref ref-type="bibr" rid="bib125">Shirato et al., 2018</xref>; <xref ref-type="bibr" rid="bib165">Zhou et al., 2015</xref>). Surprisingly, the antiretroviral protease inhibitor nelfinavir was unique in blocking fusion (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), a compound whose therapeutic potential was identified by others (<xref ref-type="bibr" rid="bib107">Musarrat et al., 2020</xref>). Given that other serine protease inhibitors (AEBSF, leupeptin, camostat) lacked efficacy, inhibition by nelfinavir may be related to its proteolysis-independent targets (<xref ref-type="bibr" rid="bib8">Brüning et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">De Gassart et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Kirby et al., 2011</xref>).</p><p>Next, we screened drugs that target specific routes of endocytosis or steps in the secretory pathway. Notably, no single endocytic route (clathrin, caveolae, macropinocytosis) was essential (<xref ref-type="fig" rid="fig3">Figure 3D</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E,F</xref>), and markers of each pathway did not co-localize with spike at sites of membrane-fusion or in the vesicles that resulted (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Nevertheless, certain drugs prevented syncytia formation (<xref ref-type="fig" rid="fig3">Figure 3E,F</xref>). For example, apilimod, a promising COVID-19 drug candidate that inhibits PIKFYVE kinase (<xref ref-type="bibr" rid="bib11">Cai et al., 2013</xref>; <xref ref-type="bibr" rid="bib72">Kang et al., 2020</xref>; <xref ref-type="bibr" rid="bib116">Riva et al., 2020</xref>), was particularly potent (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), however less so than in the case of infection studies (<xref ref-type="bibr" rid="bib72">Kang et al., 2020</xref>; <xref ref-type="bibr" rid="bib116">Riva et al., 2020</xref>). Inhibition of actin polymerization blocked fusion (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), consistent with a putative role for cortical actomyosin-generated mechanical forces in fusion pore formation (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="bibr" rid="bib18">Chan et al., 2020b</xref>; <xref ref-type="bibr" rid="bib124">Shilagardi et al., 2013</xref>). Finally, several drugs that perturb membrane lipid composition were identified (MBCD/lovastatin, genistein, nystatin) (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). These compounds could conceivably act by permeabilizing the plasma membrane. To rule out this possibility, cell fusion was examined following treatment with membrane permeabilizers digitonin or ethanol, both of which had no effect on fusion at non-toxic concentrations (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Finally, most compounds acted similarly in the VeroE6 heterokaryon assay (<xref ref-type="fig" rid="fig3">Figure 3F</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>), which expresses endogenous ACE2. We therefore conclude that our syncytium-based screening platform can identify fusion-inhibiting drugs that act independently of canonical entry pathways and might uncover yet-to-be described determinants of membrane fusion.</p></sec><sec id="s2-4"><title>A drug repurposing screen implicates membrane lipid composition in cell-cell fusion</title><p>To gain further mechanistic insight into cell-cell fusion, we performed a drug repurposing screen of ~6000 small molecules at 30 μM (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Of these, 167 (2.8%) were inhibitory ‘hits’, which signified non-toxic compounds with a decrease in fusion greater than 3-standard deviations from the mean (z-score&lt;-3) (<xref ref-type="fig" rid="fig4">Figure 4B</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). To validate, we performed 7-point dose-responses for the top-80 most potent compounds, the vast majority of which replicated (<xref ref-type="fig" rid="fig4">Figure 4C</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B</xref>). Compounds were then unblinded to select experimenters. Reassuringly, 23 of these hits were redundant across the combined libraries (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), and several were identified in previous virus entry screens (<xref ref-type="bibr" rid="bib12">Caly et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Carbajo-Lozoya et al., 2012</xref>; <xref ref-type="bibr" rid="bib64">Hoffmann et al., 2020c</xref>; <xref ref-type="bibr" rid="bib76">Kindrachuk et al., 2015</xref>; <xref ref-type="bibr" rid="bib116">Riva et al., 2020</xref>; <xref ref-type="bibr" rid="bib156">Yamamoto et al., 2016</xref>). We eliminated batch-dependent effects, purchasing top compounds from independent vendors, and replicating dose-response measurements for 23 of 24 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). To assess cell type specificity, dose-response studies for the same molecules were performed in the VeroE6 heterokaryon assay (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). In almost all cases, inhibition of fusion occurred at lower compound concentrations relative to the U2OS assay, possibly due to differences in ACE2 levels between cell lines (e.g. 1–5 μM exogenous ACE2 in U2OS cells is likely much higher than endogenous ACE2 in VeroE6 cells; see Materials and methods).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>A drug repurposing screen implicates membrane lipid composition in cell-cell fusion.</title><p>(<bold>A</bold>) High-throughput pipeline and workflow of small molecule screen (~6000 compounds, 30 µM) in ACE2-U2OS heterokaryon assay. ‘Hits’ refer to non-toxic compounds with a decrease in fusion of &gt;3 standard deviations relative to plate negative control. 7-point dose-response was determined for top-80 inhibitors, followed by validation of select compounds (n = 24; obtained from different vendors) in both ACE2-U2OS and VeroE6 heterokaryon assays. (<bold>B</bold>) Results of compound screen. Plot: fraction fused vs. toxicity z-score. Red dots indicate compounds with decreased fusion (z-score&lt;-3); blue inset, potential hits following toxicity filtering (z-score &lt;3); blue circles, quality-controlled hits (inhibitory, non-toxic compounds with normal fluorescence); gray inset, compounds with increase in fraction cells fused (z-score &gt;5) but no toxicity (‘enhancers’, see <xref ref-type="fig" rid="fig6">Figure 6J</xref>); right histogram, compound density as function of fraction fused z-score. Chemical structures are displayed for select validated hits. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> for raw data. (<bold>C</bold>) Dose-responses for select hits in enriched substructure classes (see <bold>F</bold>): imidazoles (e.g. azole antifungals, green) and macrocyclic lactones (ivermectin-like, yellow; rapalogs, pink). Mean and SEM: n = 3 biological replicates (16 images per). (<bold>D</bold>) Box-and-whisker plots of select physicochemical properties (lipophilicity, logD; ring systems) for non-hits (blue), inhibitory hits (red), and GPCR inhibitors (purple) as calculated in ChemAxon. Boxes encompass 25–75% of variance; whiskers, 10–90%. Mean values are indicated by ‘+”; median values, lines. Statistical significance was assessed by Mann-Whitney U test: p-values of &lt;0.05 and&lt;0.001 are represented by * and **, respectively. (<bold>E</bold>) Lack of correlation between inhibitory hit EC<sub>50</sub> (see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>) and lipophilicity according to linear regression analysis conducted in GraphPad Prism. (<bold>F</bold>) Three substructure classes based on two scaffolds were identified to have high statistical enrichment in hits over non-hits: dicholorophenethyl-imidazoles (found in azole antifungals, green) and tetrahydropyrans with alkyl moieties (found in macrocyclic lactones; yellow and pink indicate ivemectin-like and rapalog compounds, respectively). See also <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>–<xref ref-type="fig" rid="fig4s2">2</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>A drug repurposing screen implicates membrane lipid composition in cell-cell fusion.</title><p>(<bold>A</bold>) Summary of 7-point dose-response for top-80 inhibitors in indicated heterokaryon assay (ACE2-U2OS vs. VeroE6). Asterisks reference compounds tested and validated by re-purchase from independent manufacturers. Heat-map indicates relative compound potency (bright red = higher). (<bold>B</bold>) Dose-response relationships for compounds (grouped by colored box) present in multiple small molecule libraries, each of whose replicates were identified as top-80 inhibitory hits. Mean and SEM: n = 3 biological replicates (16 images per).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>A drug repurposing screen implicates membrane lipid composition in cell-cell fusion.</title><p>(<bold>A</bold>) Analysis and comparison of 20 physicochemical properties for non-hit and hit libraries. P-values assessed with a Mann-Whitney U test. Dark and light blue represent p-values&lt;0.001 and&lt;0.05, respectively. White indicates no significant differences. (<bold>B</bold>) Similar to (<bold>A</bold>), but inhibitory hits vs. a control GPCR inhibitor library obtained from literature. (<bold>C</bold>) List of top-10 most frequent scaffolds and substructures in the hit library as analyzed by Scaffold Hopper and RDKit Substructure Search, respectively. Enrichment significance relative to the starting library was assessed with two-tailed Z-scores used to calculate p-values. Dark and light blue represent p-values&lt;0.001 and&lt;0.05, respectively. White indicates no significant differences.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig4-figsupp2-v2.tif"/></fig></fig-group><p>Given their unusually high EC<sub>50</sub> (&gt;10 μM) (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>) and the rapid kinetics of fusion, identified small molecules might act directly on the lipid bilayer (<xref ref-type="bibr" rid="bib140">Tsuchiya, 2015</xref>), possibly by virtue of shared physicochemical or structural features. To assess this, we compared 20 physicochemical parameters (ChemAxon) for non-hits vs. hits, using GPCR inhibitors (~35% of FDA-approved drugs) (<xref ref-type="bibr" rid="bib131">Sriram and Insel, 2018</xref>) as a control library (<xref ref-type="fig" rid="fig4">Figure 4D</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A,B</xref>). Among several statistically significant differences, hits were more lipophilic (LogD) and featured a greater number of ring systems (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Reassuringly, little correlation was observed between EC<sub>50</sub> values and lipophilicity (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), indicating that the trend is not a result of a general increase in lipophilicity with avidity, as is commonly observed for promiscuous compounds in phenotypic screens (<xref ref-type="bibr" rid="bib134">Tarcsay and Keserű, 2013</xref>).</p><p>Next, we asked whether specific chemical scaffolds are over-represented in hit compounds relative to ineffective compounds (<xref ref-type="fig" rid="fig4">Figure 4F</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). Two scaffold classes (and corresponding substructures) reached particularly high statistical enrichment: dicholorophenethyl-imidazoles (found in azole antifungals) and tetrahydropyran-containing macrocyclic lactones (found in both ivermectin- and rapamycin-like compounds) (<xref ref-type="fig" rid="fig4">Figure 4C,F</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). Such molecules can directly interact with the plasma membrane (<xref ref-type="bibr" rid="bib46">François et al., 2009</xref>), perturbing cholesterol (e.g. production, transport) (<xref ref-type="bibr" rid="bib2">Bauer et al., 2018</xref>; <xref ref-type="bibr" rid="bib98">Mast et al., 2013</xref>; <xref ref-type="bibr" rid="bib139">Trinh et al., 2017</xref>; <xref ref-type="bibr" rid="bib155">Xu et al., 2010</xref>), and have been implicated as promising repurposed drugs for COVID-19 treatment, albeit by different mechanism of action (<xref ref-type="bibr" rid="bib12">Caly et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Gordon et al., 2020</xref>; <xref ref-type="bibr" rid="bib76">Kindrachuk et al., 2015</xref>; <xref ref-type="bibr" rid="bib115">Rajter et al., 2021</xref>).</p></sec><sec id="s2-5"><title>Highly unusual membrane-proximal regions of spike are needed for fusion</title><p>Based on the prevalence of lipophilic hits from the small-molecule screen, we posited that membrane-proximal regions of spike and/or ACE2 associate with essential plasma membrane lipids (e.g. cholesterol) to facilitate cell-cell fusion. To test this, we replaced the transmembrane and cytoplasmic domains of both ACE2 and spike with the previously used B7 TM (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). While ‘chimeric’ ACE2 similarly promoted cell fusion relative to wild-type (WT), chimeric spike protein lost this ability (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). To determine critical elements that differentiate WT and chimeric spike from one another, we mutated its transmembrane (TM) and cytoplasmic domains (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), assessing fusion in co-culture models (<xref ref-type="fig" rid="fig1">Figures 1A</xref> and <xref ref-type="fig" rid="fig3">3A</xref>). Replacement of spike’s transmembrane domain with single-pass TMs of unrelated proteins (B7, ITGA1) blocked fusion, despite similar subcellular localization and ACE2-binding (<xref ref-type="fig" rid="fig5">Figure 5C,L</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–C</xref>). Inclusion of a small extracellular motif of B7 not only eliminated fusion, but also impaired the ability of the chimeric spike to form synapse-like clusters with ACE2 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). This is likely indicative of an essential role of spike’s membrane-proximal aromatic residues in cholesterol engagement (<xref ref-type="bibr" rid="bib66">Hu et al., 2019a</xref>), as suggested by work on related coronaviruses (<xref ref-type="bibr" rid="bib27">Corver et al., 2009</xref>; <xref ref-type="bibr" rid="bib35">de Jesus and Allen, 2013</xref>; <xref ref-type="bibr" rid="bib44">Epand et al., 2003</xref>; <xref ref-type="bibr" rid="bib91">Liao et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Lu et al., 2008b</xref>; <xref ref-type="bibr" rid="bib103">Meher et al., 2019</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Highly unusual membrane-proximal regions of spike are needed for fusion.</title><p>(<bold>A</bold>) Representative images of co-cultured (24 hr) U2OS cell lines, stably expressing indicated fluorescently tagged ACE2 or spike. ‘B7 TM’ indicates swap of endogenous transmembrane (TM) and cytoplasmic domain (CTD) of spike or ACE2 with that of the monomeric, single-pass, B7 transmembrane protein, along with its membrane-proximal extracellular region (30-amino acid spacer). White asterisks indicate nuclei in syncytia; red, in isolation. Note lack of arrowheads (synapses) in middle condition. See <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> for residue composition of such ‘chimeric’ proteins. (<bold>B</bold>) Graphical representation of SARS-CoV-2 spike’s TM alpha-helix and membrane-proximal regions, with residues colored by chemical properties (yellow, aromatic; cysteine, magenta; hydrophobic, gray; non-charged hydrophilic, green; charged hydrophilic; blue; proline, red). Of note: aromatic-rich region at ectodomain-TM interface, cysteine-rich cytoplasmic domain (CTD). (<bold>C</bold>) ACE2-U2OS heterokaryon assay but with co-cultured HNRNPA1-EYFP cells expressing spike variants (indicated). Relative CTD cysteine content for variants is depicted with heat map (top; dark red = more cysteines, white = none). Mean and SEM: n = 4 biological replicates (16 images per). See <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref> for all tested spike variants in both ACE2-U2OS and VeroE6 heterokaryon assays; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>, for representative images of ACE2-mCherry U2OS cells co-cultured with GFP-tagged spike variants. p-values of &lt;0.01, &lt;0.001, and &lt;0.0001 are represented by *, **, and ***, respectively. (<bold>D</bold>) Cartoon representation of SARS-CoV-2 spike with highest cysteine content in a 20-amino acid sliding window, which guided bioinformatic analyses shown in (<bold>E–H</bold>). (<bold>E</bold>) Schematic of bioinformatic analysis performed, whereby 20-residue windows around the N- and C-terminal sides of transmembrane helices were scanned for local cysteine density. Pie charts: summary of total set of viral proteins retrieved and analyzed for the human virus proteome (left) and human proteome (right); green slice references proportion of proteins with one or more predicted transmembrane helixes. (<bold>F</bold>) Conservation of cysteine-rich CTD between spike proteins of highly pathogenic human coronaviruses. The only difference between the CTD of SARS-CoV-1 and SARS-CoV-2 is acquisition of an additional cysteine in the latter. MERS is substantially different, yet retains enrichment of cysteines. (<bold>G</bold>) Histogram of fractional cysteine scores for viral proteins, with high-fraction hits explicitly annotated. SARS-CoV-2 spike protein has the highest local cysteine density of any viral protein, closely followed by spike proteins from other coronaviruses. (<bold>H</bold>) Similar to (<bold>G</bold>), but for human proteins with one or more predicted transmembrane helix. Red: ‘spike-like’ transmembrane proteins with high cytoplasmic cysteine content and aromatic residues at ectodomain-membrane interface. (<bold>I</bold>) Similar to (<bold>C</bold>), but using spike variants with cysteines mutated to alanine (2 of 10 vs. 10 of 10). (<bold>J</bold>) Representative images for 24 hr co-culture of ACE2-mCherry (magenta) U2OS cells with those expressing GFP-tagged spike variant (green). White asterisks indicate nuclei in syncytia; red, those in isolation; arrowhead, synapses (select examples noted). (<bold>K</bold>) Dose-response relationship for 2-bromopalmitate (2-BP, inhibitor of cysteine palmitoylation), in both ACE2-U2OS (top) and VeroE6 (bottom) heterokaryon assays. Blue indicates number of nuclei (proxy for toxicity); black, percent cells fused; both normalized to DMSO control. Mean and SEM: n = 4 biological replicates (16 images per). (<bold>L</bold>) Similar to (<bold>C</bold>), but assesses kinetics of fusion by varying co-culture time prior to fixation. See <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref> for other tested spike variants. See also <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>; <xref ref-type="supplementary-material" rid="supp2">Supplementary files 2</xref>–<xref ref-type="supplementary-material" rid="supp4">4</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Highly unusual membrane-proximal regions of spike are needed for fusion.</title><p>(<bold>A</bold>) ACE2-U2OS heterokaryon assay, but assesses kinetics of fusion by varying length of co-culture with spike variant (indicated)-expressing HNRNPA1-EYFP cells. Mean and SEM: n = 4 biological replicates (16 images per). (<bold>B</bold>) Similar to (<bold>A</bold>) but for all studied spike variants at a single time-point (5 hr) and examined in both ACE2-U2OS (top) and VeroE6 (bottom) heterokaryon assays. Mean and SEM: n = 4 biological replicates (16 images per). p-values of &lt;0.01, &lt;0.001, and &lt;0.0001 are represented by *, **, and ***, respectively. (<bold>C</bold>) Representative images of ACE2-mCherry (magenta) cells co-cultured for 24 hr with U2OS cells expressing GFP-tagged spike variant (green, labeled). White asterisks indicate nuclei in syncytia; red, in isolation; arrowhead, synapses between cells (select examples noted). (<bold>D</bold>) Top: Gene ontology (PantherDB) for cysteine-rich human transmembrane (TM) proteins, assessing significance of enrichment relative to the entire human proteome. Bottom: similar but for ‘spike-like’ human proteins (aromatics at TM interface, high cysteine content in cytoplasm CTD).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig5-figsupp1-v2.tif"/></fig></fig-group><p>In parallel, we serially truncated the spike cytoplasmic domain (CTD). Removal of its COPII-binding, ER-Golgi retrieval motif (<xref ref-type="bibr" rid="bib15">Cattin-Ortolá et al., 2020</xref>; <xref ref-type="bibr" rid="bib100">McBride et al., 2007</xref>) (1–1268) had no effect, nor did deletion of its subsequent acidic patch (1–1256) (<xref ref-type="fig" rid="fig5">Figure 5C,L</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–C</xref>). However, removal of an additional 11 amino acids (1–1245) decreased fusion, and further truncation (1–1239) completely blocked it (<xref ref-type="fig" rid="fig5">Figure 5C,L</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–C</xref>). Relative fusion correlated with overall cysteine content of the CTD (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). These findings are consistent with previous studies on similar coronaviruses, which suggested that membrane-proximal cysteines are post-translationally modified with palmitoylated lipid moieties (<xref ref-type="bibr" rid="bib101">McBride and Machamer, 2010a</xref>; <xref ref-type="bibr" rid="bib113">Petit et al., 2007</xref>; <xref ref-type="bibr" rid="bib127">Sobocińska et al., 2017</xref>).</p><p>Palmitoylated proteins typically feature only a few cysteines available for modification (<xref ref-type="bibr" rid="bib21">Chlanda et al., 2017</xref>; <xref ref-type="bibr" rid="bib149">Wan et al., 2007</xref>). We wondered whether spike CTD’s peculiarly high cysteine content was unique amongst viral proteins, and performed a bioinformatic analysis of all viral transmembrane proteins, ranking them on maximal cysteine content in 20 amino-acid sliding windows (<xref ref-type="fig" rid="fig5">Figure 5D–G</xref>). Of all proteins in viruses that infect humans, SARS-CoV-2 spike features the highest cysteine content, followed closely by spike proteins in related coronaviruses, then hepatitis E ORF3 (<xref ref-type="fig" rid="fig5">Figure 5G</xref>; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>); it should be noted that ORF3 is palmitoylated and critical to viral egress (<xref ref-type="bibr" rid="bib36">Ding et al., 2017</xref>; <xref ref-type="bibr" rid="bib53">Gouttenoire et al., 2018</xref>). Consistent with studies on similar coronavirus spike proteins (<xref ref-type="bibr" rid="bib90">Liao et al., 2006</xref>; <xref ref-type="bibr" rid="bib101">McBride and Machamer, 2010a</xref>; <xref ref-type="bibr" rid="bib113">Petit et al., 2007</xref>), mutagenesis of all spike cysteines to alanine severely diminishes cell-cell fusion in both U2OS and Vero models (<xref ref-type="fig" rid="fig5">Figure 5I–L</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B–C</xref>). To examine the role of cysteine palmitoylation, we assessed fusion upon treatment with palmitoylation inhibitor, 2-bromopalmitate (2-BP) (<xref ref-type="bibr" rid="bib97">Martin, 2013</xref>). The effect was modest in U2OS cells, but more pronounced in Vero cells, suggesting that cysteine palmitoylation is indeed likely central (<xref ref-type="fig" rid="fig5">Figure 5K</xref>). However, we note that the EC50 for 2-BP is typically 10–15 μM (<xref ref-type="bibr" rid="bib164">Zheng et al., 2013</xref>), which is lower than our obtained values. One possibility for the discrepancy is that our co-cultures are performed at high density, and synapse formation is fast (time scale of minutes) relative to biochemical pathways that modify subcellular localization (e.g. post-translational palmitoylation). Given the relatively modest and cell type-dependent effect of 2-BP treatment, future work using biochemical approaches will be required to confirm the role of palmitoylation and the precise mechanism by which spike’s aromatic-rich transmembrane domain associates with cholesterol to drive membrane fusion.</p><p>Inspired by the synapse-like structures observed in living cells (<xref ref-type="fig" rid="fig1">Figure 1</xref>), we asked whether SARS-CoV-2 spike features amino acid motifs similar to human proteins that drive similar assemblies. Of the thousands of human transmembrane proteins, only 15 were ‘spike-like’, featuring both high membrane-proximal cysteine and aromatic content (<xref ref-type="fig" rid="fig5">Figure 5H</xref>; <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Remarkably, the top four are all critical to forming specific types of adhesion junctions: three to tricellular tight junctions (ILDR1, ILDR2, LSR) and one to kidney/intestine tight junctions (IGSF5) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>; <xref ref-type="bibr" rid="bib60">Higashi et al., 2013</xref>; <xref ref-type="bibr" rid="bib61">Hirabayashi et al., 2003</xref>). In light of the important role for palmitoylation in tricellular tight junction assembly (<xref ref-type="bibr" rid="bib108">Oda et al., 2020</xref>), these findings suggest that SARS-CoV-2 may operate by a similar mechanism to promote adhesion and transcellular interfaces, an exciting possibility to be explored in future studies.</p></sec><sec id="s2-6"><title>Spike requires membrane cholesterol for fusion but via a raft-independent mechanism</title><p>Together, these data suggest that membrane fusion requires spike association with specific elements of the plasma membrane. If so, such assemblies would display slow dynamics relative to transmembrane proteins that more freely diffuse in the two-dimensional lipid bilayer. To test this idea, we utilized fluorescence recovery after photobleaching (FRAP) to determine the recovery rate of a fluorescent molecule in a bleached region, and thereby infer relative molecular diffusion coefficients (<xref ref-type="bibr" rid="bib130">Soumpasis, 1983</xref>). FRAP experiments were performed on a series of GFP-tagged spike variants and controls (B7 TM and ACE2) to determine whether its transmembrane domain and/or cysteine-rich CTD influence diffusion. Recovery for GFP-tagged ACE2, B7 TM-anchored RBD, and the B7 transmembrane control were similar (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), approximating diffusion times for commonly studied transmembrane proteins (<xref ref-type="bibr" rid="bib32">Day et al., 2012</xref>). In contrast, RBD attached to the native TM/CTD of spike featured significantly reduced recovery, with FL spike displaying even slower dynamics (<xref ref-type="fig" rid="fig6">Figure 6A–C</xref>). Swapping the B7 TM for spike TM/CTD rescued the rapid recovery, whereas exchange of just the TM or removal of cysteine-containing regions had an intermediate effect (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Conversely, deletion of regions shown to bind specific intracellular proteins (e.g. COPII-binding ER-Golgi retrieval motif, 1268–1273) had no effect (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), implicating lipid-protein and not protein-protein interactions in spike’s dynamics.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Spike requires membrane cholesterol for fusion but via a raft-independent mechanism.</title><p>(<bold>A</bold>) Representative trial for fluorescence recovery after photobleaching (FRAP) of spike FL-GFP (green) on U2OS cell plasma membrane. Time since bleach (lightning bolt) of region of interest (red circle) is indicated. (<bold>B</bold>) Quantification of (<bold>A</bold>) and related trials, with each colored line specifying a separate FRAP experiment (n = 6 total). (<bold>C</bold>) Calculated half maximal fluorescence recovery (t<sub>1/2</sub>) for indicated GFP-tagged spike variants. Each hollow red dot indicates the t<sub>1/2</sub> for a single FRAP trial. Mean and SEM: n = 4–6 technical replicates (one per cell). Heat map (top): relative cysteine content of tested spike variant (dark red = high cysteine content, white = none). (<bold>D</bold>) Ex vivo phase separation assay for relative partitioning (K<sub>p</sub>) into lipid raft ordered phase (L<sub>o</sub>) of giant plasma membrane vesicles (GPMVs). Left: quantification of GFP-tagged protein K<sub>p</sub> with DHPE serving as lipid raft/L<sub>o</sub> marker; AnnV, non-raft/L<sub>d</sub> protein marker; LAT, raft/L<sub>o</sub> protein marker. Mean and SEM: n = 3 biological replicates (colored dot;&gt;10 GPMV technical replicates per). Right: representative images. (<bold>E</bold>) U2OS cells expressing spike-GFP (yellow) and SCARB1-iRFP (cyan) were co-cultured with ACE2-mCherry (magenta) cells and cell-cell fusion events were captured with live cell microscopy. Representative images show co-localization between spike and SCARB1 at synapses that precede fusion (top, arrow); and in extracellular deposits (bottom). Scale-bar, 5 µm. See <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A,B</xref> for individual fluorescence channels. (<bold>F</bold>) Graphical schematic for ACE2-U2OS assay dose-response and interpretation. Fraction of cells fused (black curve) relative to cell count (blue curve), both normalized by the plate negative control, indicates compound effectiveness (pink, strong inhibitor; gray, weak inhibitor; white, no-effect; green, enhancer). (<bold>G</bold>) Lack of dose-dependent inhibition of fusion by sphingolipid-depleting, and raft-disrupting drug, myriocin, in ACE2-U2OS heterokaryon assay. Mean and SEM: n = 4 biological replicates (16 images per). (<bold>H</bold>) Similar to (<bold>G</bold>), but measuring effect of cholesterol-lowering drugs in ACE2-U2OS heterokaryon assay. Mean and SEM: n = 4 biological replicates (16 images per). (<bold>I</bold>) Similar to (<bold>G</bold>), but with MBCD-conjugated cholesterol, which increases plasma membrane cholesterol content. See <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref> for controls (i.e. other MBCD-conjugated lipids). (<bold>J</bold>) Similar to (<bold>G</bold>), but testing potential fusion-enhancing compounds (see <xref ref-type="fig" rid="fig4">Figure 4B</xref>, gray inset), which include allylamine antifungals (e.g. naftifine) and anesthetics (e.g. bupivacaine, propofol). See <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref> for similar effects by other small molecules belonging to these compound classes. See also <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>; <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Spike requires membrane cholesterol for fusion via a raft-independent mechanism.</title><p>(<bold>A</bold>) Individual fluorescence channels for merge image shown in <xref ref-type="fig" rid="fig6">Figure 6E</xref> (top). Arrow indicates co-localization between cholesterol-binding protein SCARB1-iRFP (cyan) and spike-GFP (yellow) at transcellular synapses. (<bold>B</bold>) Individual fluorescence channels for merge image shown in <xref ref-type="fig" rid="fig6">Figure 6E</xref> (bottom). (<bold>C</bold>) Representative images of extracellular membrane deposits that contain both cholesterol (CholEsteryl-BODIPY stain, orange) and spike-GFP (green). (<bold>D</bold>) Graphical schematic for ACE2-U2OS assay dose-response and interpretation. Fraction of cells fused (black curve) relative to cell count (blue curve), both normalized by the plate negative control, indicates compound effectiveness (pink, strong inhibitor; gray, weak inhibitor; white, no-effect; green, enhancer). (<bold>E</bold>) Dose-response analysis of control MBCD-conjugated lipids in ACE2-U2OS heterokaryon assay. Black line indicates fraction of cells fused; blue, cell count (toxicity measure); both of which are normalized to DMSO negative control. Mean and SEM: n = 4 biological replicates (16 images per). (<bold>F</bold>) Similar to (<bold>E</bold>), but with compounds predicted by drug repurposing screen to enhance fusion. Drug class indicated.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Given that membrane-proximal regions (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>) of spike regulate diffusivity and fusogen behavior, an intriguing possibility is that such features conspire to facilitate engagement of cholesterol-rich membrane domains (or ‘lipid rafts’) (<xref ref-type="bibr" rid="bib85">Levental et al., 2020</xref>; <xref ref-type="bibr" rid="bib112">Pelkmans and Helenius, 2003</xref>; <xref ref-type="bibr" rid="bib126">Simons and Ikonen, 1997</xref>). Our findings on the requirement for spike’s cysteine residues in fusion is interesting in this context, since palmitoylation of other proteins can drive association with these 10–50 nm protein-lipid clusters in the plasma membrane (<xref ref-type="bibr" rid="bib83">Levental et al., 2010</xref>). While challenging to study in living cells, lipid rafts can be readily interrogated using ex vivo, phase separation assays as a micron-scale proxy for cholesterol association at the nano-scale (<xref ref-type="bibr" rid="bib86">Levental and Levental, 2015</xref>; <xref ref-type="bibr" rid="bib144">Veatch, 2007</xref>; <xref ref-type="bibr" rid="bib146">Veatch and Keller, 2003</xref>). A particularly powerful example employs chemical-induced giant plasma membrane vesicles (GPMVs) from cells expressing a protein of interest (e.g. spike-GFP), allowing membrane components to reach equilibrium at reduced temperature (<xref ref-type="bibr" rid="bib3">Baumgart et al., 2007</xref>; <xref ref-type="bibr" rid="bib65">Holowka and Baird, 1983</xref>; <xref ref-type="bibr" rid="bib82">Levental et al., 2009</xref>; <xref ref-type="bibr" rid="bib120">Sengupta et al., 2008</xref>; <xref ref-type="bibr" rid="bib145">Veatch et al., 2008</xref>). Given previous results using indirect detergent fractionation readouts (<xref ref-type="bibr" rid="bib102">McBride and Machamer, 2010b</xref>; <xref ref-type="bibr" rid="bib113">Petit et al., 2007</xref>), we were surprised to observe that SARS-CoV-2 spike does not partition strongly into GPMVs’ dense, ordered phase (L<sub>o</sub>) (<xref ref-type="fig" rid="fig6">Figure 6D</xref>), which is enriched for cholesterol and sphingolipids (<xref ref-type="bibr" rid="bib82">Levental et al., 2009</xref>; <xref ref-type="bibr" rid="bib84">Levental et al., 2011</xref>). Moreover, in our cell fusion assay, treatment with the raft-disrupting drug myriocin, which depletes sphingolipids from the plasma membrane (<xref ref-type="bibr" rid="bib14">Castello-Serrano et al., 2020</xref>), did not inhibit fusion (<xref ref-type="fig" rid="fig6">Figure 6F,G</xref>). Thus, SARS-CoV-2 spike protein facilitates membrane-fusion in a manner that could be dependent on palmitoylation of its uniquely cysteine-rich CTD, but through a mechanism unique from canonical membrane nanodomains, although we cannot rule out a discrepancy in lipid raft properties between GPMVs and living cells (<xref ref-type="bibr" rid="bib85">Levental et al., 2020</xref>).</p><p>Despite lack of partitioning into the cholesterol-rich ordered phase of GPMVs, we noted that long-term culture caused spike (but not ACE2) to accumulate in immobile deposits on the glass surface of the culture dish (<xref ref-type="fig" rid="fig6">Figure 6E</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Recent studies determined that cholesterol-rich membrane components are particularly prone to sloughing from the cell and sticking to glass surfaces (<xref ref-type="bibr" rid="bib57">He et al., 2018</xref>; <xref ref-type="bibr" rid="bib67">Hu et al., 2019b</xref>). We thus co-expressed the cholesterol-binding protein SCARB1 (<xref ref-type="bibr" rid="bib93">Linton et al., 2017</xref>) with spike or stained spike cells with fluorescently labeled cholesterol. Both cholesterol markers co-localized with immobilized spike deposits (<xref ref-type="fig" rid="fig6">Figure 6E</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A–C</xref>). Taken together, the data suggests that spike potentially associates with a specific population of cholesterol, which is biochemically distinct from the sphingomyelin-associated lipid complexes enriched in canonical rafts (<xref ref-type="bibr" rid="bib30">Das et al., 2014</xref>; <xref ref-type="bibr" rid="bib42">Endapally et al., 2019a</xref>; <xref ref-type="bibr" rid="bib77">Kinnebrew et al., 2019</xref>). Future studies will be needed to assess the nature of such cholesterol pools, potentially using toxin-based probes that discriminate between free and inaccessible forms (<xref ref-type="bibr" rid="bib30">Das et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Endapally et al., 2019b</xref>), and how each is affected by the identified lipophilic compounds (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>To interrogate the role of cholesterol in cell fusion, we tested drugs that disrupt cholesterol synthesis (zaragozic acid) or reduce plasma membrane cholesterol (25-hydroxycholesterol; methyl-beta-cyclodextrin or ‘MBCD’) in the U2OS-ACE2 heterokaryon assay. All compounds inhibited fusion in a dose-dependent manner (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). However, such drugs can indirectly lead to cholesterol-independent changes in membrane lipid composition, especially at high concentrations (<xref ref-type="bibr" rid="bib169">Zidovetzki and Levitan, 2007</xref>), and many require incubation periods longer than the duration of the cell-cell fusion assay to exert their full effect. To more directly study the role of cholesterol levels, we harnessed MBCD’s ability to shuttle specific lipids into the plasma membrane (<xref ref-type="bibr" rid="bib169">Zidovetzki and Levitan, 2007</xref>). Unlike MBCD-conjugated linoleic acid and oleic acid, cholesterol greatly enhanced fusion (<xref ref-type="fig" rid="fig6">Figure 6I</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D,E</xref>).</p><p>We surmised that the drug repurposing screen identified compounds that act similarly, thus implicating a counteracting plasma membrane property that increases fusion. Indeed, a small subset of compounds, which include allylamine antifungals (naftifine and terbinafine) and anesthetics (ropivacaine, bupivacaine, propofol), enhance fusion in a dose-dependent manner (<xref ref-type="fig" rid="fig6">Figure 6J</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>). Whether this is related to an opposing effect on lipid bilayer composition and dynamics relative to drugs that reduce fusion requires further inquiry using a suite of biophysical approaches. However, the latter possibility is intriguing in light of extensive literature on anesthetics and membrane mobility (<xref ref-type="bibr" rid="bib26">Cornell et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Goldstein, 1984</xref>; <xref ref-type="bibr" rid="bib55">Gray et al., 2013</xref>; <xref ref-type="bibr" rid="bib141">Tsuchiya and Mizogami, 2013</xref>).</p></sec><sec id="s2-7"><title>SARS-CoV-2 infection depends on membrane cholesterol of the virus but not the host cell</title><p>Our findings on ACE2/spike-mediated fusion, using both U2OS and VeroE6 cells, suggest that many effective compounds prevent fusion by depleting cholesterol from the plasma membrane (<xref ref-type="fig" rid="fig6">Figure 6</xref>). While the relevance of such drugs for syncytium formation and disease pathogenesis in vivo remains circumstantial (<xref ref-type="fig" rid="fig2">Figure 2</xref>), the data nonetheless has implications for virus assembly and entry. Specifically, we predict that such compounds would lack efficacy in virus entry models (<xref ref-type="bibr" rid="bib20">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Dittmar et al., 2020</xref>; <xref ref-type="bibr" rid="bib116">Riva et al., 2020</xref>; <xref ref-type="bibr" rid="bib151">Wei et al., 2020</xref>; <xref ref-type="bibr" rid="bib168">Zhu et al., 2020b</xref>), instead requiring perturbation of the spike-containing virus membrane derived from the donor cell. To test this, we quantified spike-pseudotyped MLV particle entry into ACE2/TMPRSS2-expressing A549 acceptor cells (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), which are primarily infected via the direct fusion pathway (<xref ref-type="bibr" rid="bib63">Hoffmann et al., 2020b</xref>; <xref ref-type="bibr" rid="bib125">Shirato et al., 2018</xref>; <xref ref-type="bibr" rid="bib168">Zhu et al., 2020b</xref>). Apilimod, a PIKFYVE inhibitor and promising therapeutic in multiple SARS-CoV-2 models (<xref ref-type="bibr" rid="bib72">Kang et al., 2020</xref>; <xref ref-type="bibr" rid="bib116">Riva et al., 2020</xref>) including heterokaryon assays tested herein (<xref ref-type="fig" rid="fig3">Figure 3E</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>), inhibited (but did not completely block) entry at nanomolar concentrations (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). This may indicate that multiple pathways (i.e. endocytic and direct fusion) are used to enter A549-ACE2/TMPRSS2 cells, which will be important to determine in future studies. By contrast, 25-hydroxycholesterol, which lowers plasma membrane cholesterol by redirection to the cell interior (<xref ref-type="bibr" rid="bib1">Abrams et al., 2020</xref>; <xref ref-type="bibr" rid="bib69">Im et al., 2005</xref>; <xref ref-type="bibr" rid="bib150">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib158">Yuan et al., 2020</xref>; <xref ref-type="bibr" rid="bib159">Zang et al., 2020a</xref>; <xref ref-type="bibr" rid="bib168">Zhu et al., 2020b</xref>; <xref ref-type="bibr" rid="bib171">Zu et al., 2020</xref>), had no effect (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). However, MBCD, which directly ‘strips’ plasma membrane cholesterol without engaging intracellular targets (<xref ref-type="bibr" rid="bib169">Zidovetzki and Levitan, 2007</xref>), blocked virus entry (<xref ref-type="fig" rid="fig7">Figure 7D</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>SARS-CoV-2 infection depends on membrane cholesterol of the virus but not the host cell.</title><p>(<bold>A</bold>) Schematic representation of pseudotyped virus entry assay in ACE2/TMPRSS2-expressing A549 acceptor cells, which are primarily infected via direct fusion pathway. Pseudovirus encodes <italic>Gaussia</italic> luciferase gene, which allows luminescence-based measure of relative entry as a function of compound concentration. (<bold>B</bold>) Dose-dependent inhibition of pseudovirus entry (luminescence, arbitrary units) for a positive control compound (apilimod, PIKFYVE inhibitor), relative to control (1 = no effect; 0 = complete block). Mean and SEM indicated for six replicates. P-values of &lt;0.05, &lt;0.01, &lt;0.001, and &lt;0.0001 are represented by *, **, *** and ****, respectively. (<bold>C</bold>) Similar to (<bold>B</bold>), but for cholesterol-transport disrupting drug, 25-hydroxycholesterol. (<bold>D</bold>) Similar to (<bold>B</bold>), but for plasma membrane cholesterol-stripping compound, MBCD. (<bold>E</bold>) Schematic of SARS-CoV-2 infection assays in ACE2/TMPRSS2 A549 acceptor cells. Relative infection is determined by RT-qPCR or immunohistochemistry of the SARS-CoV-2 nucleocapsid protein (N). (<bold>F</bold>) Representative immunofluorescence (nucleocapsid protein, red; nuclei/DAPI, blue) of A549 cells, 48 hr post-infection by SARS-CoV-2. Top: cells pre-treated with indicated dose of MBCD, followed by wash; bottom: pre-treatment of virus. (<bold>G</bold>) Similar to (<bold>F</bold>), but using RT-qPCR to quantify viral titer (RNA copies per mL cell media) following MBCD-treatment of virus (top) or cells (bottom). Identical controls plotted on both graphs for visualization purposes: UT = untreated cells, NI = non infected cells. Mean and SEM indicated for n = 4 independent biological replicates (black dots). p-values of &lt;0.05 and&lt;0.01 are represented by * and **, respectively. (<bold>H</bold>) Graphical model of the biomolecular interactions required for SARS-CoV-2 spike-mediated membrane fusion. Bottom: palmitoylated cysteines (blue) act as multivalent membrane contacts, anchoring trimeric spike peplomers (green) to the phospholipid bilayer (black) and potentially allowing transient higher order assemblies of trimers. Aromatic residues (e.g. tryptophans) at the spike ectodomain-membrane interface associate with accessible cholesterol (yellow) to promote synapse-like clusters with ACE2 receptors (red) on apposing membranes. Without these collective interactions, spike’s fusion machinery (e.g. fusion peptide and heptad repeats) is unable to surmount the energetically costly barrier to lipid bilayer mixing, both in virus-cell (top, left) and cell-cell fusion (top, right).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65962-fig7-v2.tif"/></fig><p>Given the relative potency of MBCD in the pseudovirus entry model vs. syncytia assays (<xref ref-type="fig" rid="fig6">Figure 6H</xref>, <xref ref-type="fig" rid="fig7">7D</xref>), we hypothesized that it acts by depleting cholesterol from the viral membrane and not the host cell. To discriminate these possibilities, we used the same ACE2/TMPRSS2-expressing A549 cell line, but with a clinical isolate of SARS-CoV-2 virus (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). Addition of virus in absence of drug resulted in significant infection of the cell layer, with many cells appearing as multi-nucleated following infection (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). Pre-treatment of cells with millimolar doses of MBCD, which strongly inhibits both co-culture syncytia formation and pseudovirus entry, had no effect on infection as determined by RT-PCR and immunohistochemistry (<xref ref-type="fig" rid="fig7">Figure 7F,G</xref>). In striking contrast, pre-treatment of SARS-CoV-2 with low micromolar MBCD completely blocked infection (<xref ref-type="fig" rid="fig7">Figure 7F,G</xref>). Therefore, cholesterol content of SARS-CoV-2 viral particles, but not the host cell, is critical to infectivity (<xref ref-type="fig" rid="fig7">Figure 7H</xref>). However, the molecular basis of this cholesterol-dependent infectivity, that is whether it indeed results specifically from cholesterol-dependent spike fusogenicity or includes contributions from confounding effects such as large-scale virus permeabilization (<xref ref-type="bibr" rid="bib54">Graham et al., 2003</xref>), remains to be determined.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Unprecedented resources devoted to the COVID-19 pandemic have allowed identification of promising stopgap therapeutic measures, as reaching effective vaccination coverage among populations will take time. Moreover, the global health impact of COVID-19 will linger for many years, since vaccination programs lag behind in developing nations, and vaccine-evading SARS-CoV-2 variants are constantly evolving (<xref ref-type="bibr" rid="bib31">Davies et al., 2021</xref>; <xref ref-type="bibr" rid="bib152">Wibmer et al., 2021</xref>). Virus entry-based assays were particularly critical to discovering essential receptors (ACE2) and proteases for SARS-CoV-2 infection, along with promising repurposed drugs (<xref ref-type="bibr" rid="bib37">Dittmar et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib63">Hoffmann et al., 2020b</xref>; <xref ref-type="bibr" rid="bib81">Lan et al., 2020</xref>; <xref ref-type="bibr" rid="bib109">Ou et al., 2020</xref>; <xref ref-type="bibr" rid="bib116">Riva et al., 2020</xref>; <xref ref-type="bibr" rid="bib122">Shang et al., 2020</xref>; <xref ref-type="bibr" rid="bib148">Walls et al., 2020</xref>; <xref ref-type="bibr" rid="bib151">Wei et al., 2020</xref>; <xref ref-type="bibr" rid="bib153">Wrapp et al., 2020</xref>; <xref ref-type="bibr" rid="bib157">Yan et al., 2020</xref>; <xref ref-type="bibr" rid="bib168">Zhu et al., 2020b</xref>). However, many fundamental aspects of the SARS-CoV-2 infectious cycle remain poorly understood, hampering efforts for effective treatment. In particular, commonly used approaches are poorly equipped to interrogate factors that contribute to the formation of a fusion-competent virus, particularly in a high-throughput manner amenable to both small molecule and genetic screens. Here, we show that in vitro SARS-CoV-2 spike and ACE2 cell co-culture assays overcome this limitation, and uncover a critical role for viral membrane composition in infection and formation of pathological syncytia.</p><p>Our approach relies on a combination of high-throughput screening, quantitative live cell imaging, and viral infection assays, all of which implicate biophysical aspects of the plasma membrane, particularly cholesterol-rich regions, in facilitating spike-mediated membrane fusion. While consistent with pioneering work on related coronaviruses (<xref ref-type="bibr" rid="bib16">Cervin and Anderson, 1991</xref>; <xref ref-type="bibr" rid="bib33">Daya et al., 1988</xref>) as well as more recent studies on SARS-CoV-2 (<xref ref-type="bibr" rid="bib150">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib158">Yuan et al., 2020</xref>; <xref ref-type="bibr" rid="bib159">Zang et al., 2020a</xref>; <xref ref-type="bibr" rid="bib168">Zhu et al., 2020b</xref>; <xref ref-type="bibr" rid="bib171">Zu et al., 2020</xref>), our approach allows unprecedented live cell access into the initial steps of membrane fusion. Further, our novel high-throughput cell-cell fusion assay not only negates safety concerns associated with a deadly virus, but may allow rapid interrogation of the pathogenic nature of newly emerging spike variants (<xref ref-type="bibr" rid="bib31">Davies et al., 2021</xref>; <xref ref-type="bibr" rid="bib152">Wibmer et al., 2021</xref>).</p><p>Cholesterol is known to preferentially interact with certain membrane proteins, particularly those modified with specific lipid moieties (e.g. palmitic acid) (<xref ref-type="bibr" rid="bib83">Levental et al., 2010</xref>; <xref ref-type="bibr" rid="bib97">Martin, 2013</xref>; <xref ref-type="bibr" rid="bib127">Sobocińska et al., 2017</xref>), together clustering into nanodomains which have been referred to as lipid rafts (<xref ref-type="bibr" rid="bib85">Levental et al., 2020</xref>; <xref ref-type="bibr" rid="bib126">Simons and Ikonen, 1997</xref>; <xref ref-type="bibr" rid="bib147">Veatch and Keller, 2005</xref>). In the context of SARS-CoV-2 spike, such cholesterol-rich nanodomains could potentially facilitate the energetically-unfavorable process of lipid bilayer mixing (<xref ref-type="bibr" rid="bib59">Heald-Sargent and Gallagher, 2012</xref>; <xref ref-type="bibr" rid="bib75">Kim and Chen, 2019</xref>; <xref ref-type="bibr" rid="bib136">Tenchov et al., 2006</xref>). However, given its lack of partitioning into ordered GPMV domains (<xref ref-type="fig" rid="fig6">Figure 6D</xref>), spike may form nanoscale clusters by a different mechanism. A favored model is that an accessible population of cholesterol, independent of sphingolipids and rafts (<xref ref-type="bibr" rid="bib30">Das et al., 2014</xref>; <xref ref-type="bibr" rid="bib77">Kinnebrew et al., 2019</xref>), interacts directly with spike trimers and mediates formation of higher-order protein-lipid assemblies (<xref ref-type="fig" rid="fig7">Figure 7H</xref>). Precedent for this model is provided by raft-independent yet cholesterol-dependent mechanisms of biomolecular clustering essential for influenza infection (<xref ref-type="bibr" rid="bib52">Goronzy et al., 2018</xref>; <xref ref-type="bibr" rid="bib161">Zawada et al., 2016</xref>). Spike’s cysteine-rich CTD could further amplify this effect, potentially via palmitoylated moieties, or, by directly promoting dynamic protein oligomers, similar to what was recently described for the <italic>orthoreovirus</italic> p14 FAST protein (<xref ref-type="bibr" rid="bib17">Chan et al., 2020a</xref>). The interplay between oligomerization, palmitoylation, cholesterol association, and membrane dynamics, and how each of these properties are affected by compounds identified in our screen, will require additional methodologies beyond the scope of this study.</p><p>In strong support for a key role of lipid structure and composition in spike-mediated membrane fusion, many compound classes over-represented in our drug repurposing screen are implicated in perturbation of the lipid bilayer (e.g. antifungal azoles, rapalogs/mTOR inhibitors, ivermectin analogs) (<xref ref-type="fig" rid="fig4">Figure 4C–F</xref>; <xref ref-type="bibr" rid="bib2">Bauer et al., 2018</xref>; <xref ref-type="bibr" rid="bib58">Head et al., 2017</xref>; <xref ref-type="bibr" rid="bib94">Long et al., 2020</xref>; <xref ref-type="bibr" rid="bib98">Mast et al., 2013</xref>; <xref ref-type="bibr" rid="bib139">Trinh et al., 2017</xref>; <xref ref-type="bibr" rid="bib155">Xu et al., 2010</xref>). Interestingly, anti-fungals appear to be enriched in both fusion-inhibiting and -promoting hits. However, the latter tended to favor allylamines rather than azoles, implicating physicochemical and structural differences in direction of effect despite similar action on fungal ergosterol synthesis. We further note that our screen identified anesthetics as promoters of fusion (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig6">6J</xref>). This is intriguing, given that anesthetics are chemically diverse, hydrophobic molecules, which perturb lipid mobility and ordering in membranes (<xref ref-type="bibr" rid="bib26">Cornell et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Goldstein, 1984</xref>; <xref ref-type="bibr" rid="bib55">Gray et al., 2013</xref>; <xref ref-type="bibr" rid="bib141">Tsuchiya and Mizogami, 2013</xref>). Whether such similarities can be extended to other fusion-promoting compounds remains to be determined, as is the root membrane-based property that discriminates them from drugs that prevent syncytia formation.</p><p>Our high-throughput screening approach uses transcellular membrane fusion as a proxy for virus entry into the host cell. However, beyond a screening tool, we present findings that suggest direct pathological relevance for syncytia. Specifically, human cell populations expressing ACE2 or spike cause cellular pathology with unexpected parallels to COVID-19 patient histology, who feature pervasive multinucleated cells in lung tissue (<xref ref-type="fig" rid="fig2">Figure 2</xref>; <xref ref-type="bibr" rid="bib48">Giacca et al., 2020</xref>; <xref ref-type="bibr" rid="bib138">Tian et al., 2020</xref>). These COVID-19 patient syncytia are similar to those found in other respiratory viral infections (<xref ref-type="bibr" rid="bib47">Frankel et al., 1996</xref>; <xref ref-type="bibr" rid="bib70">Johnson et al., 2007</xref>; <xref ref-type="bibr" rid="bib99">Maudgal and Missotten, 1978</xref>). Whether COVID-19 syncytia arise by the cellular pathways described in this work is unclear, although recent data is supportive. For example, contemporary studies report syncytia in cultured cells following exposure to infectious SARS-CoV-2 (<xref ref-type="bibr" rid="bib10">Buchrieser et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Cattin-Ortolá et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib109">Ou et al., 2020</xref>; <xref ref-type="bibr" rid="bib110">Papa et al., 2020</xref>; <xref ref-type="bibr" rid="bib154">Xia et al., 2020</xref>; <xref ref-type="bibr" rid="bib160">Zang et al., 2020b</xref>), an observation that we extend to ACE2/TMPRSS2 A549 cells (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). Further, the synapses that precede fusion (<xref ref-type="fig" rid="fig1">Figure 1</xref>) superficially resemble the virus-filled filopodia observed following SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib7">Bouhaddou et al., 2020</xref>). We hypothesize that such structures arise via intercellular interactions between ACE2 and virus-unincorporated spike clusters, but cannot rule out the proposed kinase-based mechanism (<xref ref-type="bibr" rid="bib7">Bouhaddou et al., 2020</xref>).</p><p>Whether or not syncytia play a major role in COVID-19 disease progression, the fact that lipid-targeting drugs disrupt spike-mediated membrane fusion has implications for treatment. Indeed, cholesterol-tuned viral infectivity was similarly shown using both spike-pseudotyped MLV and patient isolates of SARS-CoV-2. These data provide strong evidence that viral spike-cholesterol association, and not lipid composition of the host cell membrane or resultant endocytic pathway, mediates effects reported in this study (<xref ref-type="fig" rid="fig7">Figure 7</xref>) and perhaps others (<xref ref-type="bibr" rid="bib168">Zhu et al., 2020b</xref>). Ultimately, viral membranes are produced from the membranes of infected host cells, suggesting that lipid-targeting treatments might disrupt formation of fusion-competent virus particles. Given the advanced state of hyperlipidemia drug development (e.g. statins) (<xref ref-type="bibr" rid="bib50">Goldstein and Brown, 2015</xref>), insights from this work may be of immediate significance for COVID-19 treatment. Consistent with this, retrospective analyses of patient outcomes observed significant reductions in mortality for those prescribed cholesterol-lowering statins (<xref ref-type="bibr" rid="bib29">Daniels et al., 2020</xref>; <xref ref-type="bibr" rid="bib163">Zhang et al., 2020</xref>). A critical role for cholesterol in virus assembly may explain this observation, and could partially account for why COVID-19 risk factors (e.g. menopause, obesity, age) (<xref ref-type="bibr" rid="bib28">Costeira et al., 2020</xref>; <xref ref-type="bibr" rid="bib166">Zhou et al., 2020</xref>) similarly correlate with differential sterol processing. Additional work is clearly required, particularly with respect to the open question of what degree of cholesterol decrease would be required for effective treatment, but in the context of the rapidly evolving landscape of COVID-19 treatment options, our findings underscore the potential utility of statins and other lipid modifying treatments.</p><p>Invariably, opportunistic infections hijack physiological cellular processes to ensure their survival (<xref ref-type="bibr" rid="bib112">Pelkmans and Helenius, 2003</xref>). To this end, we speculate that physiological and pathological synapses and resulting syncytia (or lack there of) arise in part from shared lipid bilayer properties at the nanoscale. Consistent with this concept, actin-dependent, ACE2/spike fusion events proceed from ‘finger-like’ projections and synapses between cells to fusion pore dilation and membrane collapse, closely resembling the orderly biogenesis of myoblast-derived syncytia (<xref ref-type="bibr" rid="bib19">Chen et al., 2008</xref>; <xref ref-type="bibr" rid="bib38">Duan et al., 2018</xref>; <xref ref-type="bibr" rid="bib75">Kim and Chen, 2019</xref>; <xref ref-type="bibr" rid="bib123">Shi et al., 2017</xref>; <xref ref-type="bibr" rid="bib124">Shilagardi et al., 2013</xref>). Second, we highlight the remarkable similarities between SARS-CoV-2 spike and tricellular tight junction proteins (<xref ref-type="bibr" rid="bib60">Higashi et al., 2013</xref>; <xref ref-type="bibr" rid="bib108">Oda et al., 2020</xref>; <xref ref-type="bibr" rid="bib128">Sohet et al., 2015</xref>), specifically with respect to membrane-anchoring cysteines and aromatics (<xref ref-type="fig" rid="fig5">Figure 5H</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D,E</xref>). These observations suggest that both pathological viruses and adherent cells independently evolved proteins with abnormally strong affinity for the plasma membrane to ensure stability of transcellular complexes (<xref ref-type="fig" rid="fig7">Figure 7H</xref>), whether to initiate fusion or maintain tissue integrity. We thus envision that assays presented herein may have broad utility for understanding the biophysics of synapse and fusion pore assembly, representing an exciting example of how inquiry into viral pathogenesis illuminates physiological function.</p><sec id="s3-1"><title>Materials availability</title><p>Plasmids and cell lines generated in this study are available from the lead contact.</p></sec><sec id="s3-2"><title>Experimental model and subject details</title><p>Select cell lines (VeroE6, Calu3, A549) were obtained from ATCC at the onset of the study and validated by the vendor. Following passage and usage by experimenters, all human cell lines (HEK293T, U2OS, Beas2B, Calu3, A549) were validated by STR profiling (ATCC) with 100% match between submitted samples and database profiles. All cell lines tested negative for mycoplasma (method: Universal Mycoplasma Detection Kit, ATCC 30–1012K). No commonly misidentified cell lines from the list maintained by the International Cell Line Authentication Committee were used for experiments in this study. Please see METHOD DETAILS for additional information on cell lines and culture conditions.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type (species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-TTF-1 (clone 8G7G3/1)</td><td valign="top">Agilent Dako</td><td valign="top">IR05661-2</td><td valign="top">(1:200)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti-SARS-CoV nucleocapsid (N) protein</td><td valign="top">Rockland</td><td valign="top">200–401-A50</td><td valign="top">(1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat polyclonal anti-rabbit IgG- Alexafluor 568</td><td valign="top">Thermo Fisher</td><td valign="top">A11011</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Biological sample (virus)</td><td valign="top">2019-nCoV (SARS-CoV-2)/USA-WA1/2020</td><td valign="top">Center for Disease Control, BEI</td><td valign="top">MN985325</td><td valign="top"/></tr><tr><td valign="top">Biological sample (<italic>Homo sapiens</italic>)</td><td valign="top">Formalin-fixed, paraffin-embedded, autopsy lung tissue (39 deceased patients or ‘decedents’)</td><td valign="top">Brigham and Women’s Hospital, Autopsy Division</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Dulbecco’s Modified Eagle Medium (DMEM), High Glucose, Pyruvate</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">11995065</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Eagle’s Minimum Essential Media (EMEM)</td><td valign="top">ATCC</td><td valign="top">ATCC 30–2003</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Opti-MEM Reduced Serum Medium</td><td valign="top">Thermo Fisher</td><td valign="top">31985062</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Penicillin-Streptomycin (10,000 U/mL)</td><td valign="top">Thermo Fisher</td><td valign="top">15140122</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Fetal Bovine Serum, Inactivated</td><td valign="top">Atlanta Biologicals</td><td valign="top">S11150H</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">In-Fusion HD Cloning Plus</td><td valign="top">Takara Bio</td><td valign="top">638910</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Lipofectamine 3000 Transfection Reagent</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">L3000008</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Polybrene</td><td valign="top">Sigma-Aldrich</td><td valign="top">TR-1003-G</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Paraformaldehyde (16%)</td><td valign="top">Electron Microscopy Services</td><td valign="top">15710</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Phusion High-Fidelity DNA Polymerase</td><td valign="top">New England Biolabs</td><td valign="top">M0530L</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Texas Red DHPE</td><td valign="top">Thermo Fisher</td><td valign="top">T1395MP</td><td valign="top"/></tr><tr><td valign="top">Recombinant protein</td><td valign="top">Annexin V 647</td><td valign="top">Thermo Fisher</td><td valign="top">A13204</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Small molecule library: LOPAC-1280 (1278 compounds, 96-well)</td><td valign="top">Sigma-Aldrich</td><td valign="top">LO1280-1KT</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Small molecule library: LOPAC-Pfizer (90 Pfizer-drugs, 96-well)</td><td valign="top">Sigma-Aldrich</td><td valign="top">LO5100</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Small molecule library: L1200 (355 kinase inhibitors, 96-well)</td><td valign="top">Selleck Chemicals</td><td valign="top">L1200</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Small molecule library: L1900 (120 epigenetic compounds, 96-well)</td><td valign="top">Selleck Chemicals</td><td valign="top">L1900</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Small molecule library: L2300 (378 cancer compounds, 96-well)</td><td valign="top">Selleck Chemicals</td><td valign="top">L2300</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Small molecule library: L4200 (1364 FDA-approved drugs, 96-well)</td><td valign="top">TargetMol</td><td valign="top">L4200</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Small molecule library: Spectrum collection (2400 bioactive compounds, 96-well)</td><td valign="top">Microsource Discovery</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Nelfinavir mesylate</td><td valign="top">R and D Systems</td><td valign="top">3766/10</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Heparin</td><td valign="top">Sigma-Aldrich</td><td valign="top">H3393\</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Nocodazole</td><td valign="top">Sigma-Aldrich</td><td valign="top">487928</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Amiloride/EIPA</td><td valign="top">Sigma-Aldrich</td><td valign="top">A3085</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Wortmannin</td><td valign="top">Sigma-Aldrich</td><td valign="top">W1628-1MG</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Chlorpromazine</td><td valign="top">Sigma-Aldrich</td><td valign="top">215921–500 MG</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Filipin</td><td valign="top">Sigma-Aldrich</td><td valign="top">F4767-1MG</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Nystatin</td><td valign="top">Thermo Fisher</td><td valign="top">BP29495</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Leupeptin</td><td valign="top">Sigma-Aldrich</td><td valign="top">L2884-5MG</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">AEBSF</td><td valign="top">Sigma-Aldrich</td><td valign="top">A8456</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Furin inhibitor II (polyarginine)</td><td valign="top">Sigma-Aldrich</td><td valign="top">344931</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Decanoyl-RVKR-CMK (chloromethylketone)</td><td valign="top">Tocris</td><td valign="top">3501</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Methyl-Beta-cyclodextrin (MBCD)</td><td valign="top">Sigma-Aldrich</td><td valign="top">C4555-1G</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Lovastatin</td><td valign="top">Sigma-Aldrich</td><td valign="top">438185</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Camostat mesylate</td><td valign="top">Sigma-Aldrich</td><td valign="top">SML0057</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">E-64D (EST)</td><td valign="top">Sigma-Aldrich</td><td valign="top">33000</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Ammonium chloride</td><td valign="top">Sigma-Aldrich</td><td valign="top">A9434</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Chloroquine diphosphate</td><td valign="top">Sigma-Aldrich</td><td valign="top">C6628</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Gefitinib</td><td valign="top">Sigma-Aldrich</td><td valign="top">SML1657</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">BAPTA-AM</td><td valign="top">Sigma-Aldrich</td><td valign="top">196419</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Latrunculin A</td><td valign="top">Invitrogen</td><td valign="top">428026</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Rottlerin</td><td valign="top">Sigma-Aldrich</td><td valign="top">557370-</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Dynasore</td><td valign="top">Sigma-Aldrich</td><td valign="top">324410</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Sodium chlorate</td><td valign="top">Sigma-Aldrich</td><td valign="top">403016</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Protease inhibitor cocktail</td><td valign="top">Sigma-Aldrich</td><td valign="top">P1860-1ML</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Ouabain</td><td valign="top">Sigma-Aldrich</td><td valign="top">4995–1 GM</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Rostafuroxin/PST2238</td><td valign="top">Sigma-Aldrich</td><td valign="top">SML1139</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Silmitasertib</td><td valign="top">Selleck Chemicals</td><td valign="top">S2248</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">R-406</td><td valign="top">Selleck Chemicals</td><td valign="top">.S2194</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Apilimod</td><td valign="top">Selleck Chemicals</td><td valign="top">S6414</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Bafilomycin A</td><td valign="top">Enzo</td><td valign="top">BML-CM110</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">2-Bromopalmitic acid (2 BP)</td><td valign="top">Sigma-Aldrich</td><td valign="top">238422–10G</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">MG132</td><td valign="top">Sigma-Aldrich</td><td valign="top">M8699</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Monensin</td><td valign="top">Sigma-Aldrich</td><td valign="top">M5273</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Brefeldin A</td><td valign="top">Sigma-Aldrich</td><td valign="top">B5936</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Cycloheximide</td><td valign="top">Sigma-Aldrich</td><td valign="top">C4859-1ML</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Dimethyl sulfoxide (DMSO)</td><td valign="top">Sigma-Aldrich</td><td valign="top">D2650</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Actinomycin D</td><td valign="top">Sigma-Aldrich</td><td valign="top">A5156-1VL</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Staurosporine</td><td valign="top">AbCam</td><td valign="top">ab120056</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">ISRIB</td><td valign="top">Sigma-Aldrich</td><td valign="top">SML0843</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">3-Methyladenine</td><td valign="top">Sigma-Aldrich</td><td valign="top">M9281</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Z-FA-FMK</td><td valign="top">Selleck Chemicals</td><td valign="top">S7391</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">NSC 23766</td><td valign="top">Selleck Chemicals</td><td valign="top">S8031</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Z-VAD-FMK</td><td valign="top">Selleck Chemicals</td><td valign="top">S7023</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">AZD8055</td><td valign="top">Selleck Chemicals</td><td valign="top">S1555</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">25-Hydroxycholesterol</td><td valign="top">Sigma-Aldrich</td><td valign="top">H1015</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Aprotinin (BPTI)</td><td valign="top">Selleck Chemicals</td><td valign="top">.S7377</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Genistein</td><td valign="top">Selleck Chemicals</td><td valign="top">S1342</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Oleic acid (MBCD-conjugated)</td><td valign="top">Sigma-Aldrich</td><td valign="top">O1257</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Cholesterol (MBCD-conjugated)</td><td valign="top">Sigma-Aldrich</td><td valign="top">C4951</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Linoleic acid (MBCD-conjugated)</td><td valign="top">Sigma-Aldrich</td><td valign="top">L5900</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Myriocin</td><td valign="top">Sigma-Aldrich</td><td valign="top">M1177-5MG</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Zaragozic Acid A</td><td valign="top">Cayman</td><td valign="top">17452</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Digitonin</td><td valign="top">Sigma-Aldrich</td><td valign="top">D141</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Bortezomib</td><td valign="top">Selleck Chemicals</td><td valign="top">S1013</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Bupivacaine hydrochloride</td><td valign="top">Sigma-Aldrich</td><td valign="top">PHR1128</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Ropivacaine hydrochloride</td><td valign="top">Selleck Chemicals</td><td valign="top">S4058</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Naftifine hydrochloride</td><td valign="top">Cayman</td><td valign="top">19234</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Terbinafine hydrochloride</td><td valign="top">Cayman</td><td valign="top">10011619</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Propofol</td><td valign="top">Sigma-Aldrich</td><td valign="top">P-076–1 ML</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Puromycin</td><td valign="top">Sigma-Aldrich</td><td valign="top">P7255</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Blasticidin S</td><td valign="top">VWR</td><td valign="top">1859–25</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DAPI</td><td valign="top">Sigma-Aldrich</td><td valign="top">D9542</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Hoechst 33342 Solution</td><td valign="top">Thermo Fisher</td><td valign="top">62249</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">AMG 9810</td><td valign="top">Cayman</td><td valign="top">14715</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Apomorphine hydrochloride</td><td valign="top">ApexBio</td><td valign="top">B6936</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Avanafil</td><td valign="top">Cayman</td><td valign="top">23024</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">BML-277</td><td valign="top">Cayman</td><td valign="top">17552</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Canagliflozin</td><td valign="top">Cayman</td><td valign="top">11575</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Chlorohexidine</td><td valign="top">Targetmol</td><td valign="top">T1147</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">CP-471474</td><td valign="top">Cayman</td><td valign="top">29442</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Gossypol</td><td valign="top">ApexBio</td><td valign="top">N2135</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Indacaterol maleate</td><td valign="top">ApexBio</td><td valign="top">B1369</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">JFD00244</td><td valign="top">Cayman</td><td valign="top">14648</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Miconazole nitrate</td><td valign="top">Cayman</td><td valign="top">15420</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Moxidectin</td><td valign="top">ApexBio</td><td valign="top">B3611</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">PD-407824</td><td valign="top">Cayman</td><td valign="top">25989</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Rapamycin</td><td valign="top">Targetmol</td><td valign="top">T1537</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Ritanserin</td><td valign="top">Tocris</td><td valign="top">1955</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Rolapitant hydrochloride</td><td valign="top">Targetmol</td><td valign="top">T3724</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Scriptaid</td><td valign="top">ApexBio</td><td valign="top">A4106</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">SKI II</td><td valign="top">Cayman</td><td valign="top">10009222</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Sorafenib</td><td valign="top">Cayman</td><td valign="top">10009644</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">TAK-285</td><td valign="top">MCE</td><td valign="top">HY-15196</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Ticagrelor</td><td valign="top">Cayman</td><td valign="top">15425</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">TW-37</td><td valign="top">Cayman</td><td valign="top">20999</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">UK-356618</td><td valign="top">ApexBio</td><td valign="top">A4440</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Vorapaxar</td><td valign="top">ApexBio</td><td valign="top">A8809</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">CholEsteryl BODIPY (FL C12)</td><td valign="top">Thermo Fisher</td><td valign="top">C3927MP</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Fibronectin from bovine plasma</td><td valign="top">Sigma-Aldrich</td><td valign="top">F1141-5MG</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>Homo sapiens,</italic> female)</td><td valign="top">HEK293T</td><td valign="top">Marc Diamond, UTSW</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>, female)</td><td valign="top">U2OS</td><td valign="top">Tom Muir, Princeton</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>H. sapiens,</italic> male)</td><td valign="top">Beas2B</td><td valign="top">Celeste Nelson, Princeton</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>H. sapien, males</italic>)</td><td valign="top">A549 (ACE2/TMPRSS2)</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>H. sapiens,</italic> male)</td><td valign="top">Calu3</td><td valign="top">ATCC</td><td valign="top">HTB-55</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>Cercopithecus aethiops</italic>, female)</td><td valign="top">VeroE6 (monkey)</td><td valign="top">ATCC</td><td valign="top">CRL-1586</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>, female)</td><td valign="top">U2OS, various</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>C. aethiops</italic>, female)</td><td valign="top">VeroE6 (monkey), various</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">SCARB1-GFP</td><td valign="top">Addgene</td><td valign="top">#86979</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">GFP1-10</td><td valign="top">Addgene</td><td valign="top">#80409</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">GFP11 × 7-mCherry-a-tubulin</td><td valign="top">Addgene</td><td valign="top">#70218</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">LAMP1-mCherry</td><td valign="top">Addgene</td><td valign="top">#45147</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">mCherry-CAV1</td><td valign="top">Addgene</td><td valign="top">#55008</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">GFP-EEA1</td><td valign="top">Addgene</td><td valign="top">#42307</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">SARS-CoV-1-Spike</td><td valign="top">Addgene</td><td valign="top">#145031</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">RAC1 (<italic>H. sapiens</italic>) in pANT7_cGST</td><td valign="top">DNASU</td><td valign="top">CD00632727</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">ACE2 cDNA in pcDNA3.1</td><td valign="top">Genscript</td><td valign="top">OHu20260</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">SARS-CoV-2 (2019-nCoV) Spike ORF (Codon Optimized)</td><td valign="top">Sino Biological</td><td valign="top">VG40589-UT</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pCAGGS-SARS-CoV2-S</td><td valign="top">BEI Resources, NIH</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pMLV gag-pol</td><td valign="top">Ploss Lab, Princeton</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLMN8-Gluc</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">p-LAT Transmembrane-mRFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">PSP (lentivirus packaging plasmid)</td><td valign="top">Marc Diamond, UTSW</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">VSVG (lentivirus packaging plasmid)</td><td valign="top">Marc Diamond, UTSW</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5 lentiviral vector (Ubiquitin C promoter)</td><td valign="top"><xref ref-type="bibr" rid="bib118">Sanders et al., 2014</xref></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-mGFP-Standardized glycine-serine (GS) Linker-AscI Site-STOP</td><td valign="top"><xref ref-type="bibr" rid="bib119">Sanders et al., 2020</xref></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-mCherry-Standardized GS Linker-AscI Site-STOP</td><td valign="top"><xref ref-type="bibr" rid="bib119">Sanders et al., 2020</xref></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-miRFP670-Standardized GS Linker-AscI Site-STOP</td><td valign="top"><xref ref-type="bibr" rid="bib119">Sanders et al., 2020</xref></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-NheI Site-Standardized GS Linker-mGFP</td><td valign="top"><xref ref-type="bibr" rid="bib119">Sanders et al., 2020</xref></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-NheI Site-Standardized GS Linker-mCherry</td><td valign="top"><xref ref-type="bibr" rid="bib119">Sanders et al., 2020</xref></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-NheI Site-Standardized GS Linker-miRFP670</td><td valign="top"><xref ref-type="bibr" rid="bib119">Sanders et al., 2020</xref></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-NheI Site-Standardized GS Linker-EYFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-HNRNPA1-EYFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-FUS-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-GFP1-10</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-GFP11 × 7</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-mGFP-EEA1</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-miRFP670-EEA1</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-mGFP-RAC1</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-miRFP670-RAC1</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-mGFP-CAV1</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-miRFP670-CAV1</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-LAMP1-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-LAMP1- miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-SCARB1-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-SCARB1-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-MYMK-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-MYMK-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-MYMK-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-MYMX-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-MYMX-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-MYMX-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-p14 (<italic>Reptilian orthoreovirus</italic>)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-p14 (<italic>Reptilian orthoreovirus</italic>)-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-p14 (<italic>Reptilian orthoreovirus</italic>)- miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Albumin signal sequence (SS)−8 amino acid GS Linker-B7 Transmembrane (TM)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Albumin SS-8 amino acid GS Linker-B7 TM-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Albumin SS-8 amino acid GS Linker-B7 TM-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-ACE2-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-ACE2-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-ACE2-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-ACE2 Ectodomain-8 amino acid GS Linker-B7 TM/CTD-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-ACE2 Ectodomain-8 amino acid GS Linker-B7 TM-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-ACE2 Ectodomain-8 amino acid GS Linker-B7 TM-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-SARS-CoV-1 Spike-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-SARS-CoV-1 Spike-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-SARS-CoV-1 Spike-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike Full-length (FL) (1–1273)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike Full-length (FL) (1–1273)-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike Full-length (FL) (1–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-RBD (319-541)−8 amino acid GS Linker-B7 TM/CTD-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-RBD (319-541)−8 amino acid GS Linker-B7 TM/CTD-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-RBD (319-541)−8 amino acid GS Linker-B7 TM/CTD-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-RBD (319-541)-WT TM/CTD (1203–1273)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-RBD (319-541)-WT TM/CTD (1203–1273)-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-RBD (319-541)-WT TM/CTD (1203–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike Ectodomain (1–1213)−8 amino acid GS Linker-B7 TM/CTD-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike Ectodomain (1–1213)−8 amino acid GS Linker-B7 TM/CTD-mCherry</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike Ectodomain (1–1213)−8 amino acid GS Linker-B7 TM/CTD-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike B7 TM Swap with Extracellular Linker (1-1213-8 amino acid GS linker-B7 TM-1235–1273)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike B7 TM Swap with Extracellular Linker (1-1213-8 amino acid GS linker-B7 TM-1235–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike B7 TM Swap (1–1213-B7 TM-1235–1273)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike B7 TM Swap (1–1213-B7 TM-1235–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ITGA1 TM Swap (1–1213-ITGA1 TM-1235–1273)--mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ITGA1 TM Swap (1–1213-ITGA1 TM-1235–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1268-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1268-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1266-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1266-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1263-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1263-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1260-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1260-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1256-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1256-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1245-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1245-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1239-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1239-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1234 (ΔCTD)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike 1–1234 (ΔCTD)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike CysAlaMutant (C1235A/C1236A/C1240A/C1241A/C1243A/C1247A/C1248A/C1250A/C1253A/C1254A)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike CysAlaMutant (C1235A/C1236A/C1240A/C1241A/C1243A/C1247A/C1248A/C1250A/C1253A/C1254A)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike C1235A/C1236A-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike C1235A/C1236A-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-ΔNTD (319–1273)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-ΔNTD (319–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔRBD (1–318, 540–1273)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔRBD (1–318, 540–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔFusionPeptide (1–787, 807–1273)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔFusionPeptide (1–787, 807–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔHR1 (1–919, 971–1273)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔHR1 (1–919, 971–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔHR2 (1–1162, 1203–1273)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔHR2 (1–1162, 1203–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔBothCleavageSites (‘CS’) (Δ685/Δ686/Δ815/Δ816)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔBothCS (Δ685/Δ686/Δ815/Δ816)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔS1/S2CS (Δ685/Δ686)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔS1/S2CS (Δ685/Δ686)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔS2’CS (Δ815/Δ816)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike ΔS2’CS (Δ815/Δ816)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S813G-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S813G-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S816G-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S816G-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike R815A-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike R815A-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike R815K-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike R815K-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike R815A/S816G-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike R815A/S816G-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike R815K/S816G-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike R815K/S816G-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S813G/R815A-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S813G/R815A-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S813G/R815K-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S813G/R815K-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S1 (1–685)-WT TM/CTD (1203–1273)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S1 (1–685)-WT TM/CTD (1203–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S1 (1–685)−8 amino acid GS Linker-B7 TM/CTD-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike S1 (1–685)−8 amino acid GS Linker-B7 TM/CTD-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-S2 (686–1273)-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-S2 (686–1273)-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-S2 (686–1213)−8 amino acid GS Linker-B7 TM/CTD Swap-mGFP</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FM5-Spike SS (1-12)-S2 (686–1213)−8 amino acid GS Linker B7 TM/CTD Swap-miRFP670</td><td valign="top">This study</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">ChemAxon Physicochemical Property Analysis</td><td valign="top">Morgan et al., <italic>Angew. Chem. Int. Ed.,</italic> 2018</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://chemaxon.com/">https://chemaxon.com/</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">R Software Mann-Whitney U Statistical Analysis</td><td valign="top">Morgan et al., <italic>Angew. Chem. Int. Ed.,</italic> 2018</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">NCGC Scaffold Hopper</td><td valign="top">NCATS Chemical Genomics Centre (NCGC)</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://tripod.nih.gov">https://tripod.nih.gov</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">RDKit Substructure Analysis</td><td valign="top">RDKit</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.rdkit.org/">https://www.rdkit.org/</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Python Software</td><td valign="top">Python</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.python.org/">https://www.python.org/</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">GraphPad Prism Nonlinear Regression</td><td valign="top">GraphPad</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">MATLAB R2017b</td><td valign="top">Mathworks</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.mathworks.com/">https://www.mathworks.com/</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">ImageJ</td><td valign="top">Schneider et al., <italic>Nature Methods</italic>, 2012</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">PANTHER v14.0 Gene Ontology</td><td valign="top">Mi et al., <italic>Nature Protocols</italic>, 2019</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://pantherdb.org">https://pantherdb.org</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">BioRender (Paid Academic Plan)</td><td valign="top">BioRender</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://bio-render.com">https://bio-render.com</ext-link></td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Plasmid construction</title><p>Lentiviral plasmids encoding fluorescently tagged proteins of interest were cloned as described in previous work (<xref ref-type="bibr" rid="bib119">Sanders et al., 2020</xref>), which introduced monomeric fluorescent protein (mGFP, mCherry, miRFP670) lentiviral vectors (FM5, ubiquitin C promoter) with standardized linkers/overlaps to allow Gibson assembly-based cloning in high-throughput. With the exception of IDT-synthesized open-reading frames (p14, MYMK, MYMX), DNA fragments coding proteins of interest were amplified by PCR (oligonucleotides synthesized by IDT; see KEY RESOURCES table for origin of cDNA template), using Phusion High-Fidelity DNA Polymerase (New England Biolabs or ‘NEB’). Gibson assembly (In-Fusion HD cloning kit, Takara) was used to insert gel-purified DNA (Qiagen, Gel Extraction Kit) into the desired lentiviral vector, linearized by NheI restriction enzyme (NEB) or AscI restriction enzyme (NEB) digestion. DNA was extracted from transformed Stellar competent bacteria (Takara) by mini-prep (Qiagen). DNA inserts were confirmed by Sanger sequencing (GENEWIZ), reading from both ends of the open reading frame.</p><p>To generate pLMN8-Gluc, the secreted version of Gluc gene was PCR amplified using Q5 polymerase (NEB) using gene specific primers purchased from IDT. The PCR amplicon was inserted into the SfiI-digested pLMN8 plasmid (<xref ref-type="bibr" rid="bib114">Ploss et al., 2009</xref>) via In-Fusion cloning (Takara). The sequence of the resulting pLMN8 plasmid encoding secreted Gluc (pLMN8-Gluc) was confirmed by Sanger sequencing (Eton Bioscience). Mammalian cell, codon optimized pCAGGS-SARS-CoV-2 spike (S) was kindly provided by BEI resources (NIH). Retroviruses pseudotyped with vesicular stomatitis virus G protein (VSV-G) were used as positive controls. pLMN8-Gluc and pMLV gag-pol plasmids were amplified in NEB stable competent cells (NEB); pCAGGS-SARS-CoV-2 spike and pVSV-G, DH5α competent cells (ThermoFisher), then plasmids were purified by Nucleobond Xtra Midi (Takara).</p></sec><sec id="s4-2"><title>Cell culture</title><p>A549, VeroE6, and Calu3 cells were obtained from the American Type Culture Collection (ATCC), and all human cell lines were validated by STR profiling (ATCC). 293 T cells were a kind gift from Marc Diamond (UT Southwestern); U2OS cells, Tom Muir (Princeton University); Beas2B cells, Celeste Nelson (Princeton University); A549 cells expressing human ACE2 and TMPRSS2 (A549-hACE2/TMPRSS2), Mohsan Saeed (Boston University). All cell lines were grown in Dulbecco’s Modified Eagle’s Medium (DMEM with high glucose and pyruvate, ThermoFisher) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals) and 1% penicillin/streptomycin (P/S, Gibco), with the exception of: A549-ACE2/TMPRSS2, which were additionally maintained under puromycin (Sigma) and blasticidin (VWR) selection (both at 0.5 μg/mL); and Calu3 cells, which were grown in Eagle’s minimum essential media (EMEM, ATCC) with 10% FBS and 1% P/S. All cells were propagated at 37°C in a 5% CO<sub>2</sub>, 20% O<sub>2</sub> environment.</p></sec><sec id="s4-3"><title>Lentivirus production</title><p>Lentiviruses encoding fluorescently tagged proteins of interest were produced by using a previously optimized protocol (<xref ref-type="bibr" rid="bib118">Sanders et al., 2014</xref>). Briefly, HEK293T cells were co-transfected with indicated FM5 construct and two helper plasmids (VSVG and PSP) with Lipofectamine-3000 (Invitrogen). Lipid-based transfection reagents were avoided with exception of virus production. Supernatant was collected 2–3 days post-transfection, cell debris was pelleted/discarded using centrifugation (1000xg), and lentivirus-containing media was used to infect indicated cell line in 96-well plates or stored at −80°C.</p></sec><sec id="s4-4"><title>Generation of stable U2OS and VeroE6 cell lines</title><p>U2OS cells were selected for this study due to their flat morphology (ideal for live cell imaging), ease of lentivirus transduction, and absence of most proteins critical for SARS-CoV-2 fusion. For example, ACE2, TMPRSS proteases, and IFITM proteins are not detectable, whereas the FURIN enzyme is present at &lt;500 copies per cell (<xref ref-type="bibr" rid="bib4">Beck et al., 2011</xref>). Experimenters are thus able to control relative levels of such proteins in stable populations of U2OS cells by transducing different amounts of lentivirus. Approximate concentrations of exogenous fusion proteins are estimated in different subcellular compartments (e.g. plasma membrane, endoplasmic reticulum) using fluorescence correlation spectroscopy (FCS) calibration curves established for a given laser scanning confocal microscope (<xref ref-type="bibr" rid="bib119">Sanders et al., 2020</xref>). In contrast to U2OS cells, VeroE6 cells express endogenous ACE2, but likewise, do not express TMPRSS2, and are infected by the endocytic pathway (<xref ref-type="bibr" rid="bib62">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib63">Hoffmann et al., 2020b</xref>).</p><p>For both U2OS and VeroE6 cells, lentivirus transduction was performed in 96-well plates as described (<xref ref-type="bibr" rid="bib119">Sanders et al., 2020</xref>) with minor modifications. For large, inefficiently packaged spike constructs, 180 μL lentivirus supernatant was added to a single well of 96-well dish prior to cell plating. For smaller constructs, 30 or 60 μL lentivirus supernatant was applied. Wells containing pre-added lentivirus received PBS-washed and trypsinized cells, so cell populations were at ~10–20% confluency upon adhesion to the dish surface. Cells were grown for three days in lentivirus to obtain confluence, which maximizes viral transduction efficiency and protein expression (<xref ref-type="bibr" rid="bib119">Sanders et al., 2020</xref>). Confluent cells, now stably expressing fusion proteins of interest, were washed with PBS, trypsinized, and passaged to fibronectin-coated glass (CellVis) for initial expression comparisons using confocal microscopy (Day 4). If expression was relatively low or all cells did not express the protein of interest, lentivirus transduction was repeated in 96-well dishes, up to two additional times. In the case of described spike variants, expression at the plasma membrane was similar, with the exception of select variants that suffered from misfolding problems and were not studied further (see below).</p><p>In parallel to preliminary expression check by confocal microscopy, stable cell populations were expanded first in 12-well then six-well dishes. At confluence in 6-well (~Day 10), cells were frozen in liquid nitrogen (freezing media = 90% fetal bovine serum, 10% DMSO) for long-term storage and subsequent use. The described multiple passage and expansion approach eliminates cells expressing lethal levels of fluorescent fusion proteins. Further, this protocol minimizes high over-expression artifacts (e.g. stress response) and membrane perturbations common with lipid-based transfection reagents such as Lipofectamine-3000.</p><p>In all experiments, at least 90% (typically close to 100%) of cells in a given population expressed indicated protein(s) at time of freezing (~Day 10) and live cell imaging experiments (Day 10 or after). All stable cell populations featured &lt;5 μM protein of interest on plasma membrane at time of live cell imaging experiments (much less if averaged across entire cell), as estimated by FCS calibration curves (<xref ref-type="bibr" rid="bib119">Sanders et al., 2020</xref>). For ACE2, B7 TM, and Spike RBD cells, fusion protein was present at an estimated 1–5 μM at the plasma membrane. In the case of spike variants that acted similarly to the wild-type version, concentrations greater than 1 μM were unattainable, as toxicity occurred at higher levels. A negative correlation between spike variants’ ability to promote fusion and maximal expression level was noted, likely because spike features a slight propensity to promote cell-cell fusion even in the absence of ACE2, perhaps due to weak interaction with a different receptor protein. For example, SARS-CoV-1 spike could be expressed several fold higher than SARS-CoV-2 spike.</p><p>For all described fluorescent fusion proteins, proper localization to the cell’s plasma membrane was confirmed by live cell confocal microscopy at ~Day 4 and ~Day 10 (relative to lentivirus transduction). In the case of certain spike variants (e.g. Δ815/Δ816, ‘ΔS2’CS’), expression was unexpectedly low despite multiple rounds of lentivirus transduction. In these cases, tagged protein was confined to the endoplasmic reticulum. Such behavior was independent of fluorescent tag (e.g. mCherry, miRFP670, mGFP) and is assumed to to indicate misfolding, which decreases the likelihood of necessary post-translational processing (e.g. glycosylation) for productive secretion. These constructs were discarded or not studied in detail, as relationship between phenotype and cleavage site (or domain deletion) would be impossible to determine. Due to misfolding of Δ815/Δ816 (“ΔS2’CS), additional S2’ cleavage site variants (e.g. S813G) were generated to assess its role in cell-cell fusion. For these variants, localization to plasma membrane and subsequent binding to ACE2 was confirmed (transcellular synapses) and essentiality for membrane fusion was addressed.</p></sec><sec id="s4-5"><title>Live cell confocal microscopy</title><p>Stable cell lines were plated on fibronectin-coated, 96-well glass bottom dishes (Cellvis) and immediately imaged (in the case of experiments requiring observation of individual fusion events) or following 24 hr culture (e.g. comparison of relative fusion between spike variants). A Nikon A1 laser-scanning confocal microscope equipped with 60x oil immersion lens (numerical aperture of 1.4) was used to collect confocal images. A humidified incubator kept cells at 37°C and 5% CO<sub>2</sub>. Proteins tagged with EYFP, mGFP (‘GFP’), mCherry, or miRFP670 (‘iRFP’) were imaged with 488, 488, 560, and 640 nm laser lines, respectively, and settings were optimized to minimize photobleaching and to negate bleed-through between channels. With the exception of heterokaryon co-culture assays, all confocal microscopy was performed on living cells to eliminated fixation-associated artifacts in subcellular localization.</p></sec><sec id="s4-6"><title>MBCD TMR-cholesterol labeling and TIRF imaging</title><p>Cells were incubated with TopFluor TMR-cholesterol (Avanti Polar Lipids #810385) complexed with methyl-beta-cyclodextrin (MβCD) in a 1:10 ratio (chol: MβCD). Total Internal Reflection Fluorescence (TIRF) Microscopy Images were collected on Nikon A1R + STORM (Nikon Ti2 frame) equipped with 405 nm, 488 nm, 561 nm, and 640 nm laser sources (Nikon LUN-F), a Princeton Instruments ProEM EMCCD camera, and SR HP Apo TIRF 100x/1.49 oil lens (MRD01995). The N-STORM module was used in TIRF mode and the TIRF angle was adjusted manually.</p></sec><sec id="s4-7"><title>Heterokaryon co-culture assay</title><p>U2OS cells expressing SARS-CoV-2 spike-iRFP and ACE2-iRFP with their respective nuclear markers HNRNPA1-EYFP and FUS-mCherry were grown in 10-cm cell culture dishes (ThermoFisher), trypsinized with 0.05% EDTA-trypsin (ThermoFisher), resuspended in DMEM (10% FBS, 1% P/S), and mixed in 1:1 ratio. 5.4 × 10<sup>6</sup> cells were immediately seeded per well into a glass-bottomed 384-well plate (CellVis) to a total of 80 μL volume using a Multidrop Combi SMART liquid-handling dispenser (ThermoFisher). Unless indicated, cells were incubated at 37°C for 5-hr, fixed with 4% paraformaldehyde (Electron Microscopy Services 16% PFA stock solution from freshly opened glass ampules was added directly to media to minimize variability between wells) for 10-min, washed with DPBS (Gibco), and stained with Hoechst (200 ng/mL). For VeroE6 cells co-cultures, the above procedure was followed exactly, replacing the ACE2-expressing U2OS cells with VeroE6 cells expressing FUS-mCherry nuclear markers. Unlike U2OS cells (<xref ref-type="bibr" rid="bib4">Beck et al., 2011</xref>), VeroE6 monkey cells feature endogenous ACE2 expression and are readily infected with SARS-CoV-2 virus (<xref ref-type="bibr" rid="bib62">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib63">Hoffmann et al., 2020b</xref>). For all effective compounds, manual inspection of representative images was performed to rule out the possibility that small molecules acted by inhibiting nucleocytoplasmic transport: in this scenario, tagged RNA-binding proteins would accumulate in cytosol or be unevenly distributed between nuclei of a single syncytium. This was never observed. See Quantification and statistical analysis for details on statistical comparisons.</p></sec><sec id="s4-8"><title>Targeted compound dose-response assays</title><p>For the targeted compound screen (<xref ref-type="fig" rid="fig3">Figure 3</xref>), compounds were purchased and dissolved in water, methanol or DMSO to achieve stock solutions at ~2000-fold concentration commonly reported by literature. Serial dilutions (7-doses, threefold dilutions unless indicated) were prepared in 20 μL DMEM per well and 5.4 × 10<sup>6</sup> cells of each cell type (40 μL volume per) were added to a final volume of 100 μL (0.5% DMSO). Heterokaryon co-culture assays were carried out as described above. Compounds were determined to be effective if the maximum dose z-score was &lt;-3. Strong vs. weak inhibitor designations were based on arbitrary cutoffs in relative fusion and were reproducible across independent experiments (i.e. dose-responses performed on separate days). See Quantification and statistical analysis for details on statistical comparisons.</p></sec><sec id="s4-9"><title>Unbiased drug repurposing screen</title><p>For drug repurposing screen of 5985 compound library (derived from seven different commercial small molecule libraries; see KEY RESOURCES table), the described ACE2-U2OS heterokaryon assay was carried out by adding co-culture to 384-well plates with compounds pre-dispensed. Specifically, 240 nL of compound (10 mM, in dissolved in DMSO) was added using ECHO 550 (Labcyte) liquid dispenser to generate a final compound concentration of 30 μM upon addition of 80 μL cell co-culture.</p></sec><sec id="s4-10"><title>Dose-response validation of hits from drug repurposing screen</title><p>For 7-point, dose-response assay, appropriate volumes of compound as 10 mM DMSO solution were dispensed using ECHO 550 (Labcyte) liquid dispenser to generate final concentrations of 40, 20, 10, 5.0, 2.5, 1.25, 0.625 μM upon addition of 80 μL cell co-culture. Wells were back-filled as necessary to keep the total DMSO volume of 320 nL consistent for all wells, including negative control, so as to maintain 0.4% DMSO concentration. To validate the top-24 hits, compounds were purchased from independent suppliers, dissolved in DMSO at 10 mM stock concentrations, and dispensed in 7-point dilutions according to procedure above. See Quantification and statistical analysis for details on statistical comparisons.</p></sec><sec id="s4-11"><title>Automated fixed cell confocal imaging and data acquisition</title><p>Heterokaryon assay development, characterization and high-throughput screening were carried out on a Eclipse Ti2 inverted scanning confocal microscope (Nikon) equipped with an automated Water Immersion Dispenser (WID). Wells were characterized by 16 full field of view regions (211 × 211 μm) imaged with a 60x, 1.2-numerical aperture, water-immersion, Nikon objective with 512 × 512 resolution. Bi-directional scanning with Hoechst (405 excitation/425–475 emission filter; channel 1), GFP (488/500–550; channel 2), and mCherry (561/570–620; channel 3) channels were acquired by a line series through a 50 µm pinhole at a rate of one image per second. An automated image acquisition protocol was developed in the Nikon NIS-Elements JOBS module to navigate within each well and over the 384-well plate. Automated image processing and all subsequent analyses were implemented in MATLAB R2017b.</p></sec><sec id="s4-12"><title>Fluorescence recovery after photobleaching (FRAP)</title><p>Stable U2OS cell lines expressing indicated GFP-labeled proteins of interest were cultured for 24 hr on a 96-well glass-bottom dish (CellVis) and imaged using a Nikon A1 laser-scanning confocal microscope as described. Photobleaching was performed by scanning a 488 nm laser over a circular region of interest ~6.5 µm in diameter, while focusing on the plasma membrane of single cells, validated by carefully tuning the focus to a plane bellow the non-fluorescent nuclei until they were no longer observable (compare transmitted light and fluorescent images in <xref ref-type="fig" rid="fig6">Figure 6A</xref>) and fluorescence signal within the surrounding area reached its maximum. See Quantification and statistical analysis for analysis.</p></sec><sec id="s4-13"><title>Protein partitioning measurements in giant plasma membrane vesicles (GPMVs)</title><p>Cell membranes were stained with 5 μg/ml of Texas Red DHPE or Annexin V 647 (ThermoFisher), respectively, red or far-red fluorescent lipid dyes that strongly partition to disordered phases (<xref ref-type="bibr" rid="bib3">Baumgart et al., 2007</xref>; <xref ref-type="bibr" rid="bib80">Klymchenko and Kreder, 2014</xref>; <xref ref-type="bibr" rid="bib132">Stone et al., 2017</xref>). Following staining, GPMVs were isolated as described (<xref ref-type="bibr" rid="bib121">Sezgin et al., 2012</xref>) from U2OS stable cells lines expressing the protein of interest (LAT results were obtained from transient co-transfections). Briefly, GPMV formation was induced by 2 mM N-ethylmaleimide (NEM) in hypotonic buffer containing 100 mM NaCl, 10 mM HEPES, and 2 mM CaCl<sub>2</sub>, pH 7.4. To quantify partitioning, GPMVs were observed on an inverted epifluorescence microscope (Nikon) at 4°C after treatment with 200 µM DCA to stabilize phase separation; this treatment has been previously demonstrated not to affect raft affinity of various proteins (<xref ref-type="bibr" rid="bib14">Castello-Serrano et al., 2020</xref>). The partition coefficient (K<sub>p,raft</sub>) for each protein was calculated from fluorescence intensity of the construct in the raft and non-raft phase for &gt;10 vesicles/trial, with multiple independent experiments (n = 3) for each construct.</p></sec><sec id="s4-14"><title>Generation of retroviral pseudoparticles</title><p>All pseudotyped retroviruses were generated by co-transfection of plasmids encoding (1) a provirus containing the Gaussia luciferase reporter gene (LMN8-Gluc), (2) mouse leukemia virus (MLV) gag-pol (<xref ref-type="bibr" rid="bib114">Ploss et al., 2009</xref>), and (3) codon-optimized SARS-CoV-2 spike.</p><p>On the day prior to transfection, 1.4 × 10<sup>7</sup> 293 T cells were seeded in a 150 mm tissue culture dish. The following day, a total of 15 μg of total DNA was transfected using 90 μL X-tremeGENE HP DNA Transfection Regent (Roche). To generate luciferase reporter SARS CoV-2-Spp and VSV-Gpp controls, (1) pLMN8-Gluc, (2) MLV gag-pol, and (3) either SARS CoV-2 spike or VSV-G were co-transfected at a ratio of 4.5:4.5:1, giving rise to SARS-CoV-2pp and VSV-Gpp, respectively. No envelope pseudoparticles (NEpp) was also generated using (1) pLMN8-Gluc and (2) MLV gag-pol at a ratio of 1:1. Media was replaced after 6–18 hr with DMEM containing 3% FBS, nonessential amino acids (NEAA, 0.1 mM, ThermoFisher), HEPES (20 mM, ThermoFisher), polybrene (4 μg/mL, Sigma-Aldrich). Supernatants were harvested at 48- and 72 hr after transfection, pooled and filtered (0.45 μm pore size), aliquoted, and stored at −80°C until usage.</p></sec><sec id="s4-15"><title>Pseudovirus blocking assay</title><p>Blocking assays with luciferase reporter pseudovirus were performed in poly-L-lysine coated flat-bottom 96-well plates using 1.5 × 10<sup>4</sup> A549-ACE2-TMPRSS2 cells per well. The next day, all compounds (10 mM diluted in DMSO) except for MBCD were diluted to 50 μM by DMEM containing 3% FBS, NEAA (0.1 mM), HEPES (20 mM), polybrene (4 μg/ml) and penicillin-streptomycin. MBCD (40 mM diluted in PBS) was diluted to 2 mM by DMEM containing 0.5% DMSO, 3% FBS, NEAA (0.1 mM), HEPES (20 mM), polybrene (4 μg/ml), and penicillin-streptomycin. The final concentration of DMSO for all compounds was 0.5%. Two-fold serial dilutions of all compounds were co-cultured with cells for 2 hr at 37°C, and subsequently, the same volume of pseudovirus was added into the cells and incubated for 4 hr at 37°C. After incubation, wells were washed once with 100 μl Hank’s Buffered Saline Solution (HBSS, ThermoFisher), and the media changed to 100 μL DMEM containing 3% FBS, NEAA (0.1 mM), HEPES (20 mM), polybrene (4 μg/mL), and penicillin-streptomycin. Each plate featured positive (no pseudovirus) and negative (DMSO only) controls (n = 6 biological replicates) for quantification.</p></sec><sec id="s4-16"><title>Pseudovirus luciferase assay</title><p>Luciferase assay were performed 48 hr after incubation. The supernatants were collected to assess Gaussia luciferase activity using Genecopoeia Luc-Pair Renilla luciferase HS Assay Kit (GeneCopoeia) following the manufacturer’s instruction and measured on a Tristar2 LB942 luminometer (Berthold Technologies). See Quantification and statistical analysis for details on statistical comparisons.</p></sec><sec id="s4-17"><title>SARS-CoV-2 isolate stock preparation and titration</title><p>All replication-competent SARS-CoV-2 experiments were performed in a biosafety level 3 laboratory (BSL-3) at the Boston University’ National Emerging Infectious Diseases Laboratories. 2019-nCoV/USA-WA1/2020 isolate (NCBI accession number: MN985325) of SARS-CoV-2 was obtained from the Centers for Disease Control and Prevention and BEI Resources. To generate the passage 1 (P1) virus stock, Vero E6 cells, pre-seeded the day before at a density of 10 million cells, were infected in T175 flasks with the master stock, diluted in 10 mL final volume of Opti-MEM. Following virus adsorption to the cells at 37°C for 1 hr, 15 mL DMEM containing 10% FBS and 1x penicillin/streptomycin was added to the flask. The next day, media was removed, cell were rinsed with 1x PBS and 25 mL of fresh DMEM containing 2% FBS was added. Two days later, when the cytopathic effect of the virus was clearly visible, culture medium was collected, filtered through a 0.2 μm filter, and stored at −80°C. Our P2 working stock of the virus was prepared by infecting Vero E6 cells with the P1 stock, at a multiplicity of infection (MOI) of 0.1. Cell culture media was harvested at day 2 and day 3 post infection, and after the last harvest, ultracentrifuged (Beckman Coulter Optima L-100k; SW32 Ti rotor) for 2 hr at 25,000 rpm over a 20% sucrose cushion. Following centrifugation, the media and sucrose were discarded and pellets were left to dry for 5 min at room temperature. Pellets were then resuspended over night at 4°C in 500 μL of 1x PBS. The next day, concentrated virions were aliquoted at stored at −80°C.</p><p>The titer of our viral stock was determined by plaque assay. Vero E6 cells were seeded into a 12-well plate at a density of 2.5 × 10<sup>5</sup> cells per well, and infected the next day with serial 10-fold dilutions of the virus stock for 1 hr at 37°C. Following virus adsorption, 1 mL of overlay media, consisting of 2x DMEM supplemented with 4% FBS and mixed at a 1:1 ratio with 1.2% Avicel (DuPont; RC-581), was added in each well. Three days later, the overlay medium was removed, the cell monolayer was washed with 1x PBS and fixed for 30 min at room temperature with 4% paraformaldehyde. Fixed cells were then washed with 1x PBS and stained for 1 hr at room temperature with 0.1% crystal violet prepared in 10% ethanol/water. After rinsing with tap water, the number of plaques were counted and the virus titer was calculated. The titer of our P2 virus stock was 4 × 10<sup>8</sup> PFU/mL.</p></sec><sec id="s4-18"><title>SARS-CoV-2 cholesterol depletion assay</title><p>The day prior to infection, A549 expressing hACE2 and hTMPRSS2 cells were seeded at a density of 2 × 10<sup>4</sup> per well in a poly-L-lysine coated flat-bottom 96-well plate. The next day, MBCD initial stock was prepared at a concentration of 20 mM in 1x PBS and 2-fold serial dilutions were then made using 1x PBS. Prior to infecting cells, a 1 hr pretreatment of MBCD with SARS-CoV-2 virus or cells was carried out. Viral pretreatment was performed by mixing 25 μL of each MBCD dilution with 25 μL of SARS-CoV-2 (MOI of 0.5; 1 × 10<sup>4</sup> PFU) per well then incubated for 1 hr at 37°C. For cell pretreatment, media was removed from wells and cells were washed once with 1x PBS. Cells were then incubated for 1 hr at 37°C with 25 μL of each MBCD dilution further diluted in 25 μL of 1x PBS. Following pretreatments, media or PBS/MBCD mixes were removed from wells and wells were washed twice with 1x PBS. Untreated and MBCD-treated cells were then infected for 1 hr at 37°C with 50 μL of SARS-CoV-2 pretreated with MBCD, or with untreated SARS-CoV-2 (MOI of 0.5), respectively. One hour following virus adsorption, media was removed, cells were washed twice with PBS, and 200 μL of DMEM containing 10% FBS and 1% penicillin-streptomycin was added in each well. Forty-eight hours post infection, cell culture media was harvested and stored at −80°C. Cells were washed twice with 1x PBS, and fixed with 200 μL of 10% neutral buffered formalin for 1 hr at room temperature. Cells were then washed twice with 1x PBS, and taken out of the BSL-3 laboratory.</p></sec><sec id="s4-19"><title>SARS-CoV-2 RT-qPCR</title><p>To determine SARS-CoV-2 RNA copies, total viral RNA was isolated from cell culture media using a Zymo Research Corporation Quick-RNA Viral Kit (Zymo Research) according to manufacturer’s instructions. Viral RNA was quantified using single-step RT-quantitative real-time PCR (Quanta qScript One-Step RT-qPCR Kit; VWR) with primers and Taqman probes targeting the SARS-CoV-2 E gene as previously described (<xref ref-type="bibr" rid="bib25">Corman et al., 2020</xref>). Briefly, a 20 μL reaction mixture containing 10 μL of Quanta qScript XLT One-Step RT-qPCR ToughMix, 0.5 mM Primer E_Sarbeco_F1 (<named-content content-type="sequence">ACAGGTACGTTAATAGTTAATAGCGT</named-content>), 0.5 mM Primer E_Sarbeco_R2 (<named-content content-type="sequence">ATATTGCAGCAGTACGCA</named-content> CACA), 0.25 mM Probe E_Sarbeco_P1 (<named-content content-type="sequence">FAM-ACACTAGCCATCCTTACTGCGCTTCG</named-content>-BHQ1), and 2 μL of total RNA was subjected to RT-qPCR using Applied Biosystems QuantStudio 3 (ThermoFisher). The following cycling conditions were used: reverse transcription for 10 min at 55°C and denaturation at 94°C for 3 min followed by 45-cycles of denaturation at 94°C for 15 s and annealing/extension at 58°C for 30 s. Ct values were determined using QuantStudio Design and Analysis software V1.5.1 (ThermoFisher). For absolute quantification of viral RNA, a 389 bp fragment from the SARS-CoV-2 E gene was cloned onto pIDTBlue plasmid under an SP6 promoter using NEB PCR cloning kit (New England Biosciences). The cloned fragment was then in vitro transcribed (mMessage mMachine SP6 transcription kit; ThermoFisher) to generate a RT-qPCR standard. See Quantification and statistical analysis for details on statistical comparisons.</p></sec><sec id="s4-20"><title>SARS-CoV-2 immunofluorescence</title><p>Virus-infected cells were fixed in 4% paraformaldehyde for 30 min. The fixative was removed and the cell monolayer was washed twice with 1x PBS. The cells were permeabilized in 1x PBS + 0.1% Triton-X (PBT) for 15 min at room temperature and washed twice with 1x PBS. The cells were blocked in PBT +10% goat serum (v/v) and 1% BSA (w/v) for 1 hr at room temperature before incubating overnight at 4°C with rabbit anti-SARS-CoV nucleocapsid antibody (1:2000 dilution). The cells were then washed five times with 1x PBS and stained with Alexa568-conjugated goat anti-rabbit antibody (1:1000 dilution) in the dark at room temperature for 1 hr. The cells were washed five times with 1x PBS and counterstained with DAPI (1:1000). Images were acquired using the MuviCyte Live Cell Imaging System (PerkinElmer). Six images were captured per well with a 4x objective lens in an unbiased manner.</p></sec><sec id="s4-21"><title>Human pathology</title><p>Human pathology studies were performed with the approval of the Institutional Review Board at Brigham and Women’s Hospital. Clinical autopsies with full anatomic dissection were performed on SARS-CoV-2 decedents by a board-certified anatomic pathologist (RFP) with appropriate infectious precautions. Lung samples were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin using standard methods. Immunohistochemistry was performed on 4-µm-thick tissue sections following pressure cooker antigen retrieval (Target Retrieval Solution; pH 6.1; Agilent Dako) using a mouse monoclonal antibody directed against TTF-1 (clone 8G7G3/1; Agilent Dako) at 1:200 dilution. Control lung slides were obtained from the BWH Department of Pathology Autopsy Division archives. Glass slides were reviewed by a RFP using an Olympus BX41 microscope, and microscopic photographs were obtained with an Olympus DP27 camera and Olympus CellSens Entry software.</p></sec><sec id="s4-22"><title>Quantification and statistical analysis</title><sec id="s4-22-1"><title>Automated fixed cell image analysis</title><p>Automated image analyses were performed using MATLAB R2017b (MathWorks). The fraction of cells fused was measured by adaptive segmentation of a maximal intensity projection of the three image channels to delineate nuclei. For each nucleus, area and mean intensity of both nuclear markers in the GFP and mCherry channels was measured. Nuclei with area less than 10 μm<sup>2</sup> after gaussian filtering and erosion were removed. Remaining nuclei with mean GFP or mCherry channel signal more than 50-digital levels above background were considered nuclear marker-positive. GFP/mCherry double-positive nuclei were designated as part of a syncytium. The fraction of cells fused was calculated per well as the ratio of syncytium- to nuclear marker-positive nuclei. Total nuclei per well was z-score-normalized to the plate negative control wells and considered viable when &gt;-3.</p></sec><sec id="s4-22-2"><title>Heterokaryon co-culture assay compound screens and dose-response analysis</title><p>Cell-cell fusion assay was optimized to maximize z-factor, which describes the statistical separation between positive and negative controls and reflects quality of a screening platform (<xref ref-type="bibr" rid="bib162">Zhang et al., 1999</xref>) (see <xref ref-type="fig" rid="fig3">Figure 3A</xref>, bottom right, for equation and schematic). All statistically significant results are assessed according to the related z-score. The same reproducible assay workflow and statistical cut-offs was used for screening all compound libraries, target compounds, and dose-responses. This statistical approach allows determination of significance relative to a plate’s control wells by a cut-off of &gt;3 standard deviations from the mean of the negative control (absolute value z-score &gt;3). For a given experiment, the negative control wells and the positive control wells characterize the statistics of the entire plate (all the test wells). Effective compounds first pass the z-score cut-off for hit determination, and dose-response provide additional confirmation to the original statistically significant hit.</p></sec><sec id="s4-22-3"><title>Cell culture statistical analyses</title><p>All data plots and statistical tests were executed using GraphPad Prism (version 8.0.2) for MacOS. For each plot, number of tested biological replicates is indicated in its figure legend. For heterokaryon co-culture assays, statistical significance was assessed for spike variants relative to SARS-CoV-2 wild-type (WT) using ANOVA with multiple comparisons and Bonferroni correction. For pseudovirus blocking assays and SARS-CoV-2 RT-qPCR experiments, significance relative to sham-treated negative control was determined using unpaired two-tailed student’s T-tests.</p></sec><sec id="s4-22-4"><title>Fluorescence recovery after photobleaching (FRAP)</title><p>Analysis was performed in MATLAB R2017b (MathWorks) by selecting a circular ROI, ~4 μm in diameter, co-centered with the photobleached spot as well as a reference unbleached region of similar size for photobleaching correction. FRAP traces were corrected for photobleaching and fitted to a standard exponential decay model of the form: <inline-formula><mml:math id="inf1"><mml:mi>I</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi>A</mml:mi><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>τ</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:math></inline-formula>, with the mobile fraction <inline-formula><mml:math id="inf2"><mml:mi>A</mml:mi></mml:math></inline-formula> and the decay time constant <inline-formula><mml:math id="inf3"><mml:mi>τ</mml:mi></mml:math></inline-formula> being free parameters. Recovery half-life <inline-formula><mml:math id="inf4"><mml:msub><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> was derived using the relation <inline-formula><mml:math id="inf5"><mml:msub><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mi>τ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>.</p></sec><sec id="s4-22-5"><title>Cheminformatics analysis</title><p>SMILES strings of all analyzed compound libraries were batch-processed in ChemAxon (version 20.8.2) by first correcting each compound to its major tautomeric and protonation state at a physiologically relevant pH of 7.4. A total of 20 physicochemical parameters were calculated for each compound. A Mann Whitney U test was conducted in R software (version 3.4.3, 2017) to assess statistically significant differences between libraries.</p><p>The compounds tested in the fusion screen were divided into two libraries: ‘non-hits’, containing all non-toxic molecules that passed quality control and with a z-score (fusion) &gt;−3.0 (n = 5551); and ‘hits’, containing non-toxic molecules that passed quality and had a z-score (fusion) &lt;3.0 (n = 163). Both libraries were filtered for empty wells for which no SMILES codes were available (n = 210 in non-hits and one in hits), yielding a final number of 5504 compounds of non-hits and 162 compounds in hits.</p><p>A list of GPCR inhibitors, which represent approximately 35% of FDA-approved drugs, was provided by previous work (<xref ref-type="bibr" rid="bib131">Sriram and Insel, 2018</xref>). DrugBank (version 5.1.7) was downloaded and queried with the list to obtain SMILES codes, yielding the final GPCR library (n = 459) for batch processing and analysis in ChemAxon as described above.Box and whisker plots were plotted and linear regression analysis was conducted in GraphPad Prism (version 8.0.2) for MacOS.</p></sec><sec id="s4-22-6"><title>Scaffold and substructure enrichment analyses</title><p>Initial scaffold enrichment analysis was conducted in NCGC Scaffold Hopper software (version 1.0). The batch-processed SMILES strings from ChemAxon were input for the hit library (n = 163) to identify most common scaffolds present in this library. To assess enrichment relative to the starting library, the combined hit and non-hit libraries, that is all non-toxic molecules screened in the fusion assay that passed quality control and did not contain empty wells (n = 5714), were input in the software as well. 34 and 981 scaffolds were identified in the hit and starting libraries, respectively.</p><p>To identify the compounds containing the enriched scaffolds, SMILES strings from the top-10 enriched scaffolds in the hit group were analyzed in RDKit (version 2020.02.5) substructure search module using Python programming language (version 3.6.12) and IPython (version 7.12.0). Enrichment was assessed by conducting a pooled population comparison of the frequency of a scaffold in the hit library and the frequency of that same scaffold in the starting library. These values were then used to calculate z-scores and two-tailed p-values. Compounds containing statistically significant scaffolds (p-value&lt;0.05) were visually inspected to assess if unique and more complex substructures exist. If identified, those SMILES codes were subjected to another round of substructure search followed by two-tailed p-value calculation as described.</p></sec><sec id="s4-22-7"><title>Bioinformatics</title><p>We first acquired the complete set of viral proteins from viruses that infect humans yielding 1,391,780 proteins (data retrieved October 2020) (<xref ref-type="bibr" rid="bib142">UniProt Consortium, 2015</xref>). Next, we filtered for proteins in which two or more transmembrane prediction tools predicted an overlapping transmembrane helix or a transmembrane helix has been experimentally verified, yielding 168,094 proteins (<xref ref-type="bibr" rid="bib71">Käll et al., 2004</xref>; <xref ref-type="bibr" rid="bib129">Sonnhammer et al., 1998</xref>). Of these proteins, we applied a sliding window approach to assess local density of cysteine residues around the transmembrane helices. Specifically, we scanned the thirty-residue regions that lie on the N- or C- terminal sides of each transmembrane helix, using a window size of 20. For each protein, the transmembrane-adjacent window with the highest fraction of cysteine was taken as the protein’s cysteine fractional ‘score’. The complete set of protein scores is provided in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. To summarize high-confidence hits, we first removed redundancy by filtering for duplicate sequence entries that originated from strain-specific sequence deposition. This final set is provided as <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>, with high-density hits called out in <xref ref-type="fig" rid="fig5">Figure 5G</xref>.</p><p>In parallel, we acquired the complete set of human proteins (n = 20370) from Uniprot (data retrieved October 2020) (<xref ref-type="bibr" rid="bib142">UniProt Consortium, 2015</xref>). We then similarly filtered for predicted transmembrane proteins, yielding 5182 candidates (<xref ref-type="bibr" rid="bib71">Käll et al., 2004</xref>; <xref ref-type="bibr" rid="bib129">Sonnhammer et al., 1998</xref>). Of these proteins, we applied the same sliding window approach as for viral proteins as described above. The complete set of protein scores is provided in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>. We further subjected these putatively cysteine-rich transmembrane proteins to manual filtering to identify ‘spike-like’ human proteins, which feature cysteine motifs in cytosol and aromatics at the ectodomain-plasma membrane interface. Results are summarized in <xref ref-type="fig" rid="fig5">Figure 5H</xref> with gene ontology (PantherDB) presented in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>.</p></sec></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank all Brangwynne Lab members for helpful discussion and critiques and Evangelos Gatzogiannis for help with live cell microscopy. AD wishes to thank the Hargrove lab at Duke University, and particularly Sarah Wicks, for assistance and use of the ChemAxon analysis software, as well as Dr. Brittany Morgan for helpful discussions. This work was supported by Princeton COVID-19 research funds through the Office of the Dean for Research (CPB and AP labs); the Howard Hughes Medical Institute (CPB lab); a Boston University start-up fund and Peter Paul Career Development Professorship (FD); NIH (GM095467 and HL122531 to BDL; GM134949, GM124072, and GM120351 to IL); Volkswagen Foundation (IL); Human Frontiers Science Program (IL); a Burroughs Wellcome Fund Award for Investigators in Pathogenesis (AP); Longer Life Foundation—RGA/Washington University Collaboration (ASH); postdoctoral fellowship awards from the Uehara Memorial Foundation and JSPS Research Fellowships for Young Scientists (TT); from the SENSHIN Medical Research Foundation (S.S); and from the Natural Sciences and Engineering Research Council of Canada (CCJ).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>ASH is a consultant for Dewpoint Therapeutics.</p></fn><fn fn-type="COI-statement" id="conf3"><p>CPB is a scientific founder and consultant for Nereid Therapeutics.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Funding acquisition, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Supervision, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Supervision, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Supervision, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con17"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con18"><p>Supervision, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Supervision, Funding acquisition, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Human pathology studies were performed with the approval of the Institutional Review Board at Brigham and Women's Hospital. Clinical autopsies with full anatomic dissection were performed on SARS-CoV-2 decedents by a board-certified anatomic pathologist (RFP) with appropriate infectious precautions.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title><p>Raw data from unbiased drug repurposing screen.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65962-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Related to <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title><p>Viral transmembrane proteins with proximal cysteine-rich regions.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65962-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Related to <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title><p>Human transmembrane proteins with spike-like membrane proximal regions.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65962-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Related to <xref ref-type="fig" rid="fig3">Figures 3</xref>–<xref ref-type="fig" rid="fig7">7</xref>.</title><p>Amino acid composition of transmembrane proteins used in this study and cellular targets associated with extensively tested compounds.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65962-supp4-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-65962-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files with the exception of raw imaging data (&gt;400,000 Nikon ND2 files), which is not feasible to post online given its massive size (&gt;1.5 TB). This data is available from the lead contact upon request, assuming the interested party provides a server with sufficient storage capacity. Raw data (computed fusion scores) from the drug repurposing screen is available in Supplementary File 1; bioinformatics, Supplementary File 3.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname> <given-names>ME</given-names></name><name><surname>Johnson</surname> <given-names>KA</given-names></name><name><surname>Perelman</surname> <given-names>SS</given-names></name><name><surname>Zhang</surname> <given-names>LS</given-names></name><name><surname>Endapally</surname> <given-names>S</given-names></name><name><surname>Mar</surname> <given-names>KB</given-names></name><name><surname>Thompson</surname> <given-names>BM</given-names></name><name><surname>McDonald</surname> <given-names>JG</given-names></name><name><surname>Schoggins</surname> <given-names>JW</given-names></name><name><surname>Radhakrishnan</surname> <given-names>A</given-names></name><name><surname>Alto</surname> <given-names>NM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Oxysterols provide innate immunity to bacterial infection by mobilizing cell surface accessible cholesterol</article-title><source>Nature Microbiology</source><volume>5</volume><fpage>929</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0701-5</pub-id><pub-id pub-id-type="pmid">32284563</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname> <given-names>L</given-names></name><name><surname>Ferla</surname> <given-names>S</given-names></name><name><surname>Head</surname> <given-names>SA</given-names></name><name><surname>Bhat</surname> <given-names>S</given-names></name><name><surname>Pasunooti</surname> <given-names>KK</given-names></name><name><surname>Shi</surname> <given-names>WQ</given-names></name><name><surname>Albulescu</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>JO</given-names></name><name><surname>Brancale</surname> <given-names>A</given-names></name><name><surname>van Kuppeveld</surname> <given-names>FJM</given-names></name><name><surname>Strating</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure-activity relationship study of itraconazole, a broad-range inhibitor of Picornavirus replication that targets oxysterol-binding protein (OSBP)</article-title><source>Antiviral Research</source><volume>156</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2018.05.010</pub-id><pub-id pub-id-type="pmid">29807040</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumgart</surname> <given-names>T</given-names></name><name><surname>Hammond</surname> <given-names>AT</given-names></name><name><surname>Sengupta</surname> <given-names>P</given-names></name><name><surname>Hess</surname> <given-names>ST</given-names></name><name><surname>Holowka</surname> <given-names>DA</given-names></name><name><surname>Baird</surname> <given-names>BA</given-names></name><name><surname>Webb</surname> <given-names>WW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Large-scale fluid/fluid phase separation of proteins and lipids in giant plasma membrane vesicles</article-title><source>PNAS</source><volume>104</volume><fpage>3165</fpage><lpage>3170</lpage><pub-id pub-id-type="doi">10.1073/pnas.0611357104</pub-id><pub-id pub-id-type="pmid">17360623</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname> <given-names>M</given-names></name><name><surname>Schmidt</surname> <given-names>A</given-names></name><name><surname>Malmstroem</surname> <given-names>J</given-names></name><name><surname>Claassen</surname> <given-names>M</given-names></name><name><surname>Ori</surname> <given-names>A</given-names></name><name><surname>Szymborska</surname> <given-names>A</given-names></name><name><surname>Herzog</surname> <given-names>F</given-names></name><name><surname>Rinner</surname> <given-names>O</given-names></name><name><surname>Ellenberg</surname> <given-names>J</given-names></name><name><surname>Aebersold</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The quantitative proteome of a human cell line</article-title><source>Molecular Systems Biology</source><volume>7</volume><elocation-id>549</elocation-id><pub-id pub-id-type="doi">10.1038/msb.2011.82</pub-id><pub-id pub-id-type="pmid">22068332</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belouzard</surname> <given-names>S</given-names></name><name><surname>Millet</surname> <given-names>JK</given-names></name><name><surname>Licitra</surname> <given-names>BN</given-names></name><name><surname>Whittaker</surname> <given-names>GR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mechanisms of coronavirus cell entry mediated by the viral spike protein</article-title><source>Viruses</source><volume>4</volume><fpage>1011</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.3390/v4061011</pub-id><pub-id pub-id-type="pmid">22816037</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname> <given-names>P</given-names></name><name><surname>Ramirez-Martinez</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Cannavino</surname> <given-names>J</given-names></name><name><surname>McAnally</surname> <given-names>JR</given-names></name><name><surname>Shelton</surname> <given-names>JM</given-names></name><name><surname>Sánchez-Ortiz</surname> <given-names>E</given-names></name><name><surname>Bassel-Duby</surname> <given-names>R</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Control of muscle formation by the fusogenic micropeptide myomixer</article-title><source>Science</source><volume>356</volume><fpage>323</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1126/science.aam9361</pub-id><pub-id pub-id-type="pmid">28386024</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouhaddou</surname> <given-names>M</given-names></name><name><surname>Memon</surname> <given-names>D</given-names></name><name><surname>Meyer</surname> <given-names>B</given-names></name><name><surname>White</surname> <given-names>KM</given-names></name><name><surname>Rezelj</surname> <given-names>VV</given-names></name><name><surname>Correa Marrero</surname> <given-names>M</given-names></name><name><surname>Polacco</surname> <given-names>BJ</given-names></name><name><surname>Melnyk</surname> <given-names>JE</given-names></name><name><surname>Ulferts</surname> <given-names>S</given-names></name><name><surname>Kaake</surname> <given-names>RM</given-names></name><name><surname>Batra</surname> <given-names>J</given-names></name><name><surname>Richards</surname> <given-names>AL</given-names></name><name><surname>Stevenson</surname> <given-names>E</given-names></name><name><surname>Gordon</surname> <given-names>DE</given-names></name><name><surname>Rojc</surname> <given-names>A</given-names></name><name><surname>Obernier</surname> <given-names>K</given-names></name><name><surname>Fabius</surname> <given-names>JM</given-names></name><name><surname>Soucheray</surname> <given-names>M</given-names></name><name><surname>Miorin</surname> <given-names>L</given-names></name><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Koh</surname> <given-names>C</given-names></name><name><surname>Tran</surname> <given-names>QD</given-names></name><name><surname>Hardy</surname> <given-names>A</given-names></name><name><surname>Robinot</surname> <given-names>R</given-names></name><name><surname>Vallet</surname> <given-names>T</given-names></name><name><surname>Nilsson-Payant</surname> <given-names>BE</given-names></name><name><surname>Hernandez-Armenta</surname> <given-names>C</given-names></name><name><surname>Dunham</surname> <given-names>A</given-names></name><name><surname>Weigang</surname> <given-names>S</given-names></name><name><surname>Knerr</surname> <given-names>J</given-names></name><name><surname>Modak</surname> <given-names>M</given-names></name><name><surname>Quintero</surname> <given-names>D</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Dugourd</surname> <given-names>A</given-names></name><name><surname>Valdeolivas</surname> <given-names>A</given-names></name><name><surname>Patil</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Hüttenhain</surname> <given-names>R</given-names></name><name><surname>Cakir</surname> <given-names>M</given-names></name><name><surname>Muralidharan</surname> <given-names>M</given-names></name><name><surname>Kim</surname> <given-names>M</given-names></name><name><surname>Jang</surname> <given-names>G</given-names></name><name><surname>Tutuncuoglu</surname> <given-names>B</given-names></name><name><surname>Hiatt</surname> <given-names>J</given-names></name><name><surname>Guo</surname> <given-names>JZ</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Bouhaddou</surname> <given-names>S</given-names></name><name><surname>Mathy</surname> <given-names>CJP</given-names></name><name><surname>Gaulton</surname> <given-names>A</given-names></name><name><surname>Manners</surname> <given-names>EJ</given-names></name><name><surname>Félix</surname> <given-names>E</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Goff</surname> <given-names>M</given-names></name><name><surname>Lim</surname> <given-names>JK</given-names></name><name><surname>McBride</surname> <given-names>T</given-names></name><name><surname>O'Neal</surname> <given-names>MC</given-names></name><name><surname>Cai</surname> <given-names>Y</given-names></name><name><surname>Chang</surname> <given-names>JCJ</given-names></name><name><surname>Broadhurst</surname> <given-names>DJ</given-names></name><name><surname>Klippsten</surname> <given-names>S</given-names></name><name><surname>De Wit</surname> <given-names>E</given-names></name><name><surname>Leach</surname> <given-names>AR</given-names></name><name><surname>Kortemme</surname> <given-names>T</given-names></name><name><surname>Shoichet</surname> <given-names>B</given-names></name><name><surname>Ott</surname> <given-names>M</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>tenOever</surname> <given-names>BR</given-names></name><name><surname>Mullins</surname> <given-names>RD</given-names></name><name><surname>Fischer</surname> <given-names>ER</given-names></name><name><surname>Kochs</surname> <given-names>G</given-names></name><name><surname>Grosse</surname> <given-names>R</given-names></name><name><surname>García-Sastre</surname> <given-names>A</given-names></name><name><surname>Vignuzzi</surname> <given-names>M</given-names></name><name><surname>Johnson</surname> <given-names>JR</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name><name><surname>Swaney</surname> <given-names>DL</given-names></name><name><surname>Beltrao</surname> <given-names>P</given-names></name><name><surname>Krogan</surname> <given-names>NJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The global phosphorylation landscape of SARS-CoV-2 infection</article-title><source>Cell</source><volume>182</volume><fpage>685</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.034</pub-id><pub-id pub-id-type="pmid">32645325</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brüning</surname> <given-names>A</given-names></name><name><surname>Rahmeh</surname> <given-names>M</given-names></name><name><surname>Friese</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation</article-title><source>Molecular Oncology</source><volume>7</volume><fpage>1012</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2013.07.010</pub-id><pub-id pub-id-type="pmid">23916134</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Bryce</surname> <given-names>C</given-names></name><name><surname>Grimes</surname> <given-names>Z</given-names></name><name><surname>Pujadas</surname> <given-names>E</given-names></name><name><surname>Ahuja</surname> <given-names>S</given-names></name><name><surname>Beasley</surname> <given-names>MB</given-names></name><name><surname>Albrecht</surname> <given-names>R</given-names></name><name><surname>Hernandez</surname> <given-names>T</given-names></name><name><surname>Stock</surname> <given-names>A</given-names></name><name><surname>Zhao</surname> <given-names>Z</given-names></name><name><surname>Rasheed, Al</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. the mount sinai COVID-19 autopsy experience</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.05.18.20099960</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchrieser</surname> <given-names>J</given-names></name><name><surname>Dufloo</surname> <given-names>J</given-names></name><name><surname>Hubert</surname> <given-names>M</given-names></name><name><surname>Monel</surname> <given-names>B</given-names></name><name><surname>Planas</surname> <given-names>D</given-names></name><name><surname>Rajah</surname> <given-names>MM</given-names></name><name><surname>Planchais</surname> <given-names>C</given-names></name><name><surname>Porrot</surname> <given-names>F</given-names></name><name><surname>Guivel-Benhassine</surname> <given-names>F</given-names></name><name><surname>Van der Werf</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Syncytia formation by SARS-CoV-2 infected cells</article-title><source>EMBO J </source><volume>39</volume><elocation-id>e106267</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2020106267</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Cheung</surname> <given-names>AK</given-names></name><name><surname>Tomlinson</surname> <given-names>RC</given-names></name><name><surname>Alcázar-Román</surname> <given-names>A</given-names></name><name><surname>Murphy</surname> <given-names>L</given-names></name><name><surname>Billich</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Feng</surname> <given-names>Y</given-names></name><name><surname>Klumpp</surname> <given-names>M</given-names></name><name><surname>Rondeau</surname> <given-names>JM</given-names></name><name><surname>Fazal</surname> <given-names>AN</given-names></name><name><surname>Wilson</surname> <given-names>CJ</given-names></name><name><surname>Myer</surname> <given-names>V</given-names></name><name><surname>Joberty</surname> <given-names>G</given-names></name><name><surname>Bouwmeester</surname> <given-names>T</given-names></name><name><surname>Labow</surname> <given-names>MA</given-names></name><name><surname>Finan</surname> <given-names>PM</given-names></name><name><surname>Porter</surname> <given-names>JA</given-names></name><name><surname>Ploegh</surname> <given-names>HL</given-names></name><name><surname>Baird</surname> <given-names>D</given-names></name><name><surname>De Camilli</surname> <given-names>P</given-names></name><name><surname>Tallarico</surname> <given-names>JA</given-names></name><name><surname>Huang</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling</article-title><source>Chemistry &amp; Biology</source><volume>20</volume><fpage>912</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2013.05.010</pub-id><pub-id pub-id-type="pmid">23890009</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname> <given-names>L</given-names></name><name><surname>Druce</surname> <given-names>JD</given-names></name><name><surname>Catton</surname> <given-names>MG</given-names></name><name><surname>Jans</surname> <given-names>DA</given-names></name><name><surname>Wagstaff</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</article-title><source>Antiviral Research</source><volume>178</volume><elocation-id>104787</elocation-id><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id><pub-id pub-id-type="pmid">32251768</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbajo-Lozoya</surname> <given-names>J</given-names></name><name><surname>Müller</surname> <given-names>MA</given-names></name><name><surname>Kallies</surname> <given-names>S</given-names></name><name><surname>Thiel</surname> <given-names>V</given-names></name><name><surname>Drosten</surname> <given-names>C</given-names></name><name><surname>von Brunn</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506</article-title><source>Virus Research</source><volume>165</volume><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2012.02.002</pub-id><pub-id pub-id-type="pmid">22349148</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castello-Serrano</surname> <given-names>I</given-names></name><name><surname>Lorent</surname> <given-names>JH</given-names></name><name><surname>Ippolito</surname> <given-names>R</given-names></name><name><surname>Levental</surname> <given-names>KR</given-names></name><name><surname>Levental</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Myelin-Associated MAL and PLP are unusual among multipass transmembrane proteins in preferring ordered membrane domains</article-title><source>The Journal of Physical Chemistry B</source><volume>124</volume><fpage>5930</fpage><lpage>5939</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.0c03028</pub-id><pub-id pub-id-type="pmid">32436385</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Cattin-Ortolá</surname> <given-names>J</given-names></name><name><surname>Welch</surname> <given-names>L</given-names></name><name><surname>Maslen</surname> <given-names>SL</given-names></name><name><surname>Skehel</surname> <given-names>JM</given-names></name><name><surname>Papa</surname> <given-names>G</given-names></name><name><surname>James</surname> <given-names>LC</given-names></name><name><surname>Munro</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sequences in the cytoplasmic tail of SARS-CoV-2 spike facilitate syncytia formation</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.10.12.335562</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cervin</surname> <given-names>M</given-names></name><name><surname>Anderson</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Modulation of coronavirus-mediated cell fusion by homeostatic control of cholesterol and fatty acid metabolism</article-title><source>Journal of Medical Virology</source><volume>35</volume><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1002/jmv.1890350213</pub-id><pub-id pub-id-type="pmid">1662706</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>KMC</given-names></name><name><surname>Arthur</surname> <given-names>AL</given-names></name><name><surname>Morstein</surname> <given-names>J</given-names></name><name><surname>Jin</surname> <given-names>M</given-names></name><name><surname>Bhat</surname> <given-names>A</given-names></name><name><surname>Schlesinger</surname> <given-names>D</given-names></name><name><surname>Son</surname> <given-names>S</given-names></name><name><surname>Stevens</surname> <given-names>DA</given-names></name><name><surname>Drubin</surname> <given-names>DG</given-names></name><name><surname>Fletcher</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Evolutionarily related small viral fusogens hijack distinct but modular actin nucleation pathways to drive cell-cell fusion</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.06.03.130740</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>KMC</given-names></name><name><surname>Son</surname> <given-names>S</given-names></name><name><surname>Schmid</surname> <given-names>EM</given-names></name><name><surname>Fletcher</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>A viral fusogen hijacks the actin cytoskeleton to drive cell-cell fusion</article-title><source>eLife</source><volume>9</volume><elocation-id>e51358</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.51358</pub-id><pub-id pub-id-type="pmid">32441254</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>A</given-names></name><name><surname>Leikina</surname> <given-names>E</given-names></name><name><surname>Melikov</surname> <given-names>K</given-names></name><name><surname>Podbilewicz</surname> <given-names>B</given-names></name><name><surname>Kozlov</surname> <given-names>MM</given-names></name><name><surname>Chernomordik</surname> <given-names>LV</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Fusion-pore expansion during syncytium formation is restricted by an actin network</article-title><source>Journal of Cell Science</source><volume>121</volume><fpage>3619</fpage><lpage>3628</lpage><pub-id pub-id-type="doi">10.1242/jcs.032169</pub-id><pub-id pub-id-type="pmid">18946025</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>CZ</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Pradhan</surname> <given-names>M</given-names></name><name><surname>Gorshkov</surname> <given-names>K</given-names></name><name><surname>Petersen</surname> <given-names>J</given-names></name><name><surname>Straus</surname> <given-names>MR</given-names></name><name><surname>Zhu</surname> <given-names>W</given-names></name><name><surname>Shinn</surname> <given-names>P</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Shen</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.07.10.197988</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chlanda</surname> <given-names>P</given-names></name><name><surname>Mekhedov</surname> <given-names>E</given-names></name><name><surname>Waters</surname> <given-names>H</given-names></name><name><surname>Sodt</surname> <given-names>A</given-names></name><name><surname>Schwartz</surname> <given-names>C</given-names></name><name><surname>Nair</surname> <given-names>V</given-names></name><name><surname>Blank</surname> <given-names>PS</given-names></name><name><surname>Zimmerberg</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Palmitoylation contributes to membrane curvature in influenza A virus assembly and Hemagglutinin-Mediated membrane fusion</article-title><source>Journal of Virology</source><volume>91</volume><elocation-id>229</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.00947-17</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciechonska</surname> <given-names>M</given-names></name><name><surname>Duncan</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reovirus FAST proteins: virus-encoded cellular fusogens</article-title><source>Trends in Microbiology</source><volume>22</volume><fpage>715</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2014.08.005</pub-id><pub-id pub-id-type="pmid">25245455</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname> <given-names>LD</given-names></name><name><surname>Ziv</surname> <given-names>NE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Neuronal and synaptic protein lifetimes</article-title><source>Current Opinion in Neurobiology</source><volume>57</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2018.12.007</pub-id><pub-id pub-id-type="pmid">30677713</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compton</surname> <given-names>AA</given-names></name><name><surname>Schwartz</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>They might be giants: does syncytium formation sink or spread HIV infection?</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006099</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006099</pub-id><pub-id pub-id-type="pmid">28152024</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corman</surname> <given-names>VM</given-names></name><name><surname>Landt</surname> <given-names>O</given-names></name><name><surname>Kaiser</surname> <given-names>M</given-names></name><name><surname>Molenkamp</surname> <given-names>R</given-names></name><name><surname>Meijer</surname> <given-names>A</given-names></name><name><surname>Chu</surname> <given-names>DKW</given-names></name><name><surname>Bleicker</surname> <given-names>T</given-names></name><name><surname>Brünink</surname> <given-names>S</given-names></name><name><surname>Schneider</surname> <given-names>J</given-names></name><name><surname>Schmidt</surname> <given-names>ML</given-names></name><name><surname>Mulders</surname> <given-names>DGJC</given-names></name><name><surname>Haagmans</surname> <given-names>BL</given-names></name><name><surname>van der Veer</surname> <given-names>B</given-names></name><name><surname>van den Brink</surname> <given-names>S</given-names></name><name><surname>Wijsman</surname> <given-names>L</given-names></name><name><surname>Goderski</surname> <given-names>G</given-names></name><name><surname>Romette</surname> <given-names>J-L</given-names></name><name><surname>Ellis</surname> <given-names>J</given-names></name><name><surname>Zambon</surname> <given-names>M</given-names></name><name><surname>Peiris</surname> <given-names>M</given-names></name><name><surname>Goossens</surname> <given-names>H</given-names></name><name><surname>Reusken</surname> <given-names>C</given-names></name><name><surname>Koopmans</surname> <given-names>MPG</given-names></name><name><surname>Drosten</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</article-title><source>Eurosurveillance</source><volume>25</volume><elocation-id>2431</elocation-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.3.2000045</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornell</surname> <given-names>CE</given-names></name><name><surname>McCarthy</surname> <given-names>NLC</given-names></name><name><surname>Levental</surname> <given-names>KR</given-names></name><name><surname>Levental</surname> <given-names>I</given-names></name><name><surname>Brooks</surname> <given-names>NJ</given-names></name><name><surname>Keller</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>n-Alcohol length governs shift in L<sub>o</sub>-L<sub>d</sub>mixing temperatures in synthetic and Cell-Derived Membranes</article-title><source>Biophysical Journal</source><volume>113</volume><fpage>1200</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2017.06.066</pub-id><pub-id pub-id-type="pmid">28801104</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corver</surname> <given-names>J</given-names></name><name><surname>Broer</surname> <given-names>R</given-names></name><name><surname>van Kasteren</surname> <given-names>P</given-names></name><name><surname>Spaan</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mutagenesis of the transmembrane domain of the SARS coronavirus spike glycoprotein: refinement of the requirements for SARS coronavirus cell entry</article-title><source>Virology Journal</source><volume>6</volume><elocation-id>230</elocation-id><pub-id pub-id-type="doi">10.1186/1743-422X-6-230</pub-id><pub-id pub-id-type="pmid">20034394</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Costeira</surname> <given-names>R</given-names></name><name><surname>Lee</surname> <given-names>KA</given-names></name><name><surname>Murray</surname> <given-names>B</given-names></name><name><surname>Christiansen</surname> <given-names>C</given-names></name><name><surname>Castillo-Fernandez</surname> <given-names>J</given-names></name><name><surname>Ni Lochlainn</surname> <given-names>M</given-names></name><name><surname>Capdevila Pujol</surname> <given-names>J</given-names></name><name><surname>Buchan</surname> <given-names>I</given-names></name><name><surname>Kenny</surname> <given-names>LC</given-names></name><name><surname>Wolf</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Estrogen and COVID-19 symptoms: associations in women from the COVID symptom study</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.07.30.20164921</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniels</surname> <given-names>LB</given-names></name><name><surname>Sitapati</surname> <given-names>AM</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Zou</surname> <given-names>J</given-names></name><name><surname>Bui</surname> <given-names>QM</given-names></name><name><surname>Ren</surname> <given-names>J</given-names></name><name><surname>Longhurst</surname> <given-names>CA</given-names></name><name><surname>Criqui</surname> <given-names>MH</given-names></name><name><surname>Messer</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients</article-title><source>The American Journal of Cardiology</source><volume>136</volume><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2020.09.012</pub-id><pub-id pub-id-type="pmid">32946859</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname> <given-names>A</given-names></name><name><surname>Brown</surname> <given-names>MS</given-names></name><name><surname>Anderson</surname> <given-names>DD</given-names></name><name><surname>Goldstein</surname> <given-names>JL</given-names></name><name><surname>Radhakrishnan</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Three pools of plasma membrane cholesterol and their relation to cholesterol homeostasis</article-title><source>eLife</source><volume>3</volume><elocation-id>e02882</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.02882</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Davies</surname> <given-names>NG</given-names></name><name><surname>Jarvis</surname> <given-names>CI</given-names></name><name><surname>Edmunds</surname> <given-names>WJ</given-names></name><name><surname>Jewell</surname> <given-names>NP</given-names></name><name><surname>Diaz-Ordaz</surname> <given-names>K</given-names></name><name><surname>Keogh</surname> <given-names>RH</given-names></name><collab>CMMID COVID-19 Working Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Increased mortality in community-tested cases of SARS-CoV-2 lineage b.1.1.7</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2021.02.01.21250959</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname> <given-names>CA</given-names></name><name><surname>Kraft</surname> <given-names>LJ</given-names></name><name><surname>Kang</surname> <given-names>M</given-names></name><name><surname>Kenworthy</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Analysis of protein and lipid dynamics using confocal fluorescence recovery after photobleaching (FRAP)</article-title><source>Current Protocols in Cytometry</source><volume>Chapter 2</volume><elocation-id>Unit2.19</elocation-id><pub-id pub-id-type="doi">10.1002/0471142956.cy0219s62</pub-id><pub-id pub-id-type="pmid">23042527</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daya</surname> <given-names>M</given-names></name><name><surname>Cervin</surname> <given-names>M</given-names></name><name><surname>Anderson</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Cholesterol enhances mouse hepatitis virus-mediated cell fusion</article-title><source>Virology</source><volume>163</volume><fpage>276</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(88)90267-X</pub-id><pub-id pub-id-type="pmid">2833007</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Gassart</surname> <given-names>A</given-names></name><name><surname>Bujisic</surname> <given-names>B</given-names></name><name><surname>Zaffalon</surname> <given-names>L</given-names></name><name><surname>Decosterd</surname> <given-names>LA</given-names></name><name><surname>Di Micco</surname> <given-names>A</given-names></name><name><surname>Frera</surname> <given-names>G</given-names></name><name><surname>Tallant</surname> <given-names>R</given-names></name><name><surname>Martinon</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An inhibitor of HIV-1 protease modulates constitutive eIF2α dephosphorylation to trigger a specific integrated stress response</article-title><source>PNAS</source><volume>113</volume><fpage>E117</fpage><lpage>E126</lpage><pub-id pub-id-type="doi">10.1073/pnas.1514076113</pub-id><pub-id pub-id-type="pmid">26715744</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jesus</surname> <given-names>AJ</given-names></name><name><surname>Allen</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The role of tryptophan side chains in membrane protein anchoring and hydrophobic mismatch</article-title><source>Biochimica Et Biophysica Acta (BBA) - Biomembranes</source><volume>1828</volume><fpage>864</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2012.09.009</pub-id><pub-id pub-id-type="pmid">22989724</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname> <given-names>Q</given-names></name><name><surname>Heller</surname> <given-names>B</given-names></name><name><surname>Capuccino</surname> <given-names>JM</given-names></name><name><surname>Song</surname> <given-names>B</given-names></name><name><surname>Nimgaonkar</surname> <given-names>I</given-names></name><name><surname>Hrebikova</surname> <given-names>G</given-names></name><name><surname>Contreras</surname> <given-names>JE</given-names></name><name><surname>Ploss</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles</article-title><source>PNAS</source><volume>114</volume><fpage>1147</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1073/pnas.1614955114</pub-id><pub-id pub-id-type="pmid">28096411</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Dittmar</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>JS</given-names></name><name><surname>Whig</surname> <given-names>K</given-names></name><name><surname>Segrist</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Jurado</surname> <given-names>K</given-names></name><name><surname>Samby</surname> <given-names>K</given-names></name><name><surname>Ramage</surname> <given-names>H</given-names></name><name><surname>Schultz</surname> <given-names>D</given-names></name><name><surname>Cherry</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.06.19.161042</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname> <given-names>R</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Shilagardi</surname> <given-names>K</given-names></name><name><surname>Schiffhauer</surname> <given-names>ES</given-names></name><name><surname>Lee</surname> <given-names>DM</given-names></name><name><surname>Son</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Thomas</surname> <given-names>C</given-names></name><name><surname>Luo</surname> <given-names>T</given-names></name><name><surname>Fletcher</surname> <given-names>DA</given-names></name><name><surname>Robinson</surname> <given-names>DN</given-names></name><name><surname>Chen</surname> <given-names>EH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Spectrin is a mechanoresponsive protein shaping fusogenic synapse architecture during myoblast fusion</article-title><source>Nature Cell Biology</source><volume>20</volume><fpage>688</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0106-3</pub-id><pub-id pub-id-type="pmid">29802406</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname> <given-names>L</given-names></name><name><surname>Zheng</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Niu</surname> <given-names>Y</given-names></name><name><surname>Lou</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of Spike-Based vaccine immunogens</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>576622</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.576622</pub-id><pub-id pub-id-type="pmid">33117378</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duelli</surname> <given-names>D</given-names></name><name><surname>Lazebnik</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cell-to-cell fusion as a link between viruses and Cancer</article-title><source>Nature Reviews Cancer</source><volume>7</volume><fpage>968</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1038/nrc2272</pub-id><pub-id pub-id-type="pmid">18034186</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dustin</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The immunological synapse</article-title><source>Cancer Immunology Research</source><volume>2</volume><fpage>1023</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0161</pub-id><pub-id pub-id-type="pmid">25367977</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endapally</surname> <given-names>S</given-names></name><name><surname>Frias</surname> <given-names>D</given-names></name><name><surname>Grzemska</surname> <given-names>M</given-names></name><name><surname>Gay</surname> <given-names>A</given-names></name><name><surname>Tomchick</surname> <given-names>DR</given-names></name><name><surname>Radhakrishnan</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Molecular discrimination between two conformations of sphingomyelin in plasma membranes</article-title><source>Cell</source><volume>176</volume><fpage>1040</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.12.042</pub-id><pub-id pub-id-type="pmid">30712872</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endapally</surname> <given-names>S</given-names></name><name><surname>Infante</surname> <given-names>RE</given-names></name><name><surname>Radhakrishnan</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Monitoring and modulating intracellular cholesterol trafficking using ALOD4, a Cholesterol-Binding protein</article-title><source>Methods in Molecular Biology</source><volume>1949</volume><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9136-5_12</pub-id><pub-id pub-id-type="pmid">30790255</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epand</surname> <given-names>RM</given-names></name><name><surname>Sayer</surname> <given-names>BG</given-names></name><name><surname>Epand</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Peptide-induced formation of cholesterol-rich domains</article-title><source>Biochemistry</source><volume>42</volume><fpage>14677</fpage><lpage>14689</lpage><pub-id pub-id-type="doi">10.1021/bi035587j</pub-id><pub-id pub-id-type="pmid">14661981</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>S</given-names></name><name><surname>Sekine</surname> <given-names>S</given-names></name><name><surname>Pessino</surname> <given-names>V</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Leonetti</surname> <given-names>MD</given-names></name><name><surname>Huang</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Improved split fluorescent proteins for endogenous protein labeling</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>370</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-00494-8</pub-id><pub-id pub-id-type="pmid">28851864</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>François</surname> <given-names>IE</given-names></name><name><surname>Bink</surname> <given-names>A</given-names></name><name><surname>Vandercappellen</surname> <given-names>J</given-names></name><name><surname>Ayscough</surname> <given-names>KR</given-names></name><name><surname>Toulmay</surname> <given-names>A</given-names></name><name><surname>Schneiter</surname> <given-names>R</given-names></name><name><surname>van Gyseghem</surname> <given-names>E</given-names></name><name><surname>Van den Mooter</surname> <given-names>G</given-names></name><name><surname>Borgers</surname> <given-names>M</given-names></name><name><surname>Vandenbosch</surname> <given-names>D</given-names></name><name><surname>Coenye</surname> <given-names>T</given-names></name><name><surname>Cammue</surname> <given-names>BP</given-names></name><name><surname>Thevissen</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Membrane rafts are involved in intracellular miconazole accumulation in yeast cells</article-title><source>Journal of Biological Chemistry</source><volume>284</volume><fpage>32680</fpage><lpage>32685</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.014571</pub-id><pub-id pub-id-type="pmid">19783660</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankel</surname> <given-names>SS</given-names></name><name><surname>Wenig</surname> <given-names>BM</given-names></name><name><surname>Burke</surname> <given-names>AP</given-names></name><name><surname>Mannan</surname> <given-names>P</given-names></name><name><surname>Thompson</surname> <given-names>LD</given-names></name><name><surname>Abbondanzo</surname> <given-names>SL</given-names></name><name><surname>Nelson</surname> <given-names>AM</given-names></name><name><surname>Pope</surname> <given-names>M</given-names></name><name><surname>Steinman</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid</article-title><source>Science</source><volume>272</volume><fpage>115</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1126/science.272.5258.115</pub-id><pub-id pub-id-type="pmid">8600520</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Giacca</surname> <given-names>M</given-names></name><name><surname>Bussani</surname> <given-names>R</given-names></name><name><surname>Schneider</surname> <given-names>E</given-names></name><name><surname>Zentilin</surname> <given-names>L</given-names></name><name><surname>Collesi</surname> <given-names>C</given-names></name><name><surname>Ali</surname> <given-names>H</given-names></name><name><surname>Braga</surname> <given-names>L</given-names></name><name><surname>Secco</surname> <given-names>I</given-names></name><name><surname>Volpe</surname> <given-names>MC</given-names></name><name><surname>Colliva</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Persistence of viral RNA, widespread thrombosis and abnormal cellular syncytia are hallmarks of COVID-19 lung pathology</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.06.22.20136358</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname> <given-names>DB</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>The effects of drugs on membrane fluidity</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>24</volume><fpage>43</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1146/annurev.pa.24.040184.000355</pub-id><pub-id pub-id-type="pmid">6329077</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname> <given-names>JL</given-names></name><name><surname>Brown</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A century of cholesterol and coronaries: from plaques to genes to statins</article-title><source>Cell</source><volume>161</volume><fpage>161</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.01.036</pub-id><pub-id pub-id-type="pmid">25815993</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname> <given-names>DE</given-names></name><name><surname>Jang</surname> <given-names>GM</given-names></name><name><surname>Bouhaddou</surname> <given-names>M</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Obernier</surname> <given-names>K</given-names></name><name><surname>White</surname> <given-names>KM</given-names></name><name><surname>O'Meara</surname> <given-names>MJ</given-names></name><name><surname>Rezelj</surname> <given-names>VV</given-names></name><name><surname>Guo</surname> <given-names>JZ</given-names></name><name><surname>Swaney</surname> <given-names>DL</given-names></name><name><surname>Tummino</surname> <given-names>TA</given-names></name><name><surname>Hüttenhain</surname> <given-names>R</given-names></name><name><surname>Kaake</surname> <given-names>RM</given-names></name><name><surname>Richards</surname> <given-names>AL</given-names></name><name><surname>Tutuncuoglu</surname> <given-names>B</given-names></name><name><surname>Foussard</surname> <given-names>H</given-names></name><name><surname>Batra</surname> <given-names>J</given-names></name><name><surname>Haas</surname> <given-names>K</given-names></name><name><surname>Modak</surname> <given-names>M</given-names></name><name><surname>Kim</surname> <given-names>M</given-names></name><name><surname>Haas</surname> <given-names>P</given-names></name><name><surname>Polacco</surname> <given-names>BJ</given-names></name><name><surname>Braberg</surname> <given-names>H</given-names></name><name><surname>Fabius</surname> <given-names>JM</given-names></name><name><surname>Eckhardt</surname> <given-names>M</given-names></name><name><surname>Soucheray</surname> <given-names>M</given-names></name><name><surname>Bennett</surname> <given-names>MJ</given-names></name><name><surname>Cakir</surname> <given-names>M</given-names></name><name><surname>McGregor</surname> <given-names>MJ</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Meyer</surname> <given-names>B</given-names></name><name><surname>Roesch</surname> <given-names>F</given-names></name><name><surname>Vallet</surname> <given-names>T</given-names></name><name><surname>Mac Kain</surname> <given-names>A</given-names></name><name><surname>Miorin</surname> <given-names>L</given-names></name><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Naing</surname> <given-names>ZZC</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Peng</surname> <given-names>S</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Shen</surname> <given-names>W</given-names></name><name><surname>Kirby</surname> <given-names>IT</given-names></name><name><surname>Melnyk</surname> <given-names>JE</given-names></name><name><surname>Chorba</surname> <given-names>JS</given-names></name><name><surname>Lou</surname> <given-names>K</given-names></name><name><surname>Dai</surname> <given-names>SA</given-names></name><name><surname>Barrio-Hernandez</surname> <given-names>I</given-names></name><name><surname>Memon</surname> <given-names>D</given-names></name><name><surname>Hernandez-Armenta</surname> <given-names>C</given-names></name><name><surname>Lyu</surname> <given-names>J</given-names></name><name><surname>Mathy</surname> <given-names>CJP</given-names></name><name><surname>Perica</surname> <given-names>T</given-names></name><name><surname>Pilla</surname> <given-names>KB</given-names></name><name><surname>Ganesan</surname> <given-names>SJ</given-names></name><name><surname>Saltzberg</surname> <given-names>DJ</given-names></name><name><surname>Rakesh</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Rosenthal</surname> <given-names>SB</given-names></name><name><surname>Calviello</surname> <given-names>L</given-names></name><name><surname>Venkataramanan</surname> <given-names>S</given-names></name><name><surname>Liboy-Lugo</surname> <given-names>J</given-names></name><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>XP</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Wankowicz</surname> <given-names>SA</given-names></name><name><surname>Bohn</surname> <given-names>M</given-names></name><name><surname>Safari</surname> <given-names>M</given-names></name><name><surname>Ugur</surname> <given-names>FS</given-names></name><name><surname>Koh</surname> <given-names>C</given-names></name><name><surname>Savar</surname> <given-names>NS</given-names></name><name><surname>Tran</surname> <given-names>QD</given-names></name><name><surname>Shengjuler</surname> <given-names>D</given-names></name><name><surname>Fletcher</surname> <given-names>SJ</given-names></name><name><surname>O'Neal</surname> <given-names>MC</given-names></name><name><surname>Cai</surname> <given-names>Y</given-names></name><name><surname>Chang</surname> <given-names>JCJ</given-names></name><name><surname>Broadhurst</surname> <given-names>DJ</given-names></name><name><surname>Klippsten</surname> <given-names>S</given-names></name><name><surname>Sharp</surname> <given-names>PP</given-names></name><name><surname>Wenzell</surname> <given-names>NA</given-names></name><name><surname>Kuzuoglu-Ozturk</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>HY</given-names></name><name><surname>Trenker</surname> <given-names>R</given-names></name><name><surname>Young</surname> <given-names>JM</given-names></name><name><surname>Cavero</surname> <given-names>DA</given-names></name><name><surname>Hiatt</surname> <given-names>J</given-names></name><name><surname>Roth</surname> <given-names>TL</given-names></name><name><surname>Rathore</surname> <given-names>U</given-names></name><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Noack</surname> <given-names>J</given-names></name><name><surname>Hubert</surname> <given-names>M</given-names></name><name><surname>Stroud</surname> <given-names>RM</given-names></name><name><surname>Frankel</surname> <given-names>AD</given-names></name><name><surname>Rosenberg</surname> <given-names>OS</given-names></name><name><surname>Verba</surname> <given-names>KA</given-names></name><name><surname>Agard</surname> <given-names>DA</given-names></name><name><surname>Ott</surname> <given-names>M</given-names></name><name><surname>Emerman</surname> <given-names>M</given-names></name><name><surname>Jura</surname> <given-names>N</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name><name><surname>Verdin</surname> <given-names>E</given-names></name><name><surname>Ashworth</surname> <given-names>A</given-names></name><name><surname>Schwartz</surname> <given-names>O</given-names></name><name><surname>d'Enfert</surname> <given-names>C</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Jacobson</surname> <given-names>M</given-names></name><name><surname>Malik</surname> <given-names>HS</given-names></name><name><surname>Fujimori</surname> <given-names>DG</given-names></name><name><surname>Ideker</surname> <given-names>T</given-names></name><name><surname>Craik</surname> <given-names>CS</given-names></name><name><surname>Floor</surname> <given-names>SN</given-names></name><name><surname>Fraser</surname> <given-names>JS</given-names></name><name><surname>Gross</surname> <given-names>JD</given-names></name><name><surname>Sali</surname> <given-names>A</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name><name><surname>Ruggero</surname> <given-names>D</given-names></name><name><surname>Taunton</surname> <given-names>J</given-names></name><name><surname>Kortemme</surname> <given-names>T</given-names></name><name><surname>Beltrao</surname> <given-names>P</given-names></name><name><surname>Vignuzzi</surname> <given-names>M</given-names></name><name><surname>García-Sastre</surname> <given-names>A</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name><name><surname>Shoichet</surname> <given-names>BK</given-names></name><name><surname>Krogan</surname> <given-names>NJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title><source>Nature</source><volume>583</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id><pub-id pub-id-type="pmid">32353859</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goronzy</surname> <given-names>IN</given-names></name><name><surname>Rawle</surname> <given-names>RJ</given-names></name><name><surname>Boxer</surname> <given-names>SG</given-names></name><name><surname>Kasson</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cholesterol enhances influenza binding avidity by controlling nanoscale receptor clustering</article-title><source>Chemical Science</source><volume>9</volume><fpage>2340</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1039/C7SC03236F</pub-id><pub-id pub-id-type="pmid">29520318</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouttenoire</surname> <given-names>J</given-names></name><name><surname>Pollán</surname> <given-names>A</given-names></name><name><surname>Abrami</surname> <given-names>L</given-names></name><name><surname>Oechslin</surname> <given-names>N</given-names></name><name><surname>Mauron</surname> <given-names>J</given-names></name><name><surname>Matter</surname> <given-names>M</given-names></name><name><surname>Oppliger</surname> <given-names>J</given-names></name><name><surname>Szkolnicka</surname> <given-names>D</given-names></name><name><surname>Dao Thi</surname> <given-names>VL</given-names></name><name><surname>van der Goot</surname> <given-names>FG</given-names></name><name><surname>Moradpour</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Palmitoylation mediates membrane association of hepatitis E virus ORF3 protein and is required for infectious particle secretion</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1007471</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007471</pub-id><pub-id pub-id-type="pmid">30532200</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname> <given-names>DR</given-names></name><name><surname>Chertova</surname> <given-names>E</given-names></name><name><surname>Hilburn</surname> <given-names>JM</given-names></name><name><surname>Arthur</surname> <given-names>LO</given-names></name><name><surname>Hildreth</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts</article-title><source>Journal of Virology</source><volume>77</volume><fpage>8237</fpage><lpage>8248</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.15.8237-8248.2003</pub-id><pub-id pub-id-type="pmid">12857892</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname> <given-names>E</given-names></name><name><surname>Karslake</surname> <given-names>J</given-names></name><name><surname>Machta</surname> <given-names>BB</given-names></name><name><surname>Veatch</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Liquid general anesthetics lower critical temperatures in plasma membrane vesicles</article-title><source>Biophysical Journal</source><volume>105</volume><fpage>2751</fpage><lpage>2759</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2013.11.005</pub-id><pub-id pub-id-type="pmid">24359747</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname> <given-names>BF</given-names></name><name><surname>Corey</surname> <given-names>L</given-names></name><name><surname>Fernandes</surname> <given-names>P</given-names></name><name><surname>Gilbert</surname> <given-names>PB</given-names></name><name><surname>Hotez</surname> <given-names>PJ</given-names></name><name><surname>Rao</surname> <given-names>S</given-names></name><name><surname>Santos</surname> <given-names>MR</given-names></name><name><surname>Schuitemaker</surname> <given-names>H</given-names></name><name><surname>Watson</surname> <given-names>M</given-names></name><name><surname>Arvin</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Prospects for a safe COVID-19 vaccine</article-title><source>Science Translational Medicine</source><volume>12</volume><elocation-id>eabe0948</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abe0948</pub-id><pub-id pub-id-type="pmid">33077678</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>C</given-names></name><name><surname>Hu</surname> <given-names>X</given-names></name><name><surname>Weston</surname> <given-names>TA</given-names></name><name><surname>Jung</surname> <given-names>RS</given-names></name><name><surname>Sandhu</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Heizer</surname> <given-names>P</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Ellison</surname> <given-names>R</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Kilburn</surname> <given-names>M</given-names></name><name><surname>Bensinger</surname> <given-names>SJ</given-names></name><name><surname>Riezman</surname> <given-names>H</given-names></name><name><surname>Tontonoz</surname> <given-names>P</given-names></name><name><surname>Fong</surname> <given-names>LG</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Young</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Macrophages release plasma membrane-derived particles rich in accessible cholesterol</article-title><source>PNAS</source><volume>115</volume><fpage>E8499</fpage><lpage>E8508</lpage><pub-id pub-id-type="doi">10.1073/pnas.1810724115</pub-id><pub-id pub-id-type="pmid">30127022</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Head</surname> <given-names>SA</given-names></name><name><surname>Shi</surname> <given-names>WQ</given-names></name><name><surname>Yang</surname> <given-names>EJ</given-names></name><name><surname>Nacev</surname> <given-names>BA</given-names></name><name><surname>Hong</surname> <given-names>SY</given-names></name><name><surname>Pasunooti</surname> <given-names>KK</given-names></name><name><surname>Li</surname> <given-names>RJ</given-names></name><name><surname>Shim</surname> <given-names>JS</given-names></name><name><surname>Liu</surname> <given-names>JO</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Simultaneous targeting of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition of mTOR signaling and angiogenesis</article-title><source>ACS Chemical Biology</source><volume>12</volume><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1021/acschembio.6b00849</pub-id><pub-id pub-id-type="pmid">28103683</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heald-Sargent</surname> <given-names>T</given-names></name><name><surname>Gallagher</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Ready, set, fuse! the coronavirus spike protein and acquisition of fusion competence</article-title><source>Viruses</source><volume>4</volume><fpage>557</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.3390/v4040557</pub-id><pub-id pub-id-type="pmid">22590686</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashi</surname> <given-names>T</given-names></name><name><surname>Tokuda</surname> <given-names>S</given-names></name><name><surname>Kitajiri</surname> <given-names>S</given-names></name><name><surname>Masuda</surname> <given-names>S</given-names></name><name><surname>Nakamura</surname> <given-names>H</given-names></name><name><surname>Oda</surname> <given-names>Y</given-names></name><name><surname>Furuse</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Analysis of the 'angulin' proteins LSR, ILDR1 and ILDR2--tricellulin recruitment, epithelial barrier function and implication in deafness pathogenesis</article-title><source>Journal of Cell Science</source><volume>126</volume><fpage>966</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1242/jcs.116442</pub-id><pub-id pub-id-type="pmid">23239027</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirabayashi</surname> <given-names>S</given-names></name><name><surname>Tajima</surname> <given-names>M</given-names></name><name><surname>Yao</surname> <given-names>I</given-names></name><name><surname>Nishimura</surname> <given-names>W</given-names></name><name><surname>Mori</surname> <given-names>H</given-names></name><name><surname>Hata</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>JAM4, a junctional cell adhesion molecule interacting with a tight junction protein, MAGI-1</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>4267</fpage><lpage>4282</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.12.4267-4282.2003</pub-id><pub-id pub-id-type="pmid">12773569</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname> <given-names>M</given-names></name><name><surname>Kleine-Weber</surname> <given-names>H</given-names></name><name><surname>Pöhlmann</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells</article-title><source>Molecular Cell</source><volume>78</volume><fpage>779</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.04.022</pub-id><pub-id pub-id-type="pmid">32362314</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname> <given-names>M</given-names></name><name><surname>Kleine-Weber</surname> <given-names>H</given-names></name><name><surname>Schroeder</surname> <given-names>S</given-names></name><name><surname>Krüger</surname> <given-names>N</given-names></name><name><surname>Herrler</surname> <given-names>T</given-names></name><name><surname>Erichsen</surname> <given-names>S</given-names></name><name><surname>Schiergens</surname> <given-names>TS</given-names></name><name><surname>Herrler</surname> <given-names>G</given-names></name><name><surname>Wu</surname> <given-names>NH</given-names></name><name><surname>Nitsche</surname> <given-names>A</given-names></name><name><surname>Müller</surname> <given-names>MA</given-names></name><name><surname>Drosten</surname> <given-names>C</given-names></name><name><surname>Pöhlmann</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname> <given-names>M</given-names></name><name><surname>Schroeder</surname> <given-names>S</given-names></name><name><surname>Kleine-Weber</surname> <given-names>H</given-names></name><name><surname>Müller</surname> <given-names>MA</given-names></name><name><surname>Drosten</surname> <given-names>C</given-names></name><name><surname>Pöhlmann</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020c</year><article-title>Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>64</volume><elocation-id>269</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.00754-20</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holowka</surname> <given-names>D</given-names></name><name><surname>Baird</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Structural studies on the membrane-bound immunoglobulin E-receptor complex. 1. characterization of large plasma membrane vesicles from rat basophilic leukemia cells and insertion of amphipathic fluorescent probes</article-title><source>Biochemistry</source><volume>22</volume><fpage>3466</fpage><lpage>3474</lpage><pub-id pub-id-type="doi">10.1021/bi00283a025</pub-id><pub-id pub-id-type="pmid">6225455</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>B</given-names></name><name><surname>Höfer</surname> <given-names>CT</given-names></name><name><surname>Thiele</surname> <given-names>C</given-names></name><name><surname>Veit</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Cholesterol binding to the transmembrane region of a group 2 hemagglutinin (HA) of influenza virus is essential for virus replication, affecting both virus assembly and HA fusion activity</article-title><source>Journal of Virology</source><volume>93</volume><elocation-id>531</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.00555-19</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>X</given-names></name><name><surname>Weston</surname> <given-names>TA</given-names></name><name><surname>He</surname> <given-names>C</given-names></name><name><surname>Jung</surname> <given-names>RS</given-names></name><name><surname>Heizer</surname> <given-names>PJ</given-names></name><name><surname>Young</surname> <given-names>BD</given-names></name><name><surname>Tu</surname> <given-names>Y</given-names></name><name><surname>Tontonoz</surname> <given-names>P</given-names></name><name><surname>Wohlschlegel</surname> <given-names>JA</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Young</surname> <given-names>SG</given-names></name><name><surname>Fong</surname> <given-names>LG</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Release of cholesterol-rich particles from the macrophage plasma membrane during movement of filopodia and lamellipodia</article-title><source>eLife</source><volume>8</volume><elocation-id>e50231</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.50231</pub-id><pub-id pub-id-type="pmid">31486771</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iijima</surname> <given-names>M</given-names></name><name><surname>Suzuki</surname> <given-names>M</given-names></name><name><surname>Tanabe</surname> <given-names>A</given-names></name><name><surname>Nishimura</surname> <given-names>A</given-names></name><name><surname>Yamada</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Two motifs essential for nuclear import of the hnRNP A1 nucleocytoplasmic shuttling sequence M9 core</article-title><source>FEBS Letters</source><volume>580</volume><fpage>1365</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2006.01.058</pub-id><pub-id pub-id-type="pmid">16455081</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Im</surname> <given-names>YJ</given-names></name><name><surname>Raychaudhuri</surname> <given-names>S</given-names></name><name><surname>Prinz</surname> <given-names>WA</given-names></name><name><surname>Hurley</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Structural mechanism for sterol sensing and transport by OSBP-related proteins</article-title><source>Nature</source><volume>437</volume><fpage>154</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1038/nature03923</pub-id><pub-id pub-id-type="pmid">16136145</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>JE</given-names></name><name><surname>Gonzales</surname> <given-names>RA</given-names></name><name><surname>Olson</surname> <given-names>SJ</given-names></name><name><surname>Wright</surname> <given-names>PF</given-names></name><name><surname>Graham</surname> <given-names>BS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The histopathology of fatal untreated human respiratory syncytial virus infection</article-title><source>Modern Pathology</source><volume>20</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/modpathol.3800725</pub-id><pub-id pub-id-type="pmid">17143259</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Käll</surname> <given-names>L</given-names></name><name><surname>Krogh</surname> <given-names>A</given-names></name><name><surname>Sonnhammer</surname> <given-names>EL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A combined transmembrane topology and signal peptide prediction method</article-title><source>Journal of Molecular Biology</source><volume>338</volume><fpage>1027</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2004.03.016</pub-id><pub-id pub-id-type="pmid">15111065</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>YL</given-names></name><name><surname>Chou</surname> <given-names>YY</given-names></name><name><surname>Rothlauf</surname> <given-names>PW</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Soh</surname> <given-names>TK</given-names></name><name><surname>Cureton</surname> <given-names>D</given-names></name><name><surname>Case</surname> <given-names>JB</given-names></name><name><surname>Chen</surname> <given-names>RE</given-names></name><name><surname>Diamond</surname> <given-names>MS</given-names></name><name><surname>Whelan</surname> <given-names>SPJ</given-names></name><name><surname>Kirchhausen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2</article-title><source>PNAS</source><volume>117</volume><fpage>20803</fpage><lpage>20813</lpage><pub-id pub-id-type="doi">10.1073/pnas.2007837117</pub-id><pub-id pub-id-type="pmid">32764148</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawase</surname> <given-names>M</given-names></name><name><surname>Shirato</surname> <given-names>K</given-names></name><name><surname>van der Hoek</surname> <given-names>L</given-names></name><name><surname>Taguchi</surname> <given-names>F</given-names></name><name><surname>Matsuyama</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry</article-title><source>Journal of Virology</source><volume>86</volume><fpage>6537</fpage><lpage>6545</lpage><pub-id pub-id-type="doi">10.1128/JVI.00094-12</pub-id><pub-id pub-id-type="pmid">22496216</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname> <given-names>Z</given-names></name><name><surname>Oton</surname> <given-names>J</given-names></name><name><surname>Qu</surname> <given-names>K</given-names></name><name><surname>Cortese</surname> <given-names>M</given-names></name><name><surname>Zila</surname> <given-names>V</given-names></name><name><surname>McKeane</surname> <given-names>L</given-names></name><name><surname>Nakane</surname> <given-names>T</given-names></name><name><surname>Zivanov</surname> <given-names>J</given-names></name><name><surname>Neufeldt</surname> <given-names>CJ</given-names></name><name><surname>Cerikan</surname> <given-names>B</given-names></name><name><surname>Lu</surname> <given-names>JM</given-names></name><name><surname>Peukes</surname> <given-names>J</given-names></name><name><surname>Xiong</surname> <given-names>X</given-names></name><name><surname>Kräusslich</surname> <given-names>HG</given-names></name><name><surname>Scheres</surname> <given-names>SHW</given-names></name><name><surname>Bartenschlager</surname> <given-names>R</given-names></name><name><surname>Briggs</surname> <given-names>JAG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structures and distributions of SARS-CoV-2 spike proteins on intact virions</article-title><source>Nature</source><volume>588</volume><fpage>498</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2665-2</pub-id><pub-id pub-id-type="pmid">32805734</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Chen</surname> <given-names>EH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The fusogenic synapse at a glance</article-title><source>Journal of Cell Science</source><volume>132</volume><elocation-id>jcs213124</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.213124</pub-id><pub-id pub-id-type="pmid">31527149</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindrachuk</surname> <given-names>J</given-names></name><name><surname>Ork</surname> <given-names>B</given-names></name><name><surname>Hart</surname> <given-names>BJ</given-names></name><name><surname>Mazur</surname> <given-names>S</given-names></name><name><surname>Holbrook</surname> <given-names>MR</given-names></name><name><surname>Frieman</surname> <given-names>MB</given-names></name><name><surname>Traynor</surname> <given-names>D</given-names></name><name><surname>Johnson</surname> <given-names>RF</given-names></name><name><surname>Dyall</surname> <given-names>J</given-names></name><name><surname>Kuhn</surname> <given-names>JH</given-names></name><name><surname>Olinger</surname> <given-names>GG</given-names></name><name><surname>Hensley</surname> <given-names>LE</given-names></name><name><surname>Jahrling</surname> <given-names>PB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>59</volume><fpage>1088</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1128/AAC.03659-14</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinnebrew</surname> <given-names>M</given-names></name><name><surname>Iverson</surname> <given-names>EJ</given-names></name><name><surname>Patel</surname> <given-names>BB</given-names></name><name><surname>Pusapati</surname> <given-names>GV</given-names></name><name><surname>Kong</surname> <given-names>JH</given-names></name><name><surname>Johnson</surname> <given-names>KA</given-names></name><name><surname>Luchetti</surname> <given-names>G</given-names></name><name><surname>Eckert</surname> <given-names>KM</given-names></name><name><surname>McDonald</surname> <given-names>JG</given-names></name><name><surname>Covey</surname> <given-names>DF</given-names></name><name><surname>Siebold</surname> <given-names>C</given-names></name><name><surname>Radhakrishnan</surname> <given-names>A</given-names></name><name><surname>Rohatgi</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cholesterol accessibility at the ciliary membrane controls hedgehog signaling</article-title><source>eLife</source><volume>8</volume><elocation-id>e50051</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.50051</pub-id><pub-id pub-id-type="pmid">31657721</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname> <given-names>BJ</given-names></name><name><surname>Collier</surname> <given-names>AC</given-names></name><name><surname>Kharasch</surname> <given-names>ED</given-names></name><name><surname>Whittington</surname> <given-names>D</given-names></name><name><surname>Thummel</surname> <given-names>KE</given-names></name><name><surname>Unadkat</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir</article-title><source>Drug Metabolism and Disposition</source><volume>39</volume><fpage>1070</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1124/dmd.110.037523</pub-id><pub-id pub-id-type="pmid">21406602</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Klein</surname> <given-names>S</given-names></name><name><surname>Cortese</surname> <given-names>M</given-names></name><name><surname>Winter</surname> <given-names>SL</given-names></name><name><surname>Wachsmuth-Melm</surname> <given-names>M</given-names></name><name><surname>Neufeldt</surname> <given-names>CJ</given-names></name><name><surname>Cerikan</surname> <given-names>B</given-names></name><name><surname>Stanifer</surname> <given-names>ML</given-names></name><name><surname>Boulant</surname> <given-names>S</given-names></name><name><surname>Bartenschlager</surname> <given-names>R</given-names></name><name><surname>Chlanda</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 structure and replication characterized by in situcryo-electron tomography</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.06.23.167064</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klymchenko</surname> <given-names>AS</given-names></name><name><surname>Kreder</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fluorescent probes for lipid rafts: from model membranes to living cells</article-title><source>Chemistry &amp; Biology</source><volume>21</volume><fpage>97</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2013.11.009</pub-id><pub-id pub-id-type="pmid">24361047</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname> <given-names>J</given-names></name><name><surname>Ge</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Shan</surname> <given-names>S</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Fan</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Shi</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title><source>Nature</source><volume>581</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2180-5</pub-id><pub-id pub-id-type="pmid">32225176</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levental</surname> <given-names>I</given-names></name><name><surname>Byfield</surname> <given-names>FJ</given-names></name><name><surname>Chowdhury</surname> <given-names>P</given-names></name><name><surname>Gai</surname> <given-names>F</given-names></name><name><surname>Baumgart</surname> <given-names>T</given-names></name><name><surname>Janmey</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cholesterol-dependent phase separation in cell-derived giant plasma-membrane vesicles</article-title><source>Biochemical Journal</source><volume>424</volume><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1042/BJ20091283</pub-id><pub-id pub-id-type="pmid">19811449</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levental</surname> <given-names>I</given-names></name><name><surname>Lingwood</surname> <given-names>D</given-names></name><name><surname>Grzybek</surname> <given-names>M</given-names></name><name><surname>Coskun</surname> <given-names>U</given-names></name><name><surname>Simons</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Palmitoylation regulates raft affinity for the majority of integral raft proteins</article-title><source>PNAS</source><volume>107</volume><fpage>22050</fpage><lpage>22054</lpage><pub-id pub-id-type="doi">10.1073/pnas.1016184107</pub-id><pub-id pub-id-type="pmid">21131568</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levental</surname> <given-names>I</given-names></name><name><surname>Grzybek</surname> <given-names>M</given-names></name><name><surname>Simons</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Raft domains of variable properties and compositions in plasma membrane vesicles</article-title><source>PNAS</source><volume>108</volume><fpage>11411</fpage><lpage>11416</lpage><pub-id pub-id-type="doi">10.1073/pnas.1105996108</pub-id><pub-id pub-id-type="pmid">21709267</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levental</surname> <given-names>I</given-names></name><name><surname>Levental</surname> <given-names>KR</given-names></name><name><surname>Heberle</surname> <given-names>FA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lipid rafts: controversies resolved, mysteries remain</article-title><source>Trends in Cell Biology</source><volume>30</volume><fpage>341</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2020.01.009</pub-id><pub-id pub-id-type="pmid">32302547</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levental</surname> <given-names>KR</given-names></name><name><surname>Levental</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Isolation of giant plasma membrane vesicles for evaluation of plasma membrane structure and protein partitioning</article-title><source>Methods in Molecular Biology</source><volume>1232</volume><fpage>65</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-1752-5_6</pub-id><pub-id pub-id-type="pmid">25331128</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Moore</surname> <given-names>MJ</given-names></name><name><surname>Vasilieva</surname> <given-names>N</given-names></name><name><surname>Sui</surname> <given-names>J</given-names></name><name><surname>Wong</surname> <given-names>SK</given-names></name><name><surname>Berne</surname> <given-names>MA</given-names></name><name><surname>Somasundaran</surname> <given-names>M</given-names></name><name><surname>Sullivan</surname> <given-names>JL</given-names></name><name><surname>Luzuriaga</surname> <given-names>K</given-names></name><name><surname>Greenough</surname> <given-names>TC</given-names></name><name><surname>Choe</surname> <given-names>H</given-names></name><name><surname>Farzan</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><volume>426</volume><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="pmid">14647384</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>GM</given-names></name><name><surname>Li</surname> <given-names>YG</given-names></name><name><surname>Yamate</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>SM</given-names></name><name><surname>Ikuta</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle</article-title><source>Microbes and Infection</source><volume>9</volume><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2006.10.015</pub-id><pub-id pub-id-type="pmid">17194611</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>KW</given-names></name><name><surname>Chou</surname> <given-names>WC</given-names></name><name><surname>Lo</surname> <given-names>YC</given-names></name><name><surname>Roffler</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Design of transgenes for efficient expression of active chimeric proteins on mammalian cells</article-title><source>Biotechnology and Bioengineering</source><volume>73</volume><fpage>313</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1002/bit.1064</pub-id><pub-id pub-id-type="pmid">11283914</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>Y</given-names></name><name><surname>Yuan</surname> <given-names>Q</given-names></name><name><surname>Torres</surname> <given-names>J</given-names></name><name><surname>Tam</surname> <given-names>JP</given-names></name><name><surname>Liu</surname> <given-names>DX</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Biochemical and functional characterization of the membrane association and membrane permeabilizing activity of the severe acute respiratory syndrome coronavirus envelope protein</article-title><source>Virology</source><volume>349</volume><fpage>264</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.01.028</pub-id><pub-id pub-id-type="pmid">16507314</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>SM</given-names></name><name><surname>Neo</surname> <given-names>TL</given-names></name><name><surname>Tam</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tryptophan-dependent membrane interaction and heteromerization with the internal fusion peptide by the membrane proximal external region of SARS-CoV spike protein</article-title><source>Biochemistry</source><volume>54</volume><fpage>1819</fpage><lpage>1830</lpage><pub-id pub-id-type="doi">10.1021/bi501352u</pub-id><pub-id pub-id-type="pmid">25668103</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>YC</given-names></name><name><surname>Chen</surname> <given-names>BM</given-names></name><name><surname>Lu</surname> <given-names>WC</given-names></name><name><surname>Su</surname> <given-names>CI</given-names></name><name><surname>Prijovich</surname> <given-names>ZM</given-names></name><name><surname>Chung</surname> <given-names>WC</given-names></name><name><surname>Wu</surname> <given-names>PY</given-names></name><name><surname>Chen</surname> <given-names>KC</given-names></name><name><surname>Lee</surname> <given-names>IC</given-names></name><name><surname>Juan</surname> <given-names>TY</given-names></name><name><surname>Roffler</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The B7-1 cytoplasmic tail enhances intracellular transport and mammalian cell surface display of chimeric proteins in the absence of a linear ER export motif</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e75084</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0075084</pub-id><pub-id pub-id-type="pmid">24073236</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linton</surname> <given-names>MF</given-names></name><name><surname>Tao</surname> <given-names>H</given-names></name><name><surname>Linton</surname> <given-names>EF</given-names></name><name><surname>Yancey</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SR-BI: a multifunctional receptor in cholesterol homeostasis and atherosclerosis</article-title><source>Trends in Endocrinology &amp; Metabolism</source><volume>28</volume><fpage>461</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2017.02.001</pub-id><pub-id pub-id-type="pmid">28259375</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname> <given-names>T</given-names></name><name><surname>Qi</surname> <given-names>X</given-names></name><name><surname>Hassan</surname> <given-names>A</given-names></name><name><surname>Liang</surname> <given-names>Q</given-names></name><name><surname>De Brabander</surname> <given-names>JK</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for itraconazole-mediated NPC1 inhibition</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>152</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13917-5</pub-id><pub-id pub-id-type="pmid">31919352</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>DX</given-names></name><name><surname>Tam</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2008">2008a</year><article-title>Lipid rafts are involved in SARS-CoV entry into vero E6 cells</article-title><source>Biochemical and Biophysical Research Communications</source><volume>369</volume><fpage>344</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.02.023</pub-id><pub-id pub-id-type="pmid">18279660</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Neo</surname> <given-names>TL</given-names></name><name><surname>Liu</surname> <given-names>DX</given-names></name><name><surname>Tam</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2008">2008b</year><article-title>Importance of SARS-CoV spike protein Trp-rich region in viral infectivity</article-title><source>Biochemical and Biophysical Research Communications</source><volume>371</volume><fpage>356</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.04.044</pub-id><pub-id pub-id-type="pmid">18424264</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Chemical approaches for profiling dynamic palmitoylation</article-title><source>Biochemical Society Transactions</source><volume>41</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1042/BST20120271</pub-id><pub-id pub-id-type="pmid">23356256</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mast</surname> <given-names>N</given-names></name><name><surname>Zheng</surname> <given-names>W</given-names></name><name><surname>Stout</surname> <given-names>CD</given-names></name><name><surname>Pikuleva</surname> <given-names>IA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antifungal azoles: structural insights into undesired tight binding to Cholesterol-Metabolizing CYP46A1</article-title><source>Molecular Pharmacology</source><volume>84</volume><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1124/mol.113.085902</pub-id><pub-id pub-id-type="pmid">23604141</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maudgal</surname> <given-names>PC</given-names></name><name><surname>Missotten</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Histopathology of human superficial herpes simplex keratitis</article-title><source>British Journal of Ophthalmology</source><volume>62</volume><fpage>46</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1136/bjo.62.1.46</pub-id><pub-id pub-id-type="pmid">629910</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname> <given-names>CE</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Machamer</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The Cytoplasmic Tail of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains a Novel Endoplasmic Reticulum Retrieval Signal That Binds COPI and Promotes Interaction with Membrane Protein</article-title><source>Journal of Virology</source><volume>81</volume><fpage>2418</fpage><lpage>2428</lpage><pub-id pub-id-type="doi">10.1128/JVI.02146-06</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname> <given-names>CE</given-names></name><name><surname>Machamer</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2010">2010a</year><article-title>Palmitoylation of SARS-CoV S protein is necessary for partitioning into detergent-resistant membranes and cell-cell fusion but not interaction with M protein</article-title><source>Virology</source><volume>405</volume><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2010.05.031</pub-id><pub-id pub-id-type="pmid">20580052</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname> <given-names>CE</given-names></name><name><surname>Machamer</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2010">2010b</year><article-title>A single tyrosine in the severe acute respiratory syndrome coronavirus membrane protein cytoplasmic tail is important for efficient interaction with spike protein</article-title><source>Journal of Virology</source><volume>84</volume><fpage>1891</fpage><lpage>1901</lpage><pub-id pub-id-type="doi">10.1128/JVI.02458-09</pub-id><pub-id pub-id-type="pmid">20007283</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meher</surname> <given-names>G</given-names></name><name><surname>Bhattacharjya</surname> <given-names>S</given-names></name><name><surname>Chakraborty</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Membrane Cholesterol Modulates Oligomeric Status and Peptide-Membrane Interaction of Severe Acute Respiratory Syndrome Coronavirus Fusion Peptide</article-title><source>The Journal of Physical Chemistry B</source><volume>123</volume><fpage>10654</fpage><lpage>10662</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.9b08455</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menter</surname> <given-names>T</given-names></name><name><surname>Haslbauer</surname> <given-names>JD</given-names></name><name><surname>Nienhold</surname> <given-names>R</given-names></name><name><surname>Savic</surname> <given-names>S</given-names></name><name><surname>Hopfer</surname> <given-names>H</given-names></name><name><surname>Deigendesch</surname> <given-names>N</given-names></name><name><surname>Frank</surname> <given-names>S</given-names></name><name><surname>Turek</surname> <given-names>D</given-names></name><name><surname>Willi</surname> <given-names>N</given-names></name><name><surname>Pargger</surname> <given-names>H</given-names></name><name><surname>Bassetti</surname> <given-names>S</given-names></name><name><surname>Leuppi</surname> <given-names>JD</given-names></name><name><surname>Cathomas</surname> <given-names>G</given-names></name><name><surname>Tolnay</surname> <given-names>M</given-names></name><name><surname>Mertz</surname> <given-names>KD</given-names></name><name><surname>Tzankov</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction</article-title><source>Histopathology</source><volume>77</volume><fpage>198</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1111/his.14134</pub-id><pub-id pub-id-type="pmid">32364264</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millet</surname> <given-names>JK</given-names></name><name><surname>Whittaker</surname> <given-names>GR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Host cell entry of middle east respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein</article-title><source>PNAS</source><volume>111</volume><fpage>15214</fpage><lpage>15219</lpage><pub-id pub-id-type="doi">10.1073/pnas.1407087111</pub-id><pub-id pub-id-type="pmid">25288733</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname> <given-names>A</given-names></name><name><surname>Manjunath</surname> <given-names>K</given-names></name><name><surname>Ranjan</surname> <given-names>RK</given-names></name><name><surname>Kaushik</surname> <given-names>S</given-names></name><name><surname>Kumar</surname> <given-names>S</given-names></name><name><surname>Verma</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 pandemic: insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008762</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008762</pub-id><pub-id pub-id-type="pmid">32822426</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musarrat</surname> <given-names>F</given-names></name><name><surname>Chouljenko</surname> <given-names>V</given-names></name><name><surname>Dahal</surname> <given-names>A</given-names></name><name><surname>Nabi</surname> <given-names>R</given-names></name><name><surname>Chouljenko</surname> <given-names>T</given-names></name><name><surname>Jois</surname> <given-names>SD</given-names></name><name><surname>Kousoulas</surname> <given-names>KG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections</article-title><source>Journal of Medical Virology</source><volume>92</volume><fpage>2087</fpage><lpage>2095</lpage><pub-id pub-id-type="doi">10.1002/jmv.25985</pub-id><pub-id pub-id-type="pmid">32374457</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname> <given-names>Y</given-names></name><name><surname>Sugawara</surname> <given-names>T</given-names></name><name><surname>Fukata</surname> <given-names>Y</given-names></name><name><surname>Izumi</surname> <given-names>Y</given-names></name><name><surname>Otani</surname> <given-names>T</given-names></name><name><surname>Higashi</surname> <given-names>T</given-names></name><name><surname>Fukata</surname> <given-names>M</given-names></name><name><surname>Furuse</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The extracellular domain of angulin-1 and palmitoylation of its cytoplasmic region are required for angulin-1 assembly at Tricellular contacts</article-title><source>Journal of Biological Chemistry</source><volume>295</volume><fpage>4289</fpage><lpage>4302</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.010491</pub-id><pub-id pub-id-type="pmid">32079676</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Lei</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Mi</surname> <given-names>D</given-names></name><name><surname>Ren</surname> <given-names>L</given-names></name><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Guo</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>T</given-names></name><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Xiang</surname> <given-names>Z</given-names></name><name><surname>Mu</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Hu</surname> <given-names>K</given-names></name><name><surname>Jin</surname> <given-names>Q</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Qian</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1620</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15562-9</pub-id><pub-id pub-id-type="pmid">32221306</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Papa</surname> <given-names>G</given-names></name><name><surname>Mallery</surname> <given-names>DL</given-names></name><name><surname>Albecka</surname> <given-names>A</given-names></name><name><surname>Welch</surname> <given-names>L</given-names></name><name><surname>Cattin-Ortolá</surname> <given-names>J</given-names></name><name><surname>Luptak</surname> <given-names>J</given-names></name><name><surname>Paul</surname> <given-names>D</given-names></name><name><surname>McMahon</surname> <given-names>HT</given-names></name><name><surname>Goodfellow</surname> <given-names>IG</given-names></name><name><surname>Carter</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Furin cleavage of SARS-CoV-2 spike promotes but is not essential for infection and cell-cell fusion</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.08.13.243303</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelkmans</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Secrets of caveolae- and lipid raft-mediated endocytosis revealed by mammalian viruses</article-title><source>Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1746</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2005.06.009</pub-id><pub-id pub-id-type="pmid">16126288</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelkmans</surname> <given-names>L</given-names></name><name><surname>Helenius</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Insider information: what viruses tell us about endocytosis</article-title><source>Current Opinion in Cell Biology</source><volume>15</volume><fpage>414</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1016/S0955-0674(03)00081-4</pub-id><pub-id pub-id-type="pmid">12892781</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petit</surname> <given-names>CM</given-names></name><name><surname>Chouljenko</surname> <given-names>VN</given-names></name><name><surname>Iyer</surname> <given-names>A</given-names></name><name><surname>Colgrove</surname> <given-names>R</given-names></name><name><surname>Farzan</surname> <given-names>M</given-names></name><name><surname>Knipe</surname> <given-names>DM</given-names></name><name><surname>Kousoulas</surname> <given-names>KG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Palmitoylation of the cysteine-rich endodomain of the SARS-coronavirus spike glycoprotein is important for spike-mediated cell fusion</article-title><source>Virology</source><volume>360</volume><fpage>264</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.10.034</pub-id><pub-id pub-id-type="pmid">17134730</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ploss</surname> <given-names>A</given-names></name><name><surname>Evans</surname> <given-names>MJ</given-names></name><name><surname>Gaysinskaya</surname> <given-names>VA</given-names></name><name><surname>Panis</surname> <given-names>M</given-names></name><name><surname>You</surname> <given-names>H</given-names></name><name><surname>de Jong</surname> <given-names>YP</given-names></name><name><surname>Rice</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Human occludin is a hepatitis C virus entry factor required for infection of mouse cells</article-title><source>Nature</source><volume>457</volume><fpage>882</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1038/nature07684</pub-id><pub-id pub-id-type="pmid">19182773</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajter</surname> <given-names>JC</given-names></name><name><surname>Sherman</surname> <given-names>MS</given-names></name><name><surname>Fatteh</surname> <given-names>N</given-names></name><name><surname>Vogel</surname> <given-names>F</given-names></name><name><surname>Sacks</surname> <given-names>J</given-names></name><name><surname>Rajter</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study</article-title><source>Chest</source><volume>159</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2020.10.009</pub-id><pub-id pub-id-type="pmid">33065103</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riva</surname> <given-names>L</given-names></name><name><surname>Yuan</surname> <given-names>S</given-names></name><name><surname>Yin</surname> <given-names>X</given-names></name><name><surname>Martin-Sancho</surname> <given-names>L</given-names></name><name><surname>Matsunaga</surname> <given-names>N</given-names></name><name><surname>Pache</surname> <given-names>L</given-names></name><name><surname>Burgstaller-Muehlbacher</surname> <given-names>S</given-names></name><name><surname>De Jesus</surname> <given-names>PD</given-names></name><name><surname>Teriete</surname> <given-names>P</given-names></name><name><surname>Hull</surname> <given-names>MV</given-names></name><name><surname>Chang</surname> <given-names>MW</given-names></name><name><surname>Chan</surname> <given-names>JF</given-names></name><name><surname>Cao</surname> <given-names>J</given-names></name><name><surname>Poon</surname> <given-names>VK</given-names></name><name><surname>Herbert</surname> <given-names>KM</given-names></name><name><surname>Cheng</surname> <given-names>K</given-names></name><name><surname>Nguyen</surname> <given-names>TH</given-names></name><name><surname>Rubanov</surname> <given-names>A</given-names></name><name><surname>Pu</surname> <given-names>Y</given-names></name><name><surname>Nguyen</surname> <given-names>C</given-names></name><name><surname>Choi</surname> <given-names>A</given-names></name><name><surname>Rathnasinghe</surname> <given-names>R</given-names></name><name><surname>Schotsaert</surname> <given-names>M</given-names></name><name><surname>Miorin</surname> <given-names>L</given-names></name><name><surname>Dejosez</surname> <given-names>M</given-names></name><name><surname>Zwaka</surname> <given-names>TP</given-names></name><name><surname>Sit</surname> <given-names>KY</given-names></name><name><surname>Martinez-Sobrido</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>WC</given-names></name><name><surname>White</surname> <given-names>KM</given-names></name><name><surname>Chapman</surname> <given-names>ME</given-names></name><name><surname>Lendy</surname> <given-names>EK</given-names></name><name><surname>Glynne</surname> <given-names>RJ</given-names></name><name><surname>Albrecht</surname> <given-names>R</given-names></name><name><surname>Ruppin</surname> <given-names>E</given-names></name><name><surname>Mesecar</surname> <given-names>AD</given-names></name><name><surname>Johnson</surname> <given-names>JR</given-names></name><name><surname>Benner</surname> <given-names>C</given-names></name><name><surname>Sun</surname> <given-names>R</given-names></name><name><surname>Schultz</surname> <given-names>PG</given-names></name><name><surname>Su</surname> <given-names>AI</given-names></name><name><surname>García-Sastre</surname> <given-names>A</given-names></name><name><surname>Chatterjee</surname> <given-names>AK</given-names></name><name><surname>Yuen</surname> <given-names>KY</given-names></name><name><surname>Chanda</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing</article-title><source>Nature</source><volume>586</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2577-1</pub-id><pub-id pub-id-type="pmid">32707573</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockx</surname> <given-names>B</given-names></name><name><surname>Kuiken</surname> <given-names>T</given-names></name><name><surname>Herfst</surname> <given-names>S</given-names></name><name><surname>Bestebroer</surname> <given-names>T</given-names></name><name><surname>Lamers</surname> <given-names>MM</given-names></name><name><surname>Oude Munnink</surname> <given-names>BB</given-names></name><name><surname>de Meulder</surname> <given-names>D</given-names></name><name><surname>van Amerongen</surname> <given-names>G</given-names></name><name><surname>van den Brand</surname> <given-names>J</given-names></name><name><surname>Okba</surname> <given-names>NMA</given-names></name><name><surname>Schipper</surname> <given-names>D</given-names></name><name><surname>van Run</surname> <given-names>P</given-names></name><name><surname>Leijten</surname> <given-names>L</given-names></name><name><surname>Sikkema</surname> <given-names>R</given-names></name><name><surname>Verschoor</surname> <given-names>E</given-names></name><name><surname>Verstrepen</surname> <given-names>B</given-names></name><name><surname>Bogers</surname> <given-names>W</given-names></name><name><surname>Langermans</surname> <given-names>J</given-names></name><name><surname>Drosten</surname> <given-names>C</given-names></name><name><surname>Fentener van Vlissingen</surname> <given-names>M</given-names></name><name><surname>Fouchier</surname> <given-names>R</given-names></name><name><surname>de Swart</surname> <given-names>R</given-names></name><name><surname>Koopmans</surname> <given-names>M</given-names></name><name><surname>Haagmans</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model</article-title><source>Science</source><volume>368</volume><fpage>1012</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1126/science.abb7314</pub-id><pub-id pub-id-type="pmid">32303590</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname> <given-names>DW</given-names></name><name><surname>Kaufman</surname> <given-names>SK</given-names></name><name><surname>DeVos</surname> <given-names>SL</given-names></name><name><surname>Sharma</surname> <given-names>AM</given-names></name><name><surname>Mirbaha</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>A</given-names></name><name><surname>Barker</surname> <given-names>SJ</given-names></name><name><surname>Foley</surname> <given-names>AC</given-names></name><name><surname>Thorpe</surname> <given-names>JR</given-names></name><name><surname>Serpell</surname> <given-names>LC</given-names></name><name><surname>Miller</surname> <given-names>TM</given-names></name><name><surname>Grinberg</surname> <given-names>LT</given-names></name><name><surname>Seeley</surname> <given-names>WW</given-names></name><name><surname>Diamond</surname> <given-names>MI</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Distinct tau prion strains propagate in cells and mice and define different tauopathies</article-title><source>Neuron</source><volume>82</volume><fpage>1271</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.04.047</pub-id><pub-id pub-id-type="pmid">24857020</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname> <given-names>DW</given-names></name><name><surname>Kedersha</surname> <given-names>N</given-names></name><name><surname>Lee</surname> <given-names>DSW</given-names></name><name><surname>Strom</surname> <given-names>AR</given-names></name><name><surname>Drake</surname> <given-names>V</given-names></name><name><surname>Riback</surname> <given-names>JA</given-names></name><name><surname>Bracha</surname> <given-names>D</given-names></name><name><surname>Eeftens</surname> <given-names>JM</given-names></name><name><surname>Iwanicki</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>A</given-names></name><name><surname>Wei</surname> <given-names>MT</given-names></name><name><surname>Whitney</surname> <given-names>G</given-names></name><name><surname>Lyons</surname> <given-names>SM</given-names></name><name><surname>Anderson</surname> <given-names>P</given-names></name><name><surname>Jacobs</surname> <given-names>WM</given-names></name><name><surname>Ivanov</surname> <given-names>P</given-names></name><name><surname>Brangwynne</surname> <given-names>CP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Competing Protein-RNA interaction networks control multiphase intracellular organization</article-title><source>Cell</source><volume>181</volume><fpage>306</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.050</pub-id><pub-id pub-id-type="pmid">32302570</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname> <given-names>P</given-names></name><name><surname>Hammond</surname> <given-names>A</given-names></name><name><surname>Holowka</surname> <given-names>D</given-names></name><name><surname>Baird</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Structural determinants for partitioning of lipids and proteins between coexisting fluid phases in giant plasma membrane vesicles</article-title><source>Biochimica et Biophysica Acta (BBA) - Biomembranes</source><volume>1778</volume><fpage>20</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2007.08.028</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sezgin</surname> <given-names>E</given-names></name><name><surname>Kaiser</surname> <given-names>HJ</given-names></name><name><surname>Baumgart</surname> <given-names>T</given-names></name><name><surname>Schwille</surname> <given-names>P</given-names></name><name><surname>Simons</surname> <given-names>K</given-names></name><name><surname>Levental</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Elucidating membrane structure and protein behavior using giant plasma membrane vesicles</article-title><source>Nature Protocols</source><volume>7</volume><fpage>1042</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.059</pub-id><pub-id pub-id-type="pmid">22555243</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname> <given-names>J</given-names></name><name><surname>Wan</surname> <given-names>Y</given-names></name><name><surname>Luo</surname> <given-names>C</given-names></name><name><surname>Ye</surname> <given-names>G</given-names></name><name><surname>Geng</surname> <given-names>Q</given-names></name><name><surname>Auerbach</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cell entry mechanisms of SARS-CoV-2</article-title><source>PNAS</source><volume>117</volume><fpage>11727</fpage><lpage>11734</lpage><pub-id pub-id-type="doi">10.1073/pnas.2003138117</pub-id><pub-id pub-id-type="pmid">32376634</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>J</given-names></name><name><surname>Bi</surname> <given-names>P</given-names></name><name><surname>Pei</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Grishin</surname> <given-names>NV</given-names></name><name><surname>Bassel-Duby</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>EH</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Requirement of the fusogenic micropeptide myomixer for muscle formation in zebrafish</article-title><source>PNAS</source><volume>114</volume><fpage>11950</fpage><lpage>11955</lpage><pub-id pub-id-type="doi">10.1073/pnas.1715229114</pub-id><pub-id pub-id-type="pmid">29078404</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shilagardi</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Luo</surname> <given-names>F</given-names></name><name><surname>Marikar</surname> <given-names>F</given-names></name><name><surname>Duan</surname> <given-names>R</given-names></name><name><surname>Jin</surname> <given-names>P</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Murnen</surname> <given-names>K</given-names></name><name><surname>Chen</surname> <given-names>EH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Actin-propelled invasive membrane protrusions promote fusogenic protein engagement during cell-cell fusion</article-title><source>Science</source><volume>340</volume><fpage>359</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1126/science.1234781</pub-id><pub-id pub-id-type="pmid">23470732</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirato</surname> <given-names>K</given-names></name><name><surname>Kawase</surname> <given-names>M</given-names></name><name><surname>Matsuyama</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry</article-title><source>Virology</source><volume>517</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2017.11.012</pub-id><pub-id pub-id-type="pmid">29217279</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simons</surname> <given-names>K</given-names></name><name><surname>Ikonen</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Functional rafts in cell membranes</article-title><source>Nature</source><volume>387</volume><fpage>569</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1038/42408</pub-id><pub-id pub-id-type="pmid">9177342</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobocińska</surname> <given-names>J</given-names></name><name><surname>Roszczenko-Jasińska</surname> <given-names>P</given-names></name><name><surname>Ciesielska</surname> <given-names>A</given-names></name><name><surname>Kwiatkowska</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Protein palmitoylation and its role in bacterial and viral infections</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>2003</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.02003</pub-id><pub-id pub-id-type="pmid">29403483</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohet</surname> <given-names>F</given-names></name><name><surname>Lin</surname> <given-names>C</given-names></name><name><surname>Munji</surname> <given-names>RN</given-names></name><name><surname>Lee</surname> <given-names>SY</given-names></name><name><surname>Ruderisch</surname> <given-names>N</given-names></name><name><surname>Soung</surname> <given-names>A</given-names></name><name><surname>Arnold</surname> <given-names>TD</given-names></name><name><surname>Derugin</surname> <given-names>N</given-names></name><name><surname>Vexler</surname> <given-names>ZS</given-names></name><name><surname>Yen</surname> <given-names>FT</given-names></name><name><surname>Daneman</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>LSR/angulin-1 is a tricellular tight junction protein involved in blood-brain barrier formation</article-title><source>Journal of Cell Biology</source><volume>208</volume><fpage>703</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1083/jcb.201410131</pub-id><pub-id pub-id-type="pmid">25753034</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Sonnhammer</surname> <given-names>EL</given-names></name><name><surname>von Heijne</surname> <given-names>G</given-names></name><name><surname>Krogh</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A hidden markov model for predicting transmembrane helices in protein sequences</article-title><conf-name>Proceedings. International Conference on Intelligent Systems for Molecular Biology</conf-name><fpage>175</fpage><lpage>182</lpage></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soumpasis</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Theoretical analysis of fluorescence photobleaching recovery experiments</article-title><source>Biophysical Journal</source><volume>41</volume><fpage>95</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(83)84410-5</pub-id><pub-id pub-id-type="pmid">6824758</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sriram</surname> <given-names>K</given-names></name><name><surname>Insel</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>G Protein-Coupled receptors as targets for approved drugs: how many targets and how many drugs?</article-title><source>Molecular Pharmacology</source><volume>93</volume><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1124/mol.117.111062</pub-id><pub-id pub-id-type="pmid">29298813</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname> <given-names>MB</given-names></name><name><surname>Shelby</surname> <given-names>SA</given-names></name><name><surname>Núñez</surname> <given-names>MF</given-names></name><name><surname>Wisser</surname> <given-names>K</given-names></name><name><surname>Veatch</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Protein sorting by lipid phase-like domains supports emergent signaling function in B lymphocyte plasma membranes</article-title><source>eLife</source><volume>6</volume><elocation-id>e19891</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.19891</pub-id><pub-id pub-id-type="pmid">28145867</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratton</surname> <given-names>CW</given-names></name><name><surname>Tang</surname> <given-names>YW</given-names></name><name><surname>Lu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pathogenesis-directed therapy of 2019 novel coronavirus disease</article-title><source>Journal of Medical Virology</source><volume>93</volume><fpage>1320</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1002/jmv.26610</pub-id><pub-id pub-id-type="pmid">33073355</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarcsay</surname> <given-names>Á</given-names></name><name><surname>Keserű</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Contributions of molecular properties to drug promiscuity</article-title><source>Journal of Medicinal Chemistry</source><volume>56</volume><fpage>1789</fpage><lpage>1795</lpage><pub-id pub-id-type="doi">10.1021/jm301514n</pub-id><pub-id pub-id-type="pmid">23356819</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tay</surname> <given-names>MZ</given-names></name><name><surname>Poh</surname> <given-names>CM</given-names></name><name><surname>Rénia</surname> <given-names>L</given-names></name><name><surname>MacAry</surname> <given-names>PA</given-names></name><name><surname>Ng</surname> <given-names>LFP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The trinity of COVID-19: immunity, inflammation and intervention</article-title><source>Nature Reviews Immunology</source><volume>20</volume><fpage>363</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0311-8</pub-id><pub-id pub-id-type="pmid">32346093</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenchov</surname> <given-names>BG</given-names></name><name><surname>MacDonald</surname> <given-names>RC</given-names></name><name><surname>Siegel</surname> <given-names>DP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cubic phases in phosphatidylcholine-cholesterol mixtures: cholesterol as membrane &quot;fusogen&quot;</article-title><source>Biophysical Journal</source><volume>91</volume><fpage>2508</fpage><lpage>2516</lpage><pub-id pub-id-type="doi">10.1529/biophysj.106.083766</pub-id><pub-id pub-id-type="pmid">16829556</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorp</surname> <given-names>EB</given-names></name><name><surname>Gallagher</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Requirements for CEACAMs and cholesterol during murine coronavirus cell entry</article-title><source>Journal of Virology</source><volume>78</volume><fpage>2682</fpage><lpage>2692</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.6.2682-2692.2004</pub-id><pub-id pub-id-type="pmid">14990688</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname> <given-names>S</given-names></name><name><surname>Hu</surname> <given-names>W</given-names></name><name><surname>Niu</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Xiao</surname> <given-names>SY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pulmonary pathology of Early-Phase 2019 novel coronavirus (COVID-19) Pneumonia in two patients with lung Cancer</article-title><source>Journal of Thoracic Oncology</source><volume>15</volume><fpage>700</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.02.010</pub-id><pub-id pub-id-type="pmid">32114094</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinh</surname> <given-names>MN</given-names></name><name><surname>Lu</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Das</surname> <given-names>A</given-names></name><name><surname>Liang</surname> <given-names>Q</given-names></name><name><surname>De Brabander</surname> <given-names>JK</given-names></name><name><surname>Brown</surname> <given-names>MS</given-names></name><name><surname>Goldstein</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Triazoles inhibit cholesterol export from lysosomes by binding to NPC1</article-title><source>PNAS</source><volume>114</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1073/pnas.1619571114</pub-id><pub-id pub-id-type="pmid">27994139</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchiya</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Membrane interactions of phytochemicals as their molecular mechanism applicable to the discovery of drug leads from plants</article-title><source>Molecules</source><volume>20</volume><fpage>18923</fpage><lpage>18966</lpage><pub-id pub-id-type="doi">10.3390/molecules201018923</pub-id><pub-id pub-id-type="pmid">26501254</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchiya</surname> <given-names>H</given-names></name><name><surname>Mizogami</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Interaction of local anesthetics with biomembranes consisting of phospholipids and cholesterol: mechanistic and clinical implications for anesthetic and cardiotoxic effects</article-title><source>Anesthesiology Research and Practice</source><volume>2013</volume><elocation-id>297141</elocation-id><pub-id pub-id-type="doi">10.1155/2013/297141</pub-id><pub-id pub-id-type="pmid">24174934</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>UniProt Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>UniProt: a hub for protein information</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>D204</fpage><lpage>D212</lpage><pub-id pub-id-type="doi">10.1093/nar/gku989</pub-id><pub-id pub-id-type="pmid">25348405</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V'kovski</surname> <given-names>P</given-names></name><name><surname>Kratzel</surname> <given-names>A</given-names></name><name><surname>Steiner</surname> <given-names>S</given-names></name><name><surname>Stalder</surname> <given-names>H</given-names></name><name><surname>Thiel</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Coronavirus biology and replication: implications for SARS-CoV-2</article-title><source>Nature Reviews Microbiology</source><volume>19</volume><fpage>155</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-00468-6</pub-id><pub-id pub-id-type="pmid">33116300</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veatch</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Electro-formation and fluorescence microscopy of giant vesicles with coexisting liquid phases</article-title><source>Methods in Molecular Biology</source><volume>398</volume><fpage>59</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/978-1-59745-513-8_6</pub-id><pub-id pub-id-type="pmid">18214374</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veatch</surname> <given-names>SL</given-names></name><name><surname>Cicuta</surname> <given-names>P</given-names></name><name><surname>Sengupta</surname> <given-names>P</given-names></name><name><surname>Honerkamp-Smith</surname> <given-names>A</given-names></name><name><surname>Holowka</surname> <given-names>D</given-names></name><name><surname>Baird</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Critical fluctuations in plasma membrane vesicles</article-title><source>ACS Chemical Biology</source><volume>3</volume><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1021/cb800012x</pub-id><pub-id pub-id-type="pmid">18484709</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veatch</surname> <given-names>SL</given-names></name><name><surname>Keller</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Separation of liquid phases in giant vesicles of ternary mixtures of phospholipids and cholesterol</article-title><source>Biophysical Journal</source><volume>85</volume><fpage>3074</fpage><lpage>3083</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(03)74726-2</pub-id><pub-id pub-id-type="pmid">14581208</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veatch</surname> <given-names>SL</given-names></name><name><surname>Keller</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Seeing spots: complex phase behavior in simple membranes</article-title><source>Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1746</volume><fpage>172</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2005.06.010</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname> <given-names>AC</given-names></name><name><surname>Park</surname> <given-names>YJ</given-names></name><name><surname>Tortorici</surname> <given-names>MA</given-names></name><name><surname>Wall</surname> <given-names>A</given-names></name><name><surname>McGuire</surname> <given-names>AT</given-names></name><name><surname>Veesler</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><volume>181</volume><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname> <given-names>J</given-names></name><name><surname>Roth</surname> <given-names>AF</given-names></name><name><surname>Bailey</surname> <given-names>AO</given-names></name><name><surname>Davis</surname> <given-names>NG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Palmitoylated proteins: purification and identification</article-title><source>Nature Protocols</source><volume>2</volume><fpage>1573</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.225</pub-id><pub-id pub-id-type="pmid">17585299</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Hui</surname> <given-names>H</given-names></name><name><surname>Tiwari</surname> <given-names>SK</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Croker</surname> <given-names>BA</given-names></name><name><surname>Rawlings</surname> <given-names>S</given-names></name><name><surname>Smith</surname> <given-names>D</given-names></name><name><surname>Carlin</surname> <given-names>AF</given-names></name><name><surname>Rana</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol</article-title><source>The EMBO Journal</source><volume>39</volume><elocation-id>e106057</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2020106057</pub-id><pub-id pub-id-type="pmid">32944968</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>J</given-names></name><name><surname>Alfajaro</surname> <given-names>MM</given-names></name><name><surname>Hanna</surname> <given-names>RE</given-names></name><name><surname>DeWeirdt</surname> <given-names>PC</given-names></name><name><surname>Strine</surname> <given-names>MS</given-names></name><name><surname>Lu-Culligan</surname> <given-names>WJ</given-names></name><name><surname>Zhang</surname> <given-names>S-M</given-names></name><name><surname>Graziano</surname> <given-names>VR</given-names></name><name><surname>Schmitz</surname> <given-names>CO</given-names></name><name><surname>Chen</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.06.16.155101</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wibmer</surname> <given-names>CK</given-names></name><name><surname>Ayres</surname> <given-names>F</given-names></name><name><surname>Hermanus</surname> <given-names>T</given-names></name><name><surname>Madzivhandila</surname> <given-names>M</given-names></name><name><surname>Kgagudi</surname> <given-names>P</given-names></name><name><surname>Oosthuysen</surname> <given-names>B</given-names></name><name><surname>Lambson</surname> <given-names>BE</given-names></name><name><surname>de Oliveira</surname> <given-names>T</given-names></name><name><surname>Vermeulen</surname> <given-names>M</given-names></name><name><surname>van der Berg</surname> <given-names>K</given-names></name><name><surname>Rossouw</surname> <given-names>T</given-names></name><name><surname>Boswell</surname> <given-names>M</given-names></name><name><surname>Ueckermann</surname> <given-names>V</given-names></name><name><surname>Meiring</surname> <given-names>S</given-names></name><name><surname>von Gottberg</surname> <given-names>A</given-names></name><name><surname>Cohen</surname> <given-names>C</given-names></name><name><surname>Morris</surname> <given-names>L</given-names></name><name><surname>Bhiman</surname> <given-names>JN</given-names></name><name><surname>Moore</surname> <given-names>PL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 501Y.V2 escapes neutralization by south african COVID-19 donor plasma</article-title><source>Nature Medicine</source><volume>27</volume><fpage>622</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01285-x</pub-id><pub-id pub-id-type="pmid">33654292</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>N</given-names></name><name><surname>Corbett</surname> <given-names>KS</given-names></name><name><surname>Goldsmith</surname> <given-names>JA</given-names></name><name><surname>Hsieh</surname> <given-names>CL</given-names></name><name><surname>Abiona</surname> <given-names>O</given-names></name><name><surname>Graham</surname> <given-names>BS</given-names></name><name><surname>McLellan</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Lan</surname> <given-names>Q</given-names></name><name><surname>Feng</surname> <given-names>S</given-names></name><name><surname>Qi</surname> <given-names>F</given-names></name><name><surname>Bao</surname> <given-names>L</given-names></name><name><surname>Du</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Qin</surname> <given-names>C</given-names></name><name><surname>Sun</surname> <given-names>F</given-names></name><name><surname>Shi</surname> <given-names>Z</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Jiang</surname> <given-names>S</given-names></name><name><surname>Lu</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</article-title><source>Cell Research</source><volume>30</volume><fpage>343</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0305-x</pub-id><pub-id pub-id-type="pmid">32231345</pub-id></element-citation></ref><ref id="bib155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Dang</surname> <given-names>Y</given-names></name><name><surname>Ren</surname> <given-names>YR</given-names></name><name><surname>Liu</surname> <given-names>JO</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cholesterol trafficking is required for mTOR activation in endothelial cells</article-title><source>PNAS</source><volume>107</volume><fpage>4764</fpage><lpage>4769</lpage><pub-id pub-id-type="doi">10.1073/pnas.0910872107</pub-id><pub-id pub-id-type="pmid">20176935</pub-id></element-citation></ref><ref id="bib156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname> <given-names>M</given-names></name><name><surname>Matsuyama</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Takeda</surname> <given-names>M</given-names></name><name><surname>Kawaguchi</surname> <given-names>Y</given-names></name><name><surname>Inoue</surname> <given-names>JI</given-names></name><name><surname>Matsuda</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S Protein-Mediated membrane fusion using the Split-Protein-Based Cell-Cell fusion assay</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>60</volume><fpage>6532</fpage><lpage>6539</lpage><pub-id pub-id-type="doi">10.1128/AAC.01043-16</pub-id><pub-id pub-id-type="pmid">27550352</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Xia</surname> <given-names>L</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title><source>Science</source><volume>367</volume><fpage>1444</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id><pub-id pub-id-type="pmid">32132184</pub-id></element-citation></ref><ref id="bib158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>S</given-names></name><name><surname>Chan</surname> <given-names>CC-Y</given-names></name><name><surname>Chik</surname> <given-names>KK-H</given-names></name><name><surname>Tsang</surname> <given-names>JO-L</given-names></name><name><surname>Liang</surname> <given-names>R</given-names></name><name><surname>Cao</surname> <given-names>J</given-names></name><name><surname>Tang</surname> <given-names>K</given-names></name><name><surname>Cai</surname> <given-names>J-P</given-names></name><name><surname>Ye</surname> <given-names>Z-W</given-names></name><name><surname>Yin</surname> <given-names>F</given-names></name><name><surname>To</surname> <given-names>KK-W</given-names></name><name><surname>Chu</surname> <given-names>H</given-names></name><name><surname>Jin</surname> <given-names>D-Y</given-names></name><name><surname>Hung</surname> <given-names>IF-N</given-names></name><name><surname>Yuen</surname> <given-names>K-Y</given-names></name><name><surname>Chan</surname> <given-names>JF-W</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Broad-Spectrum Host-Based antivirals targeting the interferon and lipogenesis pathways as potential treatment options for the pandemic coronavirus disease 2019 (COVID-19)</article-title><source>Viruses</source><volume>12</volume><elocation-id>628</elocation-id><pub-id pub-id-type="doi">10.3390/v12060628</pub-id></element-citation></ref><ref id="bib159"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zang</surname> <given-names>R</given-names></name><name><surname>Case</surname> <given-names>JB</given-names></name><name><surname>Yutuc</surname> <given-names>E</given-names></name><name><surname>Ma</surname> <given-names>X</given-names></name><name><surname>Shen</surname> <given-names>S</given-names></name><name><surname>Gomez Castro</surname> <given-names>MF</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Zeng</surname> <given-names>Q</given-names></name><name><surname>Zhao</surname> <given-names>H</given-names></name><name><surname>Son</surname> <given-names>J</given-names></name><name><surname>Rothlauf</surname> <given-names>PW</given-names></name><name><surname>Kreutzberger</surname> <given-names>AJB</given-names></name><name><surname>Hou</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Bose</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Vahey</surname> <given-names>MD</given-names></name><name><surname>Mani</surname> <given-names>K</given-names></name><name><surname>Griffiths</surname> <given-names>WJ</given-names></name><name><surname>Kirchhausen</surname> <given-names>T</given-names></name><name><surname>Fremont</surname> <given-names>DH</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Diwan</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Diamond</surname> <given-names>MS</given-names></name><name><surname>Whelan</surname> <given-names>SPJ</given-names></name><name><surname>Ding</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion</article-title><source>PNAS</source><volume>117</volume><fpage>32105</fpage><lpage>32113</lpage><pub-id pub-id-type="doi">10.1073/pnas.2012197117</pub-id><pub-id pub-id-type="pmid">33239446</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zang</surname> <given-names>R</given-names></name><name><surname>Gomez Castro</surname> <given-names>MF</given-names></name><name><surname>McCune</surname> <given-names>BT</given-names></name><name><surname>Zeng</surname> <given-names>Q</given-names></name><name><surname>Rothlauf</surname> <given-names>PW</given-names></name><name><surname>Sonnek</surname> <given-names>NM</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Brulois</surname> <given-names>KF</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Greenberg</surname> <given-names>HB</given-names></name><name><surname>Diamond</surname> <given-names>MS</given-names></name><name><surname>Ciorba</surname> <given-names>MA</given-names></name><name><surname>Whelan</surname> <given-names>SPJ</given-names></name><name><surname>Ding</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes</article-title><source>Science Immunology</source><volume>5</volume><elocation-id>eabc3582</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abc3582</pub-id><pub-id pub-id-type="pmid">32404436</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zawada</surname> <given-names>KE</given-names></name><name><surname>Wrona</surname> <given-names>D</given-names></name><name><surname>Rawle</surname> <given-names>RJ</given-names></name><name><surname>Kasson</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Influenza viral membrane fusion is sensitive to sterol concentration but surprisingly robust to sterol chemical identity</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>29842</elocation-id><pub-id pub-id-type="doi">10.1038/srep29842</pub-id><pub-id pub-id-type="pmid">27431907</pub-id></element-citation></ref><ref id="bib162"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>JH</given-names></name><name><surname>Chung</surname> <given-names>TD</given-names></name><name><surname>Oldenburg</surname> <given-names>KR</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>A simple statistical parameter for use in evaluation and validation of high throughput screening assays</article-title><source>Journal of Biomolecular Screening</source><volume>4</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1177/108705719900400206</pub-id><pub-id pub-id-type="pmid">10838414</pub-id></element-citation></ref><ref id="bib163"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>XJ</given-names></name><name><surname>Qin</surname> <given-names>JJ</given-names></name><name><surname>Cheng</surname> <given-names>X</given-names></name><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Zhao</surname> <given-names>YC</given-names></name><name><surname>Yuan</surname> <given-names>Y</given-names></name><name><surname>Lei</surname> <given-names>F</given-names></name><name><surname>Chen</surname> <given-names>MM</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Bai</surname> <given-names>L</given-names></name><name><surname>Song</surname> <given-names>X</given-names></name><name><surname>Lin</surname> <given-names>L</given-names></name><name><surname>Xia</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>F</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>She</surname> <given-names>ZG</given-names></name><name><surname>Zhu</surname> <given-names>L</given-names></name><name><surname>Ma</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>Q</given-names></name><name><surname>Ye</surname> <given-names>P</given-names></name><name><surname>Chen</surname> <given-names>G</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Mao</surname> <given-names>W</given-names></name><name><surname>Yan</surname> <given-names>Y</given-names></name><name><surname>Xiao</surname> <given-names>B</given-names></name><name><surname>Lu</surname> <given-names>Z</given-names></name><name><surname>Peng</surname> <given-names>G</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Lu</surname> <given-names>H</given-names></name><name><surname>Xia</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Liao</surname> <given-names>X</given-names></name><name><surname>Wei</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>BH</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>GN</given-names></name><name><surname>Zhang</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>PP</given-names></name><name><surname>Loomba</surname> <given-names>R</given-names></name><name><surname>Ji</surname> <given-names>YX</given-names></name><name><surname>Xia</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Cai</surname> <given-names>J</given-names></name><name><surname>Guo</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>In-Hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19</article-title><source>Cell Metabolism</source><volume>32</volume><fpage>176</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.06.015</pub-id><pub-id pub-id-type="pmid">32592657</pub-id></element-citation></ref><ref id="bib164"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>B</given-names></name><name><surname>DeRan</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Liao</surname> <given-names>X</given-names></name><name><surname>Fukata</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>2-Bromopalmitate analogues as activity-based probes to explore palmitoyl acyltransferases</article-title><source>Journal of the American Chemical Society</source><volume>135</volume><fpage>7082</fpage><lpage>7085</lpage><pub-id pub-id-type="doi">10.1021/ja311416v</pub-id><pub-id pub-id-type="pmid">23631516</pub-id></element-citation></ref><ref id="bib165"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Vedantham</surname> <given-names>P</given-names></name><name><surname>Lu</surname> <given-names>K</given-names></name><name><surname>Agudelo</surname> <given-names>J</given-names></name><name><surname>Carrion</surname> <given-names>R</given-names></name><name><surname>Nunneley</surname> <given-names>JW</given-names></name><name><surname>Barnard</surname> <given-names>D</given-names></name><name><surname>Pöhlmann</surname> <given-names>S</given-names></name><name><surname>McKerrow</surname> <given-names>JH</given-names></name><name><surname>Renslo</surname> <given-names>AR</given-names></name><name><surname>Simmons</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Protease inhibitors targeting coronavirus and Filovirus entry</article-title><source>Antiviral Research</source><volume>116</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2015.01.011</pub-id><pub-id pub-id-type="pmid">25666761</pub-id></element-citation></ref><ref id="bib166"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>F</given-names></name><name><surname>Yu</surname> <given-names>T</given-names></name><name><surname>Du</surname> <given-names>R</given-names></name><name><surname>Fan</surname> <given-names>G</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Xiang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Song</surname> <given-names>B</given-names></name><name><surname>Gu</surname> <given-names>X</given-names></name><name><surname>Guan</surname> <given-names>L</given-names></name><name><surname>Wei</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Tu</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Cao</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>The Lancet</source><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="bib167"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>N</given-names></name><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>B</given-names></name><name><surname>Song</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>X</given-names></name><name><surname>Huang</surname> <given-names>B</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name><name><surname>Lu</surname> <given-names>R</given-names></name><name><surname>Niu</surname> <given-names>P</given-names></name><name><surname>Zhan</surname> <given-names>F</given-names></name><name><surname>Ma</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Gao</surname> <given-names>GF</given-names></name><name><surname>Tan</surname> <given-names>W</given-names></name><collab>China Novel Coronavirus Investigating and Research Team</collab></person-group><year iso-8601-date="2020">2020a</year><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>New England Journal of Medicine</source><volume>382</volume><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="bib168"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Feng</surname> <given-names>F</given-names></name><name><surname>Hu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Yu</surname> <given-names>Y</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Cai</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>Z</given-names></name><name><surname>Han</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>The S1/S2 boundary of SARS-CoV-2 spike protein modulates cell entry pathways and transmission</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.08.25.266775</pub-id></element-citation></ref><ref id="bib169"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zidovetzki</surname> <given-names>R</given-names></name><name><surname>Levitan</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies</article-title><source>Biochimica Et Biophysica Acta (BBA) - Biomembranes</source><volume>1768</volume><fpage>1311</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2007.03.026</pub-id><pub-id pub-id-type="pmid">17493580</pub-id></element-citation></ref><ref id="bib170"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinszner</surname> <given-names>H</given-names></name><name><surname>Sok</surname> <given-names>J</given-names></name><name><surname>Immanuel</surname> <given-names>D</given-names></name><name><surname>Yin</surname> <given-names>Y</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling</article-title><source>Journal of Cell Science</source><volume>110 ( Pt 15</volume><fpage>1741</fpage><lpage>1750</lpage><pub-id pub-id-type="doi">10.1242/jcs.110.15.1741</pub-id><pub-id pub-id-type="pmid">9264461</pub-id></element-citation></ref><ref id="bib171"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zu</surname> <given-names>S</given-names></name><name><surname>Deng</surname> <given-names>YQ</given-names></name><name><surname>Zhou</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>XF</given-names></name><name><surname>Zhao</surname> <given-names>H</given-names></name><name><surname>Gold</surname> <given-names>S</given-names></name><name><surname>He</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Cheng</surname> <given-names>G</given-names></name><name><surname>Qin</surname> <given-names>CF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor</article-title><source>Cell Research</source><volume>30</volume><fpage>1043</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-00398-1</pub-id><pub-id pub-id-type="pmid">32811977</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65962.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Prinz</surname><given-names>William A</given-names></name><role>Reviewing Editor</role><aff><institution>National Institutes of Health</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Your study describes an important new screening method to identify compounds that inhibit SARS-CoV-2 infection and syncytia formation caused by the virus. This method and the finding that cholesterol plays a critical role in these processes are significant advances, particularly given the ongoing pandemic.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;SARS-CoV-2 Requires Cholesterol for Viral Entry and Pathological Syncytia Formation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Vivek Malhotra as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Summary:</p><p>This study investigates how SARS-CoV2, the virus that causes COVID-19 enters cells and may damage the lungs of COVID-19 patients; it identifies drugs that reduce cell-cell fusion, which appears to be correlated with disease severity. The authors identified several compounds that target cholesterol homeostasis and reduce viral-host cell membrane fusion and inhibit SARS-CoV-2 infection. Overall, the study is well done, and the screening method may be a useful tool for others, but additional evidence is required to support the claim that the identified drugs work by lowering cholesterol levels.</p><p>Essential revisions:</p><p>1. Reviewer 2 raises a number of important concerns about the viral infections results shown in Figure 7 (major points 3-5), specifically about the length of infection and the possible toxic effects of MBCD on cells and the virus. The reviewer makes a number of suggestions about how these concerns could be addressed.</p><p>2. Reviewer 1 (point 1) says that since some of the drugs identified in the screen are proposed to decrease fusion by decreasing cholesterol levels in the plasma membrane, this should be directly measured. A second-best option would be to measure total free cholesterol levels in the cells, since most free cholesterol is probably in the plasma membrane.</p><p>3. Reviewer 3 points out that much of what this study shows about syncytia formation and the role of cholesterol in infection was already known or at least suggested by earlier work (as detailed in the Reviewer's comments in &quot;Recommendations for the authors.&quot;). Please address these concerns by citing and discussing the references the Review mentions and putting your findings in context.</p><p>4. Reviewer 2 asks for a better description of the fusion assay and more discussion of cells lines were chosen (major points 1 and 2). Please address these concerns.</p><p>5. Please provide direct evidence that spike protein is palmitoylated or soften the claim that it is (Reviewer 1, point 2).</p><p><italic>Reviewer #1:</italic></p><p>This study seeks to identify factors that contribute to the formation of fusion-competent SARS-CoV-2 and the formation of pathological syncytia. Both processes remain poorly understood. Syncytia were detected in the lungs of COVID-19 who died as a direct consequence of SARS-CoV-2 infection, suggesting syncytia formation contributes to pathology. To study syncytia formation, a novel cell in vitro co-culture assay was used. It was found that expressing SARS-CoV-2 spike or ACE2 form large synapse-like structure before fusing to form syncytia. The cell fusion assay was used for a high throughput screen to identify drugs that prevent syncytia formation in vitro. Characterization of the effects of the drugs suggests cholesterol is required for viral entry and fusion.</p><p>Strengths of the study are the demonstration that syncytia formation may contributes to COVID-19 pathology and the development of a robust, rigorous assay to study syncytia formation in vitro. The screen for drugs that inhibit syncytia formation is well done and the compounds identified are likely to be useful for study the mechanism of syncytia formation. The remainder of the study is weaker, and the significance of the finding less clear. The investigations of the role of spike protein in fusion and how cholesterol affects fusion require some additional work to be convincing. Also, the idea that achievable reductions in cellular free cholesterol levels could significantly reduce spike-mediated membrane fusion, while intriguing, is not strongly supported by the findings.</p><p>1. Much of evidence that cholesterol plays an important role in spike-mediated membrane fusion is indirect or negative, like the finding that spike is not in rafts. Perhaps the strongest evidence for a specific role for cholesterol is provided by the experiments with MBCD (particularly the evidence shown in Figures 6I and S7D,E). On the other hand, since cholesterol is roughly 50% of the lipid in plasma membranes, it is not terribly surprising that removal of a large fraction of cholesterol from cells disrupt fusion. While the study suggests lipid-targeting drugs affect fusion by reducing cholesterol levels in the plasma membrane, this has not been directly tested. A demonstration that plasma membrane levels (or even total cellular free cholesterol levels) decrease when the cells used for the fusion assay are treated with drugs that inhibit fusion would significantly strengthen the conclusions of the study and its implications for treatment of COVID-19 with lipid-targeting drugs. Similarly, while it is interesting that treating virus with MBCD reduces viral fusion, it is not clear that modest reductions in viral cholesterol levels, which is probably the best one could hope for in patients, would have any effect on viral fusion efficiency.</p><p>2. While the study makes a good case that the transmembrane domain and intracellular portion of spike are necessary for efficient fusion, the claim that the membrane proximal is palmitoylated or that palmitoylation plays a role in spike-mediated fusion is not well supported. There is no direct demonstration that spike is palmitoylated. In addition, the effect of the palmitoylation inhibitor 2-BP is quite modest in U2OS cells and only better in Vero at high concentrations, given that the IC50 for 2-BP is typically 10-15 μM (e.g, PMID: 23631516). Either better evidence that palmitoylation regulates spike should be provided or the statement about the role of palmitoylation in spike-mediated fusion should be softened or removed.</p><p><italic>Reviewer #2:</italic></p><p>1. Not enough details were provided for the U2OS cells and the spike-ACE2 fusion assay in Figure 1. For instance, what are the protein levels of cellular proteases, including furin (Hoffmann, Mol Cell, 2020) and TMPRSS2/4/11D/13 (Zang, Sci Immunol, 2020; Hoffmann, bioRixv, 2020) in these cells? Is this a clonal or pooled ACE2 expression? How much ACE2 is present at the plasma membrane (by flow cytometry)? Where is the fluorescent tag (GFP or iRFP) constructed? All panels in Figure 1 should be quantified to show the percentage of fused cells and average number of nuclei in syncytia. Same with Figure S1 and other fusion assays.</p><p>2. Almost all the inhibitor experiments thus far were carried out in U2OS-ACE2 and Vero based cell assays (Figure 3-4). However, for the pseudotyped virus and authentic SARS-CoV-2 infection, the authors switched to A549-ACE2/TMPRSS2 cells, which predominantly utilizes the plasma membrane mediated entry (Hoffmann, Cell, 2020; Shang, PNAS, 2020). For instance, apilimod, which inhibits SARS-CoV-2 at nanomolar range (Kang, PNAS, 2020) is ineffective here (Figure 7B). This is likely not an inherent problem of transformed cell lines but likely alters the entry pathway utilized. The authors should clarify this better in the text and provide references.</p><p>3. Figure 7E, the length of infection (48 hr) is too long to properly access viral entry. With multiple rounds of infection, it is possible that newly synthesized viruses produced from MBCD treated cells are less infectious, thereby resulting in reduced viral antigen signals. Fixing or harvesting infected cells at 6-8 hr will yield signals strong enough to be quantified, to better focus on the entry/early stage replication.</p><p>4. Improved images are needed for Figure 7F. It seems that MBCD at higher concentrations dramatically reduced the blue DAPI staining, and yet the authors previously showed that it is not toxic to cells (Figure 6H).</p><p>5. Figure 7G, how does MBCD treatment affect viral particle integrity? In other words, is the viral RNA still associated/encapsidated within the viral capsid proteins post MBCD treatment? Plus/minus the RNase treatment in the media or ELISA of viral proteins would be good controls to include.</p><p>Overall, I think this is a nicely written and timely study. My major problem lies with viral infection experiments performed in Figure 7, which I think should be fixed to strengthen the conclusion of the manuscript.</p><p><italic>Reviewer #3:</italic></p><p>Syncytia formation has been found in the lungs of patients with SARS-CoV2 and appears to be correlated with disease severity. This phenomena is likely due to cell-cell interactions through Spike and ACE2. Using an assay based on one cell expressing S and the other ACE2 this investigation exhaustively screens existing antiviral compounds as well as compounds known to dusrupt cellular endocytic and secretory pathways to identify factors regulating syncytia formation. The ultimate finding of this study is the important role played by plasma membrane cholesterol for syncytia formation and the potential of cholesterol extracting molecules for blocking the syncytia formation.</p><p>While this is a very thorough and comprehensive study, almost all its findings have been previously reported either with CoV2 or COV1 or MHV.</p><p>1. The critical importance of syncytia formation in lungs for disease severity has been reported for CoV2 by multiple groups ( Tian et al., Hoffmann et al., Graccal et al., Buchreiser et al., ). Some of these references are missing and credit should be given.</p><p>2. Liu et al. in 2003 had reported in Nature that SARS-CoV1 S and ACE2 were sufficient to form syncytia and they used a very similar assay as to one reported here. This reference is missing from the manuscript and should be included.</p><p>3. Musarrat et al., in 2020 showed that the antiretorviral protease inhibitor nelfinavir blocks CoV2 viral fusion and prevents syncytia formation. This reference is missing from the manuscript and should be included.</p><p>4. The important role of cholesterol in b-coronavirus infections was also previously highlighted in 1988 and 1991 by the group of Anderson</p><p>and Methylbcyclodextrin was shown by them to prevent syncytia formation. These references are missing and should be credited.</p><p>Given all the above, what remains novel in this manuscript is the exhaustive screening of drugs to identify not only those that block the syncytia from forming but also those that don't have any effect. Therefore it may be a useful resource and suitable for publication.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65962.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Summary:</p><p>This study investigates how SARS-CoV2, the virus that causes COVID-19 enters cells and may damage the lungs of COVID-19 patients; it identifies drugs that reduce cell-cell fusion, which appears to be correlated with disease severity. The authors identified several compounds that target cholesterol homeostasis and reduce viral-host cell membrane fusion and inhibit SARS-CoV-2 infection. Overall, the study is well done, and the screening method may be a useful tool for others, but additional evidence is required to support the claim that the identified drugs work by lowering cholesterol levels.</p></disp-quote><p>We thank the editors and reviewers for taking the time to evaluate our manuscript, “SARS-CoV-2 Requires Cholesterol for Viral Entry and Pathological Syncytia Formation”, for publication at <italic>eLife.</italic> We were pleased to hear that reviewers were enthusiastic overall, stating that the study was “well done” and our novel, high-throughput “screening method may be a useful tool for others”. However, in the evaluation summary, it is noted that “additional evidence is required to support the claim that the identified drugs work by lowering cholesterol”. We are of the strong opinion that the data clearly shows that cholesterol reduction inhibits spike-mediated membrane fusion (see Figures 6,7). Moreover, cheminformatics (Figure 4), pharmacological interrogation of steps of secretory pathway (Figure 3), and identified EC50s for hit small molecules together provides a compelling picture that most (if not all) compounds act by altering biophysical properties of the membrane (see Figure 4).</p><p>However, we certainly respect reviewers’ stated limitations of our work and eagerly address these in the revised draft. After consulting with colleagues, we recognize that substantial new experimental data, requiring development/optimization of new techniques, would be needed to determine whether the identified lipophilic compounds (Figure 4) act exclusively at the level of cholesterol. For example, it is possible that certain compounds exert similar biophysical effects on the membrane as cholesterol reduction (e.g. altered fluidity), but exhaustive interrogation of mechanism of action for dozens of compounds is beyond the scope of this study. Given the significance of the findings for the ongoing pandemic and <italic>eLife</italic>’s COVID-19 policies (https://elifesciences.org/articles/57162), we feel it is in the public’s best interest to revise the text to highlight limitations of the current study, which we anticipate can be rigorously addressed in future experimental work.</p><p>Please note that reviewer comments are numbered (e.g. [R1-1] is shorthand for Reviewer 1, Comment 1) for easy reference across critiques and the evaluation summary (Essential Revisions, [ER]).</p><p>We hope the revised manuscript adequately addresses concerns of limitations, context in light of past work, and methodological details, and is now suitable for publication in <italic>eLife</italic>.</p><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. Reviewer 2 raises a number of important concerns about the viral infections results shown in Figure 7 (major points 3-5), specifically about the length of infection and the possible toxic effects of MBCD on cells and the virus. The reviewer makes a number of suggestions about how these concerns could be addressed.</p></disp-quote><p>Reviewer 2 raises important points/caveats with respect to our work and offers productive suggestions as to supporting experiments that would strengthen our conclusions. Please see [R2-3] to [R2-5] for detailed address of these concerns.</p><disp-quote content-type="editor-comment"><p>2. Reviewer 1 (point 1) says that since some of the drugs identified in the screen are proposed to decrease fusion by decreasing cholesterol levels in the plasma membrane, this should be directly measured. A second-best option would be to measure total free cholesterol levels in the cells, since most free cholesterol is probably in the plasma membrane.</p></disp-quote><p>To address this for the numerous lipophilic hit compounds identified by our screen (Figure 4), substantial new experimental data, based on optimization of new techniques, would be required (see [ER-0]). For example, one (potentially) facile way to measure free cholesterol would make use of toxinbased probes from the Radhakrishnan group (Das et al., 2014; Endapally et al., 2019a; Kinnebrew et al., 2019). However, such labeled probes are not yet commercially available. Thus, adaptation would require recombinant protein and labeling methodologies (Endapally et al., 2019b), which we are not equipped to deploy in a timely manner. Moreover, while providing nuance to our study, these approaches would likely not change our primary conclusions. Nonetheless, we are enthusiastic about the use of such molecular probes in follow-up studies. We note that such methods are mentioned in the current manuscript (page 7 and 9) and provide additional nuance:</p><p>Pg7: “Taken together, the data suggests that spike potentially associates with a specific population of cholesterol, which is biochemically distinct from the sphingomyelin-associated lipid complexes enriched in canonical rafts (Das et al., 2014; Endapally et al., 2019a; Kinnebrew et al., 2019). Future studies will be needed to assess the nature of such cholesterol pools, potentially using toxin-based probes that discriminate between free and inaccessible forms (Das et al., 2014; Endapally et al., 2019b), and how each is affected by the identified lipophilic compounds (Figure 4).”</p><p>Pg8: “We surmised that the drug repurposing screen identified compounds that act similarly, thus implicating a counteracting plasma membrane property that increases fusion. […] However, the latter possibility is intriguing, in light of extensive literature on anesthetics and membrane mobility (Cornell et al., 2017; Goldstein, 1984; Gray et al., 2013; Tsuchiya and Mizogami, 2013).”</p><p>Pg9: “Precedent for this model is provided by raft-independent yet cholesterol-dependent mechanisms of biomolecular clustering essential for influenza infection (Goronzy et al., 2018; Zawada et al., 2016). […] The interplay between oligomerization, palmitoylation, cholesterol association, and membrane dynamics, and how each of these properties are affected by compounds identified in our screen, will require additional methodologies beyond the scope of this study.“</p><disp-quote content-type="editor-comment"><p>3. Reviewer 3 points out that much of what this study shows about syncytia formation and the role of cholesterol in infection was already known or at least suggested by earlier work (as detailed in the Reviewer's comments in &quot;Recommendations for the authors.&quot;). Please address these concerns by citing and discussing the references the Review mentions and putting your findings in context.</p></disp-quote><p>We thank the reviewers for drawing our attention to important works that were not cited in the original version of the manuscript – our examination of previous work in the literature was extensive, but we clearly did not properly cite all studies. Such scholastic oversights have been addressed with textual changes throughout the manuscript. Please see [R2-2], [R3-1], [R3-2], [R3-3], and [R3-4] for specifics.</p><disp-quote content-type="editor-comment"><p>4. Reviewer 2 asks for a better description of the fusion assay and more discussion of cells lines were chosen (major points 1 and 2). Please address these concerns.</p></disp-quote><p>We apologize if the original version of the manuscript provided insufficient details regarding the fusion assay and selection of cell lines. We hope that specifics given to [R2-1] and [R2-2] clarify ambiguities for Reviewer 2 and other readers interested in these details.</p><disp-quote content-type="editor-comment"><p>5. Please provide direct evidence that spike protein is palmitoylated or soften the claim that it is (Reviewer 1, point 2).</p></disp-quote><p>Reviewer 1 is correct in noting that we do not specifically show that spike is palmitoylated, basing our conclusions on a palmitoylation inhibitor (2-BP) (Figure 6) and citation of past work on related coronavirus spike proteins with similar cysteine-rich cytoplasmic tails. Text changes were made to soften claims, provide nuance, and highlight alternative possibilities, which are detailed in response to [R1-2].</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>This study seeks to identify factors that contribute to the formation of fusion-competent SARS-CoV-2 and the formation of pathological syncytia. Both processes remain poorly understood. Syncytia were detected in the lungs of COVID-19 who died as a direct consequence of SARS-CoV-2 infection, suggesting syncytia formation contributes to pathology. To study syncytia formation, a novel cell in vitro co-culture assay was used. It was found that expressing SARS-CoV-2 spike or ACE2 form large synapse-like structure before fusing to form syncytia. The cell fusion assay was used for a high throughput screen to identify drugs that prevent syncytia formation in vitro. Characterization of the effects of the drugs suggests cholesterol is required for viral entry and fusion.</p><p>Strengths of the study are the demonstration that syncytia formation may contributes to COVID-19 pathology and the development of a robust, rigorous assay to study syncytia formation in vitro. The screen for drugs that inhibit syncytia formation is well done and the compounds identified are likely to be useful for study the mechanism of syncytia formation. The remainder of the study is weaker, and the significance of the finding less clear. The investigations of the role of spike protein in fusion and how cholesterol affects fusion require some additional work to be convincing. Also, the idea that achievable reductions in cellular free cholesterol levels could significantly reduce spike-mediated membrane fusion, while intriguing, is not strongly supported by the findings.</p></disp-quote><p>We thank Reviewer 1 for their overall enthusiasm for the rigor of our work and the utility of our cell fusion assay. We sympathize with the argument that additional work is needed to convincingly demonstrate the mechanism of action for many lipophilic compounds identified in our high-throughput small molecule screen (Figure 4) (see [ER-0] and [ER-2] response) and their significance for human patient pathobiology. We address specific critiques from Reviewer 1 below.</p><disp-quote content-type="editor-comment"><p>1. Much of evidence that cholesterol plays an important role in spike-mediated membrane fusion is indirect or negative, like the finding that spike is not in rafts. Perhaps the strongest evidence for a specific role for cholesterol is provided by the experiments with MBCD (particularly the evidence shown in Figures 6I and S7D,E). On the other hand, since cholesterol is roughly 50% of the lipid in plasma membranes, it is not terribly surprising that removal of a large fraction of cholesterol from cells disrupt fusion. While the study suggests lipid-targeting drugs affect fusion by reducing cholesterol levels in the plasma membrane, this has not been directly tested. A demonstration that plasma membrane levels (or even total cellular free cholesterol levels) decrease when the cells used for the fusion assay are treated with drugs that inhibit fusion would significantly strengthen the conclusions of the study and its implications for treatment of COVID-19 with lipid-targeting drugs. Similarly, while it is interesting that treating virus with MBCD reduces viral fusion, it is not clear that modest reductions in viral cholesterol levels, which is probably the best one could hope for in patients, would have any effect on viral fusion efficiency.</p></disp-quote><p>We agree with Reviewer 1 that it may not be surprising that cholesterol is important to productive SARSCoV-2 infection. We now pay particular care to citing past studies on related viruses that reached similar conclusions [ER-3]. Nevertheless, we strongly feel that the high-throughput drug screening methodology (and identified hits) are of broad interest to the scientific community, particularly given the novel assay’s ability to test compounds in the absence of BSL-3 capabilities, which are limited to a select few institutions. As detailed in text revisions described in [ER-2], future studies will assess whether all identified lipophilic compounds act by lowering total cholesterol, available free cholesterol, or via a more general impact on membrane fluidity.</p><disp-quote content-type="editor-comment"><p>2. While the study makes a good case that the transmembrane domain and intracellular portion of spike are necessary for efficient fusion, the claim that the membrane proximal is palmitoylated or that palmitoylation plays a role in spike-mediated fusion is not well supported. There is no direct demonstration that spike is palmitoylated. In addition, the effect of the palmitoylation inhibitor 2-BP is quite modest in U2OS cells and only better in Vero at high concentrations, given that the IC50 for 2-BP is typically 10-15 μM (e.g, PMID: 23631516). Either better evidence that palmitoylation regulates spike should be provided or the statement about the role of palmitoylation in spike-mediated fusion should be softened or removed.</p></disp-quote><p>Reviewer 1 is correct in noting that we do not directly show that spike is palmitoylated (e.g. by biochemistry gold standards), relying exclusively on the moderate inhibitory effect of 2-BP and citation of previous works. However, the modest effect relative to other works might be expected, given how rapidly transcellular ACE2-spike synapses and fusion events occur upon co-culture (Figure 1). Not only have we referenced the above paper detailing the IC50 for 2-BP (Zheng et al., 2013), we mention this caveat and provide nuance in response to this critique (see Page 6-7):</p><p>Pg6: “Consistent with studies on similar coronavirus spike proteins (Liao et al., 2006; McBride and Machamer, 2010a; Petit et al., 2007), mutagenesis of all spike cysteines to alanine severely diminishes cell-cell fusion in both U2OS and Vero models (Figures 5I-L; Figure 5—figure supplement 1B,C). […] Given the relatively modest and cell type-dependent effect of 2-BP treatment, future work using biochemical approaches will be required to confirm the role of palmitoylation and the precise mechanism by which spike’s aromatic-rich transmembrane domain associates with cholesterol to drive membrane fusion.”</p><p>P7: “In light of the important role for palmitoylation in tricellular tight junction assembly (Oda et al., 2020), these findings suggest that SARS-CoV-2 may operate by a similar mechanism to promote adhesion and transcellular interfaces, an exciting possibility to be explored in future studies.”</p><p>Pg7: “Thus, SARS-CoV-2 spike protein facilitates membrane-fusion in a manner that could be dependent on palmitoylation of its uniquely cysteine-rich CTD, but through a mechanism unique from canonical membrane nanodomains, although we cannot rule out a discrepancy in lipid raft properties between GPMVs and living cells (Levental et al., 2020).”</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>1. Not enough details were provided for the U2OS cells and the spike-ACE2 fusion assay in Figure 1. For instance, what are the protein levels of cellular proteases, including furin (Hoffmann, Mol Cell, 2020) and TMPRSS2/4/11D/13 (Zang, Sci Immunol, 2020; Hoffmann, bioRixv, 2020) in these cells? Is this a clonal or pooled ACE2 expression? How much ACE2 is present at the plasma membrane (by flow cytometry)? Where is the fluorescent tag (GFP or iRFP) constructed? All panels in Figure 1 should be quantified to show the percentage of fused cells and average number of nuclei in syncytia. Same with Figure S1 and other fusion assays.</p></disp-quote><p>We apologize to Reviewer #2 if insufficient details were provided to fully appreciate the experimental design and execution. We now provide additional details in the main text and methods in response to this critique (see [R2-1F]) and address each of these queries in turn below [R2-1A/B/C/D/E].</p><p>[R2-1A] Levels of cellular proteases and other proteins</p><p>This is an important consideration. We refer to the global proteomic measurements on U2OS cells performed by Beck and colleagues (Beck et al., 2011). The authors provide copy number estimates for the top 7300 most abundant proteins in U2OS cells. They estimate the following copy numbers for proteins of interest:</p><p>ACE2: not detected</p><p>FURIN: &lt;500 copies per cell</p><p>TMPRSS2: not detected</p><p>TMPRSS4: not detected</p><p>TMPRSS11D: not detected</p><p>TMPRSS13: not detected</p><p>Other TMPRSS proteins: not detected</p><p>Although not used in this study, a similar immortalized and adherent, human cell line (HeLa) benefits from highly quantitative proteomic work (Hein et al., 2015). Similar to the U2OS study, the authors do not detect the above proteins with the exception of FURIN (present at 6 nM). This is consistent with the idea that such proteins are expressed in a cell type-dependent manner, as has been noted by studies from Pohlmann’s group (Hoffmann et al., 2020) and many others.</p><p>We provide further details regarding model cell lines upon introducing the assay on page 3/5 and in the methods on page 48 in response to this critique (see [R2-1F]).</p><p>[R2-1B] Clonal or pooled ACE2 expression?</p><p>All spike and ACE2 clonal lines are pooled (i.e. polyclonal; cells express fluorescently tagged proteins at different copy numbers). Confocal microscopy confirmed that all cells expressed proteins of interest following lentivirus transduction. Please see page 48 of unformatted manuscript, which now contains additional detail.</p><p>We provide further clarity to cell line methods by adding text to methods (see [R2-1F]).</p><p>[R2-1C] How much tagged protein is on plasma membrane?</p><p>We previously developed a fluorescence correlation spectroscopy (FCS)-based calibration mechanism to estimate the concentration of mCherry- and mGFP-tagged proteins in living U2OS cells (Sanders et al., 2020). Based on these calibrations (see Figure S1 of referenced work), tagged Spike was present in most cells at high nM concentrations, whereas ACE2 was present at 1-5 μM. We do not currently have calibrations for iRFP-tagged proteins, but suspect that concentrations are roughly similar considering extent and timing of fusion, as well as lentivirus titers used to produce polyclonal cell populations. Relative expression of different iRFP-tagged variants was controlled for, however.</p><p>We attempt to clarify this issue by revising text on page 48 of the unformatted manuscript (see [R2-1F]).</p><p>[R2-1D] Where is the fluorescent tag?</p><p>The location of fluorescent tags (as well as flexible linkers used) is detailed for all examined chimeric fluorescent proteins in the Key Resources Table (page 42-46 of unformatted manuscript). In almost all cases (including all ACE2 and Spike variants), the fluorescent protein is affixed to the C-terminus (i.e. cytoplasmic side) of the transmembrane protein</p><p>No revisions were made to the text in response to this critique.</p><p>[R2-1E] Quantification of percentage cells fused?</p><p>Rigorous quantification using heterokaryon cell-cell fusion assay is provided for all spike variants in Figure 5 and Figure 5—figure supplement 1. Images in Figure 1 are representative of qualitative experiments. Similar trends were observed for spike variants regardless of fluorescent tag (mGFP, mCherry, miRFP).</p><p>However, we are sympathetic to the argument that the beginning of the paper lacks quantification for spike variants. We now add the results of a new experiment to Figure 2B, which quantifies lack of fusion for controls (see page 17).</p><p>[R2-1F] Not enough details were provided for the U2OS cells—modified text (applicable to [R2-1A,B,C]).</p><p>Pg3: “We generated pooled populations of human osteosarcoma (U2OS) cells, chosen for their flat morphology and lack of critical fusion machinery (Beck et al., 2011), which stably express fluorescently tagged ACE2 or spike (full-length, “FL” vs. receptor-binding domain, “RBD”; see Figure 1A for domain organization), using the B7 transmembrane (“TM”) domain (Liao et al., 2001; Lin et al., 2013) as a control.”</p><p>Pg5: “In almost all cases, inhibition of fusion occurred at lower compound concentrations relative to the U2OS assay, possibly due to differences in ACE2 levels between cell lines (e.g. ~1-5 µM exogenous ACE2 in U2OS cells is likely much higher than endogenous ACE2 in VeroE6 cells; see Methods).”</p><p>Pg49: “Generation of stable U2OS and VeroE6 cell lines. U2OS cells were selected for this study due to their flat morphology (ideal for live cell imaging), ease of lentivirus transduction, and absence of most proteins critical for SARS-CoV-2 fusion. […] For these variants, localization to plasma membrane and subsequent binding to ACE2 was confirmed (transcellular synapses) and essentiality for membrane fusion was addressed.”</p><disp-quote content-type="editor-comment"><p>2. Almost all the inhibitor experiments thus far were carried out in U2OS-ACE2 and Vero based cell assays (Figure 3-4). However, for the pseudotyped virus and authentic SARS-CoV-2 infection, the authors switched to A549-ACE2/TMPRSS2 cells, which predominantly utilizes the plasma membrane mediated entry (Hoffmann, Cell, 2020; Shang, PNAS, 2020). For instance, apilimod, which inhibits SARS-CoV-2 at nanomolar range (Kang, PNAS, 2020) is ineffective here (Figure 7B). This is likely not an inherent problem of transformed cell lines but likely alters the entry pathway utilized. The authors should clarify this better in the text and provide references.</p></disp-quote><p>Reviewer 2 is accurate in noting that we use different cell models in high-throughput cell-cell fusion (Figures 1-6; U20S-ACE2 and VeroE6) and pseudotyped virus/SARS-CoV-2 infection studies (Figure 7; A549-ACE2/TMPRSS2). Further, the reviewer is correct that our identified EC50s for apilimod in cell-cell fusion assays (U2OS syncytia, Figure 2E: ~15 uM; VeroE6 syncytia, Figure 3—figure supplement 2B: ~5 uM) are higher than reported by the mentioned studies (cited). However, we disagree with the reviewer’s statement that apilimod is ineffective in the A549-ACE2/TMPRSS2 pseudovirus entry assay (Figure 7B). Indeed, we show that apilimod reduces entry by ~50% at high nanomolar concentration (Figure 7B). The incomplete inhibition may reflect multiple pathways of entry (i.e. direct fusion and endocytosis). Discriminating these possibilities will be important in future studies.</p><p>For the current manuscript, the following text revisions were incorporated in light of this critique (see page 5 and 8):</p><p>Pg5: “For example, apilimod, a promising COVID-19 drug candidate that inhibits PIKFYVE kinase (Cai et al., 2013; Kang et al., 2020; Riva et al., 2020), was particularly potent (Figure 3E), however less so than in the case of infection studies (Kang et al., 2020; Riva et al., 2020).”</p><p>Pg8: “Apilimod, a PIKFYVE inhibitor and promising therapeutic in multiple SARS-CoV-2 models (Kang et al., 2020; Riva et al., 2020) including heterokaryon assays tested herein (Figures 3E; Figure 3—figure supplement 2B), inhibited (but did not completely block) entry at nanomolar concentrations (Figure 7B). […] By contrast, 25-hydroxycholesterol, which lowers plasma membrane cholesterol by redirection to the cell interior (Abrams et al., 2020; Im et al., 2005; Wang et al., 2020; Yuan et al., 2020; Zang et al., 2020a; Zhu et al., 2020; Zu et al., 2020), had no effect (Figure 7C).”</p><disp-quote content-type="editor-comment"><p>3. Figure 7E, the length of infection (48 hr) is too long to properly access viral entry. With multiple rounds of infection, it is possible that newly synthesized viruses produced from MBCD treated cells are less infectious, thereby resulting in reduced viral antigen signals. Fixing or harvesting infected cells at 6-8 hr will yield signals strong enough to be quantified, to better focus on the entry/early stage replication.</p></disp-quote><p>We thank this reviewer for her/his comment. We address these concerns below.</p><p>As viral entry is the first step of the viral life cycle, inhibiting this critical step prior to the first round of infection will echo through all subsequent rounds of infection over the next 48-hours. The MOI that we used for this experiment (i.e. 0.5) was specifically determined for that purpose, and to allow us to observe MBCD inhibitory effect at 48-hours post infection from an initial pre-treatment step.</p><p>Consistently, the MBCD effect on viral particle production was significantly detectable for several tested MBCD concentrations.</p><p>Many studies have demonstrated the relevance of pseudotyped systems to study SARS-CoV-2 entry. The SARS-CoV-2 pseudotyping assay in Figure 7B, combined with the extensive evidence in this study on membrane fusion, provide convincing evidence of the role of membrane cholesterol at the step of SARSCoV-2 entry. The purpose of the experiment employing live SARS-CoV-2 was not to demonstrate that MCBD targets virus entry, but rather to evaluate the impact of MBCD on the infectivity of authentic viral particles in a more biologically relevant context.</p><p>While we do acknowledge that multiple rounds of infection have already occurred by 48-hours postinfection, and that this could potentially lead to underestimating the inhibitory effect of MBCD, we believe that it altogether provides an accurate picture of the compound’s ability to impact viral propagation from an initial treatment step. Detection of significant viral inhibition at 6-hours postinfection by IHC or qPCR does not mean that there are no remaining viral particles left unaffected and able to further initiate new infection rounds. Additionally, it is unclear as to whether fixing cells at 6hours post-infection using a MOI 0.5 would yield a baseline level of viral infection high enough to accurately quantify MBCD inhibition. Altogether, we are confident that the experimental settings we employed in this experiment were appropriate to answer the biological question under study.</p><p>Finally, we do not have concerns about the possibility that newly synthetized viruses produced from MBCD-treated cells may be less infectious. As shown in Figure 7G (lower panel), MBCD pre-treatment of cells does not impact viral particle production regardless of the concentration tested over a 48-hour infection time course. Consequently, in the context of virus-treated cells, temporary exposure of cells to</p><p>MBCD during virus adsorption, prior to extensive washing, is unlikely to impact viral particle production.</p><p>No text revisions were made in response to this critique.</p><disp-quote content-type="editor-comment"><p>4. Improved images are needed for Figure 7F. It seems that MBCD at higher concentrations dramatically reduced the blue DAPI staining, and yet the authors previously showed that it is not toxic to cells (Figure 6H).</p></disp-quote><p>The reviewer is correct in noting that at high concentration (e.g. &gt;10 mM), MBCD is toxic to cells, and this can be observed as a reduction in DAPI signal/cell number (e.g. 10 mM panels in Figure 7F). However, there is no discrepancy between the findings in Figure 6H (U2OS-ACE2 cell-cell fusion assay; up to 1 mM MBCD tested) and Figure 7F (SARS-CoV-2 infection; up to 10 mM MBCD). It is possible that confusion resulted from use of axes with different ranges? As Reviewer 2 is right that DAPI staining is reduced in 10 mM conditions, we are of the opinion that higher-resolution images are not required to represent the quantitative data reported in Figure 7G.</p><p>No changes were made to the text in response to this critique.</p><disp-quote content-type="editor-comment"><p>5. Figure 7G, how does MBCD treatment affect viral particle integrity? In other words, is the viral RNA still associated/encapsidated within the viral capsid proteins post MBCD treatment? Plus/minus the RNase treatment in the media or ELISA of viral proteins would be good controls to include.</p></disp-quote><p>We thank Reviewer 2 for highlighting this important concern: it is conceivable that at very high MBCD concentrations, viral envelopes might disintegrate, dumping their contents into the cell media. For example, one study found this to occur for HIV and SIV at &gt;80 mM (Graham et al., 2003). In contrast, influenza particles remain intact at much higher concentrations (e.g. &gt;50 mM) (Sun and Whittaker, 2003), which is also true for hepatitis B (Bremer et al., 2009), dengue (Carro and Damonte, 2013), and cytomegalovirus (Gudleski-O'Regan et al., 2012). Regardless of virus examined, permeabilization concerns primarily arose at concentrations of an order of magnitude greater than identified for pseudotyped particle entry (Figures 7B) and SARS-CoV-2 infection (Figures 7F,G). We further note that determined EC50s are consistent with studies on other enveloped viruses (e.g. see above referenced studies). Moreover, at concentrations that might perturb viral envelope integrity, cellular toxicity is observed (Figure 7F, 10 mM panels). The reviewer offers thoughtful experimental suggestions for conclusively ruling out permeability artifacts. We discussed with collaborators whether such experiments could be performed in a reasonable time frame, and unfortunately concluded that optimization of new assays (e.g. ELISAs following sucrose-gradient ultracentrifugation) would be prohibitive.</p><p>Thus, we have revised the text to highlight the possibility that permeabilization contributes in part to the inhibition observed. The following text changes were made in response to this critique (page 8):</p><p>Pg8: “Pre-treatment of cells with millimolar doses of MBCD, which strongly inhibits both coculture syncytia formation and pseudovirus entry, had no effect on infection as determined by RT-PCR and immunohistochemistry (Figure 7F,G). […] However, the molecular basis of this cholesterol-dependent infectivity, i.e. whether it indeed results specifically from cholesterol-dependent spike fusogenicity, or includes contributions from confounding effects such as large-scale virus permeabilization (Graham et al., 2003), remains to be determined.”</p><disp-quote content-type="editor-comment"><p>Overall, I think this is a nicely written and timely study. My major problem lies with viral infection experiments performed in Figure 7, which I think should be fixed to strengthen the conclusion of the manuscript.</p><p>Reviewer #3:</p><p>Syncytia formation has been found in the lungs of patients with SARS-CoV2 and appears to be correlated with disease severity. This phenomena is likely due to cell-cell interactions through Spike and ACE2. Using an assay based on one cell expressing S and the other ACE2 this investigation exhaustively screens existing antiviral compounds as well as compounds known to dusrupt cellular endocytic and secretory pathways to identify factors regulating syncytia formation. The ultimate finding of this study is the important role played by plasma membrane cholesterol for syncytia formation and the potential of cholesterol extracting molecules for blocking the syncytia formation.</p><p>While this is a very thorough and comprehensive study, almost all its findings have been previously reported either with CoV2 or COV1 or MHV.</p></disp-quote><p>We thank the reviewer for their time and kind comments regarding the rigor of our work. With respect to novelty, it is accurate that many of our findings are consistent with those of previous studies, which we reference as appropriate and build upon with new experiments/approaches. With regard to missing citations, we apologize for the unintentional oversights and appreciate the reviewer’s careful attention to ensuring a complete accounting of previous efforts related to our findings on syncytia. This has certainly improved the revised manuscript.</p><disp-quote content-type="editor-comment"><p>1. The critical importance of syncytia formation in lungs for disease severity has been reported for CoV2 by multiple groups ( Tian et al., Hoffmann et al., Graccal et al., Buchreiser et al., ). Some of these references are missing and credit should be given.</p></disp-quote><p>We agree with the reviewer that SARS-CoV-2-associated syncytia have been reported by other groups, and reference the studies mentioned with the exception of Graccal et al. Perhaps this is a typo, as we are unable to find a Graccal study following a cursory search of the literature? If referring to Giacca et al. (<italic>medrxiv</italic> pre-print), we cite this work.</p><p>No revisions were made to the text in response to this critique.</p><disp-quote content-type="editor-comment"><p>2. Liu et al. in 2003 had reported in Nature that SARS-CoV1 S and ACE2 were sufficient to form syncytia and they used a very similar assay as to one reported here. This reference is missing from the manuscript and should be included.</p></disp-quote><p>We thank the reviewer for bringing this oversight to our attention. We admit that insufficient care was devoted to citing SARS-CoV-1 studies. The <italic>Nature</italic> manuscript from Farzan, Choe, and colleagues (Li et al., 2003) is now properly referenced.</p><p>Please see page 2 for citation of this work.</p><p>Pg2: “Pioneering work on SARS-CoV-1 (Li et al., 2003) as well as recent studies on SARS-CoV-2 identified similar syncytia (Buchrieser et al., 2020; Cattin-Ortolá et al., 2020; Hoffmann et al., 2020a; Ou et al., 2020; Papa et al., 2020; Xia et al., 2020; Zang et al., 2020b)…”</p><disp-quote content-type="editor-comment"><p>3. Musarrat et al., in 2020 showed that the antiretorviral protease inhibitor nelfinavir blocks CoV2 viral fusion and prevents syncytia formation. This reference is missing from the manuscript and should be included.</p></disp-quote><p>We thank the reviewer for bringing our attention to this study. This work from the Kousolos lab is now referenced (Musarrat et al., 2020).</p><p>Please see page 5 for newly included citation of this work.</p><p>Pg5: “Surprisingly, the antiretroviral protease inhibitor nelfinavir was unique in blocking fusion (Figure 3C), a compound whose therapeutic potential was identified by others (Musarrat et al., 2020). Given that other serine protease inhibitors (AEBSF, leupeptin, camostat) lacked efficacy, inhibition by nelfinavir may be related to its proteolysisindependent targets…”</p><disp-quote content-type="editor-comment"><p>4. The important role of cholesterol in b-coronavirus infections was also previously highlighted in 1988 and 1991 by the group of Anderson</p><p>and Methylbcyclodextrin was shown by them to prevent syncytia formation. These references are missing and should be credited.</p></disp-quote><p>This pioneering work from Anderson and colleagues on related viruses is now cited (Cervin and Anderson, 1991; Daya et al., 1988).</p><p>Please see page 9 for newly included citations and discussion of these manuscripts.</p><p>Pg9: “Our approach relies on a combination of high throughput screening, quantitative live cell imaging, and viral infection assays, all of which implicate biophysical aspects of the plasma membrane, particularly cholesterol-rich regions, in facilitating spike-mediated membrane fusion. […] Moreover, our high-throughput cell-cell fusion assay not only negates safety concerns associated with pathogenic viruses, but may allow rapid interrogation of the pathogenic nature of newly emerging spike variants that partially evade current vaccines (Davies et al., 2021; Wibder et al., 2021).”</p><disp-quote content-type="editor-comment"><p>Given all the above, what remains novel in this manuscript is the exhaustive screening of drugs to identify not only those that block the syncytia from forming but also those that don't have any effect. Therefore it may be a useful resource and suitable for publication.</p></disp-quote><p>We appreciate that the reviewer agrees that our findings are useful and suitable for publication. Given the numerous novel aspects highlighted by the reviewer, including the exhaustive high throughput screening and living cell imaging capabilities, we could not agree more.</p><p>No revisions were made to the text in response to this critique.</p></body></sub-article></article>